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Drug resistance is a serious problem in health care in general, and in malaria treatment 
in particular, rendering many of our previously considered ‘wonder drugs’ useless. 
Recently, large sums of money have been allocated for the continuous development of 
new drugs to replace the failing ones. We seem to be one step behind the evolution of 
antimalarial resistance; is it possible to get one step ahead? Are interventions which 
slow down the evolution and spread of drug-resistant malaria parasites achievable? In 
this thesis, I address these issues with experimental data, using the well-established 
rodent malaria model Plasmodium chabaudi to understand the selective advantages 
and disadvantages drug-resistant parasites endure within a vertebrate host and the 
selective pressures various drug treatment regimes exert on these parasites. 
 
Competitive interactions between drug-resistant and drug-sensitive parasites were 
observed within the host, with resistant parasites having a competitive disadvantage 
in the absence of drug treatment. The frequency of resistant parasites at the start of 
the infection was an important determinant of the strength of selection: the lower their 
frequency, the stronger the competitive suppression in non-treated hosts and the 
greater their competitive release following drug treatment. Genetically similar 
genotypes, one resistant and one sensitive, showed similar dynamics following drug 
treatment. Multiplicity of infection did not have an effect on the within-host dynamics: 
a larger number of co-infecting susceptible genotypes did not lead to greater 
competitive suppression or release of resistant parasites. Lastly, various drug 
treatment regimes were compared. Conventional drug treatment resulted in the 
greatest selective advantage for drug-resistant parasites, while less aggressive 
treatments were equally as effective, or even better, at improving host health and 
reducing overall infectiousness.  
 
These studies demonstrate that altering the within-host ecology of drug-resistant 
parasites by administering drugs and hence removing the drug-sensitive competitors 
has a large influence on the transmission potential of drug-resistant parasites. 
Furthermore, this thesis provides proof of principle that other drug treatment regimes 
different from those currently in use could better control drug-resistant parasites, 
without compromising other treatment goals. In the case of malaria, less drugs may 
mean extending the useful lifespan of that drug. 
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1. General introduction 
1.1 On kitchen salt and the eradication of malaria 
It’s the late 1950s and the prospect of highly-effective malaria control and possibly 
even malaria eradication is in sight. The incorporation of antimalarial drugs to 
common kitchen salt (known as Pinotti’s method) is going to make an end to all 
suffering from this devastating tropical disease (Pinotti 1954; Payne 1988). Now, five 
decades later, malaria remains one of the leading causes of death worldwide from a 
single infectious agent (WHO 2008).  
 
The various medicated salt projects carried out globally have taught us that this 
approach is not suitable to control malaria. Drug-resistant malaria parasites have 
prospered in many of the areas where medicated salt was distributed, particularly 
when pyrimethamine was administered; at times, these projects even resulted in an 
increase in Plasmodium falciparum infections (Verdrager 1986; Payne 1988). However, 
some early successes were achieved: in Guyana, Iran and Surinam (Bruce-Chwatt 
1980). In 1955, the much more effective Global Malaria Eradication Program was 
launched , using mostly DDT but also chloroquine treatments. These eradication 
programs, based on intense vector control, were largely responsible for the eradication 
of malaria from Europe, most of North 
America, Australia, large parts of South 
America and several countries in the 
Middle-East and Eastern Asia by the early 
1970s (Bruce-Chwatt 1980). Due to 
economic, political, organizational and 
insecticide- and drug-resistance 
problems, malaria eradication programs 
were converted into malaria control 
programs or were abandoned completely in the other regions: sub-Saharan Africa, 
parts of SouthAmerica and Southeast Asia.  
 
Nowadays, malaria eradication is, once again, firmly back on the agenda (Roll Back 
Malaria 2008; Feachem and Malaria Elimination Group 2009). The allocation of large 
Box 1.1 definitions 
malaria control: reduction of malaria 
incidence, ideally until it is no longer a 
public health problem 
malaria elimination: cessation of regional 
transmission of malaria 
malaria eradication: global extermination 
malaria transmission  
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sums of money from the Bill and Melinda Gates Foundation (Grabowsky 2008), the 
Global Fund to fight HIV, TB and Malaria, the US President’s Malaria Initiative and the 
World Bank’s Booster Programme (Mendis et al. 2009) is a great step towards this 
costly project (Mills et al. 2008). The existing international political commitment is 
also indispensable in this global undertaking. Nonetheless, malaria eradication is a 
tremendously ambitious goal (Mendis et al. 2009), which, once started, should not be 
abandoned. Early desertion of malaria eradication could worsen the situation as a 
result of drug resistance and reduced immunity in the host population (Trape et al. 
1998; Maude et al. 2009). In his instantly-famous speech, Bill Gates concluded “… we 
will not stop working, until malaria is eradicated” (Gates 2007). Whether malaria can be 
eradicated, particularly elimination from highly endemic sub-Saharan Africa, remains 
to be seen. 
 
The two most valuable intervention methods proposed in the new eradication 
programs are the use of insecticide-treated bednets (ITNs) and drug treatment with 
artemisinin-based combination therapy (ACT) (Roll Back Malaria 2008; Feachem and 
Malaria Elimination Group 2009). This approach has some striking overlaps with the 
1955 eradication program, which was highly dependent on DDT spraying and 
chloroquine drug use. The former is replaced by pyrethroids for the use on bednets, 
the latter by ACTs. Unfortunately, resistance against pyrethroids (WHO 2008) and 
decreased sensitivity to ACTs  have already been observed (Figure 1.1; Enserink 2008; 




For this reason, the malaria eradication proposals incorporate a so-called drug 
discovery pipeline for the rolling-out of new drugs to replace failing ‘old’ ones. The 
costs of the pipeline for research and development alone (i.e. excluding the costs of 
production and deployment) will be in excess of $US2.5 billion and a further $US1.5 
 
Figure 1.1 Header from a recent Reuters press release (29/09/2009). 
 
 
Chapter 1 –General introduction 
 
3
billion will be required every decade that follows (Roll Back Malaria 2008). These are 
incredible amounts of money for a disease affecting some of the poorest people on the 
planet. In addition, with failing drugs comes increased morbidity and mortality 
(Zucker et al. 2003), and a change in treatment recommendation takes time. The 
question is, are there ways to slow the evolution of drug resistance and thus the drug 
treadmill (Read and Huijben 2009)?  
 
1.2 Malaria: a global health problem 
The figures so often quoted in scientific articles speak for themselves: 3 billion people 
are currently at risk of a malaria infection, with 250 million cases annually and an 
estimate of 1 million deaths each year. Malaria is one of the leading causes of childhood 
death in Africa, with one in five deaths caused by a malaria infection (WHO 2008). 
Malaria incidence could even be higher than these estimates (Snow et al. 2005). 
Needless to say, malaria truly is a debilitating health problem, both on an individual 
and country scale, particularly in the tropical areas where some of the poorest people 
live. Besides the morbidity and mortality, malaria has a tremendous impact on the 
economy of malaria-endemic countries. Not surprisingly, poverty and malaria go hand 
in hand (Gallup and Sachs 2001). 
 
Malaria is caused by protozoan parasites of the genus Plasmodium. Four Plasmodium 
species affect human health: P. falciparum, P. vivax, P. malariae and P. ovale. A fifth 
species, the zoonotic primate malaria P. knowlesi, is able to infect humans as well 
(Singh et al. 2004). Infections with P. falciparum and P. vivax cause most of the clinical 
malaria cases worldwide, with falciparum malaria causing the most mortality, 
particularly in non-immune individuals (WHO 2008). Malaria is a vector-borne disease 
and transmitted by female mosquitoes of the genus Anopheles. The life cycle of P. 
falciparum parasites is described in box 1.2 and depicted in figure 1.2.  
 
 










Box 1.2 Plasmodium falciparum life cycle 
The Plasmodium falciparum parasite life cycle consists of a human vertebrate host and 
a mosquito host of the Anopheles genus for sexual replication. A person gets infected 
when a malaria-infected mosquito takes a blood meal, and sporozoites from the 
salivary glands are injected into the blood stream. These sporozoites migrate to the 
liver, where they develop into schizonts, which produce merozoites. The merozoites 
travel to the bloodstream, where they invade red blood cells. The parasites are now 
called trophozoites; this stage is also called the ring stage, due to the morphological 
resemblance to a diamond ring. Most of the trophozoites will multiply within the red 
blood cell, developing into schizonts and producing merozoites which can invade red 
blood cells again (asexual cycle). A small proportion of the trophozoites will develop 
into gametocytes, which can be ingested by an uninfected mosquito while taking a 
blood meal (sexual cycle). Once in the mosquito midgut, the male and female 
gametocytes develop into male and female gametes. These fuse in the insect’s gut to 
form a zygote, which in its turn develops into an ookinete. The ookinete travels across 
the midgut wall and forms an oocyst in which sporozoites develop. Finally, the oocyst 
ruptures and sporozoites move to the mosquito’s salivary glands, and the process starts 
all over again (Figure 1.2; Su et al. 2007). 
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1.3 Drug resistance and malaria  
Drug resistance in malaria is common, as it is in a wide variety of pathogens. The 
evolution of drug-resistant pathogens has caused much concern over the past decades, 
starting soon after the introduction of the first antibiotics. Resistance has arisen to 
every antibiotic in clinical use (Levy 2002) and the pharmaceutical industry is in a race 
against resistance to develop new antibiotics. The evolution of drug resistance against 
antibiotics has been referred to as a ‘crisis’ and ‘worldwide calamity’ in leading articles 
in the field of antibiotics (Neu 1992; Kunin 1993). Parasitic infectious diseases have 
similar problems with widely-spread, drug-resistant strains, such as in leishmaniasis 
(Croft et al. 2006) and African trypanosomes causing sleeping sickness (Matovu et al. 
2001). Fungal infections, the most well-known of which is Candida albicans, can be 
complicated by drug resistance (White et al. 1998). Furthermore, viral infections, most 
notably HIV/AIDS, are tremendously difficult to control as a result of multi-drug-
resistant strains (Wainberg and Friedland 1998). Finally, cancerous cells are known to 
develop resistance under pressure of chemotherapy, resulting in many deaths as a 
result of unsuccessful treatment (Goldman 2003). Thus, malaria is not unique in its 
recalcitrance to drug treatment.  
1.3.1 History of antimalarial drug resistance 
Some antimalarial drugs have been around for a long time (Figure 1.3). Though the 
Incas likely used cinchona bark for many centuries, the Spaniards claim the discovery 
of its antimalarial properties in the Americas in the sixteenth century. Several 
centuries later, in 1820, the active compounds were isolated, with quinine being 
considered the most effective. Some important discoveries in the late 19th century led 
to great changes in malaria control. In 1880, Alphonse Lavaran was the first to see 
malaria parasites under the microscope. Seventeen years later, the mosquito was 
identified as the malaria vector by Italian Giovanni Grassi and British-Indian Ronald 
Ross. In the same year, Robert Koch discovered that quinine destroyed malaria 
parasites in human blood. So far, quinine had only been used by the elite, such as 
European settlers in colonial areas. The drug was used on a self-medication basis or as 
prophylaxis. In the late 19th century though, Koch coordinated a small-scale mass 
blood screening and drug administration among plantation workers in New Guinea. 
Although very successful, it was deemed too costly and hence abandoned. For the 
coming decades, drug treatment was, once again, considered for the European settlers 
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only. Malaria control programs were carried out, but solely based on vector control 
because of the much lower costs involved. In 1934, a new antimalarial compound was 
discovered: chloroquine. Unfortunately, it was not until late during the Second World 
War that it gained more recognition and was deemed safe. Chloroquine was much 
cheaper than quinine, which opened prospects of mass drug treatments. These were 
carried out in combination with DDT spraying in the well-known Global Malaria 
Eradication Program, starting in 1955. In the 1970s, however, when it became clear 
that malaria eradication had failed in many areas, mass drug administrations were 
abandoned. Yet, chloroquine was now available for many people living in endemic 
tropical Africa at affordable prices. The result was self-medication, just as the colonial 
settlers had once done with cinchona bark and quinine. This time, however, it was 
done on a much larger scale. 
 
 
Figure 1.3 Schematic timeline of the major historical events related to antimalarial treatments 
(Talisuna et al. 2004; Webb 2009). Figure is not drawn on arithmetic scale. 
 
 
While there are anecdotal reports from 1844 and 1910 of quinine resistance (reviewed 
in Talisuna et al. 2004), up to the Second World War, when quinine treatment was 
substituted with other antimalarial drugs, no mass drug resistance against quinine had 
been observed. Resistance against chloroquine, however, emerged rather rapidly, with 
the first reports of resistance in Southeast Asia in 1957. Thailand replaced chloroquine 
as first-line drug in 1973, and other countries in Asia and South America soon 
followed. In Africa, chloroquine resistance was first found in 1978 and it quickly 
spread over the continent thereafter. Malawi was the first African country to replace 
chloroquine as first line treatment in 1993. Resistance to the replacement drug 
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sulphadoxine-pyrimethamine (SP – Fansidar®) emerged very quickly: less than one 
year after introduction in Thailand in 1967, resistance was observed. In Africa, SP 
sensitivity started to decline in the late 1980s. Both chloroquine and SP are now 
useless in most parts of the world (Talisuna et al. 2004; Hyde 2005). Many other drugs 
have been introduced over the past six decades, each with the same recurring trend: 
resistance is usually first observed within a decade after deployment (Figure 1.4; Hyde 
2005).  
 
Currently, artemisinin-derivatives are the most effective drugs available. In 2006, the 
WHO recommended ACTs for first-line treatment globally. Artemisinins work 
efficiently and fast against parasites, with a very short half-life. Artemisinin-derivatives 
also affect the transmissible gametocyte stage of the malaria parasite, which most of 
the other antimalarial drugs do not target. This may have a large impact on malaria 
transmission intensity (reviewed in Drakeley et al. 2006; Okell et al. 2008a). The 
antimalarial properties of artemisinin, or qinghaosu as it is called in Chinese medicine, 
were discovered by Chinese scientists in 1971. The active compounds are extracted 
from sweet wormwood (Artemisia annua). Initially, the parent drug artemisinin was 
used, but it was soon replaced by the more effective dihydroartemisinin and its 
derivatives artesunate and artemether (White 2008). The greatest problem with the 
artemisinin class drugs is that they are much more expensive to manufacture than 
traditional antimalarials and have a shorter shelf-life. These issues are the most 
problematic in sub-Saharan Africa (Bloland et al. 2000). Additionally, prices are 
dependent on supply and demand since the active compounds are extracted from a 
plant instead of chemical synthesis (Kindermans et al. 2007). As a result of the high 
and fluctuating prices, the drugs need to be largely subsidised to keep artemisinin-
based drugs affordable, ideally at the same price as a course of chloroquine: $0.10-
$0.20 (Arrow et al. 2004; Gelband and Seiter 2007).  
 
 




Figure 1.4 History of the introduction of antimalarial drugs (green boxes) and the first 
detection of resistance in the field (yellow explosion shape). The following abbreviations are 
used: CQ - chloroquine; PG - proguanil; Pyr - pyrimethamine; SP - sulphadoxine-pyrimethamine 
(Fansidar®); Mef – mefloquine; Hal – halofantrine; ACTs – artemisinin-based combination 
therapies; Ato – atovaquone; Ato-PG – atovaquone-proguanil combination (Malarone®); LD – 
LapDap (chlorproguanil-dapsone). Figure redrawn and adapted from Hyde (2005) and Read 
and Huijben (2009).  
 
1.3.2 Current problems with drug resistance in malaria 
As mentioned above, resistance is widespread against most widely-used antimalarial 
treatments. Widespread resistance against ACTs would be a very serious global 
problem, since there are no new front-line drugs waiting on the shelves. Unfortunately, 
resistance against ACTs is on the rise (Denis et al. 2006; WHO 2007; Enserink 2008; 
Wongsrichanalai and Meshnick 2008; Carrara et al. 2009; Lim et al. 2009). While 
treatment efficacy is still very high (over 95%; Carrara et al. 2009), the increased 
parasite clearance times that are observed are worrisome (Figure 1.5). Reduced 
parasite clearance and unusually high failure rates are reported for both artemether-
lumefantrine (Coartem®) and artesunate-mefloquine (WHO 2007), although reduced 
clearance in the former is likely a result from reduced lumefantrine absorption when 
taken without fatty food (Denis et al. 2006). Reduced susceptibility to artesunate-
mefloquine seems to be a result of resistance against both components of the drug 
(Wongsrichanalai and Meshnick 2008; Carrara et al. 2009; Lim et al. 2009). An 
increased Pfmdr1 copy number is found to be involved in in vitro resistance against 
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both mefloquine and artesunate, though other molecular mechanisms are likely 

































Figure 1.5 Parasite clearance rates (percentage of positive smear counts) on days 1-5 following 
the onset of a three day treatment of artesunate (4 mg/kg) and a single treatment of mefloquine 
(25 mg/kg) in patients with P. falciparum infections or mixed infections on the northwestern 
border of Thailand in 1995 (blue line, n=468), 2001 (green line, n=402) and 2005 (red line, 
n=393). Data from Carrara et al. (2009). 
 
1.4 The evolution of drug resistance 
Many factors influence the evolution of drug resistance. The most frequently discussed 
factors include the cost of resistance, drug pressure and time to de novo mutations. 
However, the spread of drug resistance is not determined by a simple combination of 
these.  
1.4.1 De novo mutations versus spread of resistant mutants  
The evolution of drug resistance can crudely be divided in two distinct steps. First, 
drug-resistant parasites arise by a random mutational event of one or a series of 
mutations in a specific location on a specific gene of the parasite. The chances of 
getting one such mutation has been estimated in the order of 10-9 (Paget-McNicol and 
Saul 2001). This mutated parasite has to multiply within its host to achieve a high 
enough density to be transmitted to the next host. I refer to this means of 
establishment of the mutant parasite as a de novo mutational event. The next phase is 
the transmission phase. The transmitted mutant parasites have to multiply in the new 
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host(s) and be transmitted again to other hosts. This phase is what I refer to as the 
spread of resistance. Following the initial de novo event, much stochastic loss of 
resistant mutants occurs during the early spreading phase, for instance when the 
resistant strain is incapable of growing up to large enough numbers in the next host or 
when the new host is either not bitten by a mosquito or the mosquito does not 
continue infecting a new person. A resistant strain is considered established once it 
cannot be lost by chance.  
 
The evolutionary history of resistance against chloroquine and SP tells us that the de 
novo mutational event, or at least the establishment of resistant strains, is a rare 
occurrence. Globally, resistance against both these drugs has arisen only a handful of 
times. The subsequent spread of resistance from this handful of events has led to a 
worldwide drug failure. Resistance against both chloroquine and SP in Africa has never 
arisen in Africa itself, but originated in Southeast Asia and subsequently spread to 
Africa (Wootton et al. 2002; Hastings 2004). We know this because of the following. 
 
A single resistant mutant that has spread widely would have resulted in a selective 
sweep: selection for the resistance gene will result in selection of neighbouring alleles 
as well. This process leads to a reduction of the genetic variation surrounding the 
resistance gene. A selective sweep can be measured by detection of linkage 
disequilibrium (LD): an overrepresentation of certain alleles in combination with the 
resistance gene is observed, while random assortment of genes in the population 
would be expected under neutral evolution. The presence of strong LD indicates that 
there may have been a recent selective sweep. Different selective sweeps result in 
different variation around the resistance genes and, hence, different origins can be 
detected. Linkage disequilibrium can decay after long periods of transmission and 
recombination, but since resistance has arisen relatively recently (within the past 60 
years), LD can still be detected in resistant parasites originating from patients from 
different geographical areas. Therefore, LD provides a great tool to determine the 
independence of de novo resistance mutational events (Wootton et al. 2002; Hayton 
and Su 2008).  
 
Linkage disequilibrium was found in chloroquine-resistant parasites from Africa and 
Asia. These resistant parasites shared many more alleles on the chromosome of the 
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resistance gene than chloroquine-sensitive parasites. Subsequently, at least four 
independent founder events were demonstrated (Wootton et al. 2002). Using the same 
method, sulphadoxine-pyrimethamine resistance has been shown to have only a 
handful of origins, none of which occurred in Africa (Cortese et al. 2002; Nair et al. 
2003; Roper et al. 2003; Hastings 2004). However, a more recent study argues for two 
independent origins in Africa as well (Mita et al. 2009). The different geographic 
origins and assumed spread of drug resistance against chloroquine and SP is 
summarized in figure 1.6. 
 
It appears that, at least for these antimalarials, the spread of drug resistance, rather 
than a multitude of de novo mutational events, is the main cause of the widespread 
resistance currently observed in malaria. This finding implies that our efforts to 
control drug resistance should focus as much on slowing down the spread of drug 
resistance as on reducing the likelihood of de novo mutations to occur. This is 
especially true once resistant parasites have been observed in the field. Parasites 
resistant against chloroquine and against SP have swept remarkably across the African 
continent; until we understand the factors governing the speed of this process, we will 
not be able to apply intervention methods to slow it down.  
 
There are exceptions, however, and resistance to some drugs such as atovaquone-
proguanil (Malarone®) has occurred from multiple independent origins (Musset et al. 
2007). In contrast to chloroquine and SP resistance, high-level atovaquone resistance 
is conferred by a single nucleotide polymorphism (SNP) that has a major effect on 
susceptibility to atovaquone-proguanil. Also, resistance against the sulphadoxine 
component of SP treatment (mutations in dhps gene) has arisen multiple times in 
Africa (Pearce et al. 2009). In contrast, mutations in dhfr gene, which confer a much 
greater resistance against SP than mutations in dhps gene, have arisen only a few times 
as described above. These multiple origins of resistance in dhps are likely a result of a 
weaker selective pressure against additional resistance mutations in an already 
resistant mutant. Pearce et al. propose that these dhps-resistant genes have emerged 
much more recently than dhfr-resistant parasites and chloroquine-resistant parasites. 
After an equal amount of time under selection, perhaps only one resistant dhps 
parasite strain would predominate as well. However, while resistance to some drugs 
may occur more regularly as de novo mutations than resistance to other drugs, unless 
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the source of resistant infections is predominantly caused by de novo mutations, 




Figure 1.6 The history of chloroquine and high-level pyrimethamine-sulphadoxine (SP) 
resistance inferred from molecular evolution studies. Chloroquine resistance has spread 
globally from selective sweeps from five independent origins. Notably, no sweeps began in 
Africa, where the health burden of drug resistance is greatest. Resistance to SP is tracked by 
analyses of the dhfr gene, which primarily confers resistance to the pyrimethamine component 
of the drug. The timing of two of the independent origins is unclear. SP resistance may have 
several local origins in Africa (Mita et al. 2009), but the majority of SP-resistant infections are a 
consequence of a selective sweep from a single origin in Southeast Asia. The top figure is 
redrawn from Wellems (2004) and Read and Huijben (2009), the bottom figure is a summary of 
a large body of studies (Cortese et al. 2002; Nair et al. 2003; Roper et al. 2003; Roper et al. 
2004; Maiga et al. 2007; McCollum et al. 2007; Mita et al. 2007; Hayton and Su 2008; McCollum 
et al. 2008; Saito-Nakano et al. 2008; Mita et al. 2009).  
 




1.4.2 What determines the rate of spread of resistant parasites? 
Many factors influencing the rate of spread of drug-resistant parasites have been 
identified, such as drug use practices, drug half-life, transmission intensity, clone 
multiplicity, parasite density, host immunity, within-host dynamics and the genetic 
basis of drug resistance. Many of these are incorporated in theoretical models (Curtis 
and Otoo 1986; Cross and Singer 1991; Hastings 1997; Mackinnon and Hastings 1998; 
White 1999; Hastings and D'Alessandro 2000; Koella and Antia 2003; Talisuna et al. 
2004; Mackinnon 2005; Hastings 2006; Pongtavornpinyo et al. 2008), but 
inconsistently.  
 
For instance, there is an ongoing debate about whether drug resistance is more prone 
to develop in areas with high or low transmission intensity (Bloland et al. 2000). 
Several arguments have been put forward that high transmission intensity results in a 
greater spread of drug resistance. High transmission areas have a higher clone-
multiplicity (Babiker and Walliker 1997; Arnot 1998), which gives an advantage for 
drug-resistant parasites co-infecting a host with drug-sensitive parasites when the 
infection is treated (Hastings and D'Alessandro 2000; de Roode et al. 2004; Mackinnon 
2005; Wargo et al. 2007; this thesis). Also, high transmission intensity results, by 
definition, in a higher number of parasites and thus resistant gene copies to be 
transmitted through the population, which results in more parasites being exposed to 
drugs compared to low transmission areas at the same drug pressure (Mackinnon and 
Hastings 1998). However, there are several arguments to suggest that areas of low 
transmission intensity are more prone to developing drug resistance. For instance, 
clone multiplicity results in genetic recombination, which means that the breakdown 
of multi-locus resistance genes occurs less often at low transmission intensity 
(Talisuna et al. 2004; Mackinnon 2005). Also, competitive suppression of drug-
resistant parasites may be more intense in multi-clone environments in untreated 
hosts (Chapter 5). Moreover, areas with low transmission intensity typically harbour 
more non-immune individuals, who have a higher parasite biomass (White and 
Pongtavornpinyo 2003), are more likely to have symptomatic- and, therefore, drug-
treated- infections (Talisuna et al. 2004; Mackinnon 2005; Pongtavornpinyo et al. 
2008), and have reduced capability to clear drug-resistant parasites (Cravo et al. 
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2001). Undoubtedly, all these factors, and probably more, affect the spread of drug-
resistant parasites, but the net result has yet to be established.  
 
Another unresolved factor in the rate of spread of drug resistance is the influence of 
drug pressure. Even though it is generally accepted that drug pressure increases the 
spread of resistance, the type of drug pressure and to what extent it promotes the 
spread of resistance is subject to debate (Read and Huijben 2009). It is widely agreed 
that unnecessary drug usage should be limited in order to avoid the emergence and 
spread of drug resistance. For this reason, drug usage is limited at a population level, 
often through increased implementation of better diagnostic methods, such as rapid 
diagnostic tests, to prevent presumptive treatment (Drakeley and Reyburn 2009) and 
reduced implementation of mass drug treatments. On an individual patient level, 
however, drug treatment is given to a maximum intensity, with the aim to avoid the 
evolution of drug resistance. This is an inconsistency in treatment guidelines that, at 
least on the face of it, makes little evolutionary sense. Maximum treatment imposes 
maximum selective advantage to any drug-resistant parasites that are present, greatly 
enhancing their fitness. The logic behind this is as follows. 
 
When mixed infections of highly-resistant and fully-sensitive parasites are drug-
treated, the relative fitness of resistant parasites increases simply because of the 
survival advantage resistant parasites have over drug-sensitive ones. Additionally, 
diminished competitive suppression by the susceptible parasites following drug 
treatment can increase the relative frequency of the resistant parasites even further 
(Hastings 2003). This competitive release allows the resistant parasites to fill up the 
ecological space left by susceptible parasites. Mixed infections of various genotypes are 
very common in human malaria infections (e.g. Arnot 1998; Babiker et al. 1999; Smith 
et al. 1999; Bruce et al. 2000; Jafari et al. 2004; A-Elbasit et al. 2007; Nwakanma et al. 
2008; Vafa et al. 2008; Baruah et al. 2009; Soulama et al. 2009), therefore, mixed 
infections with resistant and sensitive parasites are common as well. Direct 
experimental evidence on competition between co-infecting P. falciparum genotypes, 
particularly with drug-resistant parasites, cannot be ethically obtained from human 
infections. However, evidence from field data strongly argues for the presence of 
between-genotype competition by suppressed population densities of a genotype 
when other genotypes are present within a malaria-infected host (Daubersies et al. 
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1996; Mercereau-Puijalon 1996; Smith et al. 1999; Bruce et al. 2000; Hastings 2003; 
Talisuna et al. 2006; Bousema et al. 2008; Harrington et al. 2009). Additionally, there is 
considerable direct experimental evidence for crowding in rodent malaria models (e.g. 
Jarra and Brown 1985; Taylor et al. 1997; de Roode et al. 2004; de Roode et al. 2005a; 
de Roode et al. 2005b; Bell et al. 2006; Wargo et al. 2007; this thesis), as well as for 
competitive suppression and competitive release in mixed infections of drug-resistant 
and drug-sensitive P. chabaudi parasites. Drug-resistant parasites were competitively 
suppressed in the absence of drug treatment; drug treatment led to the competitive 
release of resistant parasites (de Roode et al. 2004; Wargo et al. 2007). Additionally, 
competitive facilitation was observed, whereby the resistant parasites increased to 
even higher parasite densities following release than they would have in the absence of 
competition (Wargo et al. 2007).  
 
Suggestive evidence for competitive release and facilitation has been observed in the 
field, where the effect of SP intermittent preventative treatment for pregnancy (IPTp) 
on resistance alleles was studied (Harrington et al. 2009). Since some women opt out 
of using IPTp, they can be used as a ‘control’ group, providing a unique opportunity to 
study the effect of drug treatment on human malaria infections. The study found that 
IPTp use was associated with increased frequency of resistance alleles in the infection. 
More strikingly, women using IPTp harbored a higher parasite density than women 
that did not use IPTp (Figure 1.7). Additionally, increased transmission success for 
multidrug-resistant parasites was observed following combination therapy with 
chloroquine and SP (Hallett et al. 2006). These results suggest competitive release and 
perhaps facilitation occurs among drug-treated P. falciparum infections when resistant 
parasites are present. 
 
Thus, drug treatment provides a great advantage to drug-resistant parasites, not only 
by means of a survival advantage, but also through competitive release. This latter 
effect may be the more powerful selective effect, playing an important role in the 








Figure 1.7 IPTp selects for increased level of parasitaemia. Placental parasitaemia was 
significantly higher in women who received any IPTp versus no IPTp (adjusted difference. 
4.9%, P = 0.03). Figure from Harrington et al. (2009). 
 
Since competitive release is the result of a complete alleviation of competitive 
suppression, the question arises: can resistant parasites be suppressed, while still 
providing a cure for the patient? Put differently, can the within-host ecology of drug-
resistant and drug-sensitive parasite co-infection be utilized to reduce the relative 
fitness of resistant parasites? Wargo et al. (2007) and Read and Huijben (2009) 
proposed the hypothesis that lower drug dosages could reach this goal, simply by 
maintaining competitive suppression on resistant parasites by not eliminating all 
competing susceptible parasites. Chapters 2 and 6 of this thesis present experimental 
tests of this hypothesis.  
1.4.3 Cost of resistance 
Much circumstantial evidence suggests that resistant malaria parasites have a lower 
fitness than sensitive parasites in the absence of chemotherapy (Walliker et al. 2005; 
Felger and Beck 2008; Babiker 2009). Suggestive evidence for a cost of resistance 
comes from progressive increases in drug sensitivity in populations where drug use 
has been discontinued. This has been seen in Malawi (Kublin et al. 2003; Mita et al. 
2003; Laufer et al. 2006), Tanzania (Temu et al. 2006), South Africa (Raman et al. 
2008), Thailand (Thaithong et al. 1988) and China (Liu et al. 1995), although there are 
also areas where a decrease of resistance has not been observed (McCollum et al. 
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2007; Yang et al. 2007). Seasonal variation in the frequency of resistant alleles in 
eastern Sudan and The Gambia is also consistent with costs of resistance. When there 
is low to no transmission during the dry season, and hence few new malaria cases and 
essentially no drug use, resistance alleles drop in frequency among the chronically-
infected patients who subsequently source the next outbreak. During the wet season, 
when high transmission ensures many new disease cases and hence high drug usage, 
resistance alleles rise in frequency (Abdel-Muhsin et al. 2004; Ord et al. 2007; Babiker 
2009).  
 
As in other pathogens, costs of resistance in malaria presumably arise from the 
metabolic costs of efflux or detoxification, or reduced biochemical efficiency associated 
with target site mutations (Hastings and Donnelly 2005); in other words, genetic 
trade-offs. Most models of malaria drug resistance evolution recognize these costs of 
resistance, but, if included at all, they are typically taken as a fixed and relatively 
modest parameter (e.g. a selective disadvantage s, so that the fitness of resistant 
mutant is 1- s, where s in the order of 0.1 or less). Additionally, it seems as if there is a 
widely held assumption that these costs can be mitigated by compensatory mutations, 
as they can be in bacteria and HIV (Levin et al. 2000), so that s can drop further 
through time. Such selection processes might explain some of the sequential 
mutational steps associated with chloroquine and SP resistance (Hastings and 
Donnelly 2005; Hastings and Watkins 2005).  
 
However, the cost of resistance is very likely dependent on the ecological environment 
of the parasite, so can not be represented as a fixed parameter such as ‘s’, but rather as 
a variable. This is because the costs of resistance are a function of the interactions 
between co-infecting strains within the host. A small metabolic cost influencing the 
growth of resistant parasites by themselves can be greatly magnified by competition 
with other genotypes (Read and Huijben 2009). Thus, the cost of resistance could be 
substantially increased with the force of infection, which is important to include in 
models on the spread of drug resistance in areas with a high level of multi-genotype 
infections. 
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1.4.4 What is so special about Southeast Asia? 
The Thai-Cambodia border seems to be the hotspot for the emergence of antimalarial 
resistance. Not only have chloroquine resistance, SP resistance and mefloquine 
resistance arisen in this region, but also the first reports of reduced ACT sensitivity 
originate from Southeast Asia (Wongsrichanalai and Meshnick 2008). What is so 
special about this region? Once we understand the specific factors that contribute to 
making the Thai-Cambodian border such a fertile ground for resistant parasites to 
emerge, interventions can be undertaken to reduce the chances of it happening again 
with future antimalarials. Unfortunately, the issue is not resolved yet. Several 
explanations have been suggested. First, there is a high level of drug use in the private 
sector, with a large abundance of counterfeit drugs (Hall et al. 2006; Newton et al. 
2008). Poor ability to diagnose malaria in this region has also been suggested 
(Wongsrichanalai and Meshnick 2008). Another option that has been put forward is a 
unique ability of the parasites in this region to develop de novo resistance mutations 
(Rathod et al. 1997).  
 
High level of drug use in the private sector may certainly contribute to the evolution of 
resistance since easy accessibility to drugs increases drug pressure. However, the use 
of counterfeit drugs per se does not necessarily result in a selection for resistance. 
Often, these drugs contain few antimalarial properties (Newton et al. 2008), and thus 
impose little selective pressure. However, a large abundance of counterfeit drugs does 
lead to widely-available cheap drugs, and hence high usage, which can still result in 
overall increased drug pressure if the counterfeit drugs contain some antimalarial 
properties. Poor ability to diagnose malaria does not necessarily result in increased 
selection for resistance either. When a patient is falsely diagnosed with malaria and is 
given drug treatment, selection for resistance is, evidently, only imposed when malaria 
parasites get exposed to these drugs. Since Southeast Asia has very low transmission 
intensity, the chance of a malaria infection occurring when there are significant levels 
of drug in the blood is much smaller than in high transmission intensity areas such as 
sub-Saharan Africa. Furthermore, in the case of artemisinin drugs, the chance of this 
occurring is very small since this drugs half-life is in the order of hours, opposed to 
weeks or even months in the case of the combination drug mefloquine (White 2002). 
Finally, there is no evidence of a regional existence of ‘high mutator strains’ of malaria 
parasites in Southeast Asia.  
 




A more plausible explanation to the high frequency of new resistant mutants arising 
from this region is the combination of low immunity and high drug usage 
(Pongtavornpinyo et al. 2008). The intensity of malaria transmission in Southeast Asia 
is much lower than in Africa, which results in a much lower immune status in 
individuals in Southeast Asia compared to Africa. Therefore, infections in this region 
are far more likely to be drug-treated than they are in Africa. Since most infections in 
this region are symptomatic, most parasites will find themselves in a new host that is 
(going to be) drug-treated, whereas a resistant parasite in Africa may need to pass 
through several asymptomatic hosts (by which it can be lost) before it, by chance, is 
transmitted to a symptomatic host (i.e. small child or pregnant woman). A recent 
mathematical model showed that via this process, resistant parasites spread more 
easily in low transmission areas than high transmission areas (Pongtavornpinyo et al. 
2008). Furthermore, low transmission areas have a characteristically lower rate of 
multi-genotype infections. This could additionally contribute to a better performance 
of resistant parasites caused by a reduced level of competition in untreated infections. 
However, fewer multi-genotype infections also mean a reduced benefit of treatment.  
 
These explanations are all theoretical speculations and we just do not know why 
resistant parasites appear so frequently in Southeast Asia. 
 
1.5 Antimalarial treatment regimes 
1.5.1 Treatment objectives 
The first and foremost objective of treating uncomplicated malaria (symptomatic 
malaria without signs of severity or evidence of vital organ dysfunction) is defined by 
the WHO as “eradication from the body of the infection that caused the illness” (WHO 
2006, pg 7). In other words, drug treatment should be effective until the last malaria 
parasite is eradicated from the patient. This approach is aimed at reaching the 
following three objectives for antimalarial treatment (WHO 2006, pg 7).  
(i) Improvement of patient health, most importantly by preventing 
progression to severe malaria and preventing additional morbidity as a 
result of treatment failure. 
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(ii) Reducing transmission intensity as a public health goal. 
(iii) Control of the emergence and spread of resistance to antimalarial drugs.  
In case of severe malaria, however, the foremost goal is to prevent death and the above 
objectives are secondary. 
 
As discussed in paragraph 1.4.2, drug pressure is the main determinant for the spread 
of drug-resistant parasites. Therefore, the approach of radical parasitological 
treatment seems to obstruct objective (iii): control of the evolution of drug resistance 
(Read and Huijben 2009). The rational for radical parasitological treatment to control 
the emergence and spread of resistance to antimalarial drugs is as follows. 
Conventional wisdom is that lower drug dosages select for de novo resistance faster 
because it exposes more parasites to low drug concentrations and leads to a selection 
for ‘tolerant’ parasites. These tolerant parasites are fewer mutational steps apart from 
high-level resistance than fully susceptible parasites (Hastings and Watkins 2006). 
Also, radical drug treatment minimizes the likelihood of parasites with the relevant 
mutations to occur by means of reducing absolute parasite numbers (WHO 2006). 
While both these rationales may be true (although the first is irrelevant in case of high 
level resistance following single point mutations) they are only relevant to reducing 
the likelihood that resistant parasites will arise in the first place. Once resistance is 
present in a population, these treatment objectives likely provide the greatest positive 
selection for resistance. However, experimental proof of this contention is missing. 
There is a great need for empirical data on the basic ecological dynamics of drug-
resistant parasites in drug-treated infections to inform current treatment guidelines.  
1.5.2 Treatment guidelines 
Combination therapy is now recommended by WHO for the treatment of falciparum 
malaria. Combination therapy is defined as combining two drugs with different drug 
targets. Therefore, synergistic drugs such as sulphadoxine and pyrimethamine (both 
targeting the folate pathway) are not considered combination therapy. Combination 
therapy has been shown to reduce the transmission success of resistant parasites in 
the absence of multi-drug resistance (Hallett et al. 2004; Okell et al. 2008b). The best 
combination therapy currently available is artemisinin-based combination therapy 
(ACT), with either artesunate, artemether, artemotil and dihydro-artemisinin as the 
first compound and another, slowly-eliminated drug as the partner drug. A slowly-
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eliminating partner drug is advised so that a shorter treatment course (3 days) can be 
given, since a 7-day course is more expensive and adherence is expected to be low 
(WHO 2006). In effect, however, this results in a mono-therapy of the combination 
drug for at least several weeks once the artemisinin derivatives are eliminated from 
the body within a couple of days after treatment. Artemisinin derivatives produce a 
rapid clearing of the parasites in the first days; subsequent complete clearance of 
parasites is dependent on the partner drug. The following four ACTs are currently 
recommended: artemether-lumefantrine (Coartem®), artesunate+amodiaquine, 
artesunate+mefloquine and artesunate+SP. The choice of ACT should be based on the 
level of resistance to the partner drug in the area. Another, non-ACT, combination 
therapy that is very effective is atovaquone-proguanil (Malarone®). However, due to 
its high costs, it is not recommended for deployment in endemic areas and is therefore 
mostly prescribed for western travellers, both as treatment and prophylaxis.  
 
Partial treatment is strongly advised against by WHO: “A full course of effective 
treatment should always be given once a decision to give antimalarial treatment has 
been reached” (WHO 2006, pg 27), to avoid the exposure of parasites to less than 
radical treatment. If treatment fails within 14 days, the infection should be treated 
with a second-line antimalarial, preferably another ACT. If treatment fails after 14 
days, the first-line treatment should be used. First-line malaria treatment should be 
changed if the treatment failure exceeds 10%. The therapeutic efficacy should be 
assessed by a treatment follow-up of at least 28 days (WHO 2006).  
 
Despite changes in treatment recommendation from the WHO, treatment practices still 
appear to be far from what is being advised. Chloroquine continues to be the most 
widely used drug, with an estimated several hundred million courses in 2006. Also 
artemisinin monotherapy is widely available nowadays (Yeung et al. 2008), albeit still 
expensive. Approximately 85 million courses of ACT have been ordered from 
manufacturers in 2006 (Gelband and Seiter 2007). Thus, while WHO advises 
otherwise, ACTs are not the mostly used drugs. With increasing funding to subsidize 
ACTs and reduce their prices, this is likely to change soon. 
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1.5.3 Resistance management 
Current resistance management is aimed at reducing the chance of de novo resistance 
mutational events from happening. General belief is that once resistance has arisen, 
there is no way of stopping it or slowing it down:  
 
“As effective and robust as the artemisinin drugs are today, it is only a matter of time 
before genetically resistant strains emerge and spread. However, practical steps can be 
taken to push that day further into the future. The logic is as follows. In the case of any 
antimalarial drug, the new development of drug resistance is a rare event: a chance 
genetic change in a single parasite in a single patient. But once that single malaria 
parasite generates multiple descendants, the math changes. Now, mosquitoes can acquire 
resistant parasites from a single individual and transmit them to other people. The 
subsequent spread of a robust, resistant clone would be similar to the spread of any 
malaria strain” (Arrow et al. 2004, pg 4). 
 
Also, a mathematical model has shown that the only way of getting rid of drug-
resistant malaria is by eradicating all malaria parasites (Maude et al. 2009). This 
model, whereby resistance is assumed to be already present in the population, predicts 
a rapid increase in resistance with interventions based on ACT drug treatment. Thus, 
the only way to control resistance, is by eliminating malaria parasites all together. In 
other words, resistance is thought to inherently spread once it has arisen. Therefore, 
current resistance management is focused on pushing the day of the first emergence of 
resistant strains further into the future.  
 
Combination therapy is a great tool to reduce the chance of resistant parasites from 
arising and therefore extending useful lifespan of a drug. The logic is as follows. The 
mutation rate of P. falciparum is estimated to be 10-9 (Paget-McNicol and Saul 2001). 
However, a malaria patient may typically harbour 1010-1012 parasites. Therefore, by 
chance alone, 10-1000 parasites may be resistant against the drug at the time of 
treatment if resistance is conferred by a single nucleotide mutation. By combining 
drugs, the number of mutations necessary for complete resistance increases. In a 
simple scenario, whereby resistance to both drugs is conferred by a single nucleotide 
mutation, the chance for a single susceptible parasite to become resistant is 10-9 ∙10-9 = 
10-18, which is much lower than the total parasite population present. The exact 
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genetics of resistance against the various drugs is not completely understood yet, but 
for most drugs it is thought that multiple mutations are necessary for a parasite to be 
fully resistant. Consequently, the likelihood of resistance arising against a combination 
of drugs can be very small (Hastings and D'Alessandro 2000; Arrow et al. 2004). 
Furthermore, by combining drugs with different resistance genes, resistance to both 
drugs can be lost following recombination due to a breakup of the two genes. 
Combining drugs to manage resistance is already a common practice in the treatment 
of tuberculosis (Blomberg and Fourie 2003) and HIV/AIDS (Yeni et al. 2002).  
 
1.6 Why this thesis 
We still do not completely understand the mechanisms behind the evolution of drug 
resistance (Read and Huijben 2009). Current treatment regimes are based on 
traditional concepts, which advise to administer high dose treatment to ensure full 
clearance of parasites. However, many of these treatment regimes, not only in malaria 
therapy, are not grounded by empirical data. For example, in antibacterial treatments, 
drugs are often administered longer than is necessary. Experimental analysis of 
patient treatment regimes to uncover whether current practices are the right ones is 
therefore deemed extremely necessary, since these practices lead to the proliferation 
of drug resistance in bacteria (Rice 2008). The same is likely true in the case of 
malaria.  
 
The importance of within host dynamics to fight drug resistance has been 
acknowledged in the past and for a wide variety of pathogens. Over a decade ago, it 
was suggested that natural competitors could be used to fight drug-resistant bacteria, 
by ‘treating’ patients, infected with resistant bacteria, with susceptible wild-type 
bacteria (Goldhaber 1994). This controversial method of using competition to control 
resistance did not receive any further attention. To the best of my knowledge, the 
potential of harnessing susceptible pathogens in a host to control resistant ones has 
been mentioned only a couple more times in the literature, for instance that “...the 
more effective a treatment is at eradicating drug-susceptible populations [...], the more it 
will promote the spread of resistant ones” (Lipsitch and Samore 2002, pg 349) and “...the 
fastest way to eliminate resistant strains is to outnumber them with susceptible strains” 
(Levy and Marshall 2004, pg s125). However, empirical tests of this hypothesis are 
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lacking. Some evidence has come from unexpected fields of research, for instance that 
of cancer treatment. Cancer is, just like malaria or other infectious diseases, currently 
treated with a high enough treatment dose to kill as many tumour cells as possible. 
However, computer models for this particular disease have shown that “if resistant 
populations [of cancerous cells] are present before administration of therapy, 
treatments designed to kill maximum numbers of cancer cells remove this inhibitory 
effect and actually promote more rapid growth of the resistant populations” (Gatenby et 
al. 2009, pg 4894). A subsequent experiment using a human ovarian cancer in a mouse 
has shown that mice that were treated aggressively quickly had a recurrence of 
resistant tumour cells, while all mice that received lower dosages, although chronically 
infested, survived (Figure 1.8; Gatenby et al. 2009). Another set of evidence comes 
from an in vitro study using the Staphylococcus aureus bacteria. This experiment 
showed that a short course of antibacterial drugs performed better at controlling the 
resistant bacterial population than the conventional longer course (Figure 1.9; 
Drusano et al. 2009), which again argues for the use of less drugs than currently 
advised. Finally, the use of reduced drug pressure is implemented already in a hospital 
in the UK to control for antibiotic-resistant Clostridium difficile. Infections with C. 
difficile are the result of high antibiotic usage, which allows the resistant gut bacteria to 
grow to large numbers in the absence of other gut bacteria. These infections cause high 
mortality in hospital patients. A reduced antibiotic prescription policy was 
implemented, in combination with a switch to different antibiotics, which resulted in a 
much reduced incidence of C. difficile (Gulihar et al. 2009).  
 
To my knowledge, no such work has been done on malaria parasites, or indeed any 
infections in vivo with the appropriate controls. Yet, drug resistance in malaria is one 
of the main hurdles in the way of malaria eradication. It is thus important to use our 
drugs in the most sensible way to slow down the evolution of resistance. While this 
thesis is based on malaria research, the logic of the arguments appears to be applicable 
to a wide range of diseases and will contribute to the empirical data necessary to start 
making changes in the conventional wisdoms that dominate treatment policies.  
 
 














































Figure 1.8 Mean tumor volume through time in mice that were inoculated with ovarian cancer 
cells and subsequently left untreated (blue circles), treated with a standard regimen of high 
dose chemotherapy (pink squares) or treated with an adaptive regimen (green triangles), 
which consisted of multiple low dosages of chemotherapy (indicated by the arrows) to control 
tumor growth. The experiment was terminated when all mice died in the untreated group and 
standard regimen group. All mice in the adaptive regimen group survived. Data are means for 




Figure 1.9 Bacterial population density in a mixture of antibacterial-resistant (blue line 
(simulation) and black diamonds (observed data)) and susceptible bacteria (total density is 
shown in red line (simulation) and black squares (observed data)) in vitro when receiving no 
antibacterial treatment (A), 4 days of treatment (B), 5 days of treatment (C) and 6 days of 
treatment (D). Treatment days are indicated by the arrows. The black line and triangles show 
the antibacterial concentration. Details are in Drusano et al. (2009). 
 





My overall objective is to understand the within-host ecology of drug-resistant 
parasites, both in untreated and drug-treated infections. Understanding the within-
host ecology of resistant parasites will lead to a better understanding of the evolution 
of drug resistance. This understanding may be a first step towards evolutionary-
informed interventions, aimed at controlling the spread of drug resistance. 
 
While one thesis is too short to fulfill the highly ambitious overall objective, in this 
thesis I have dealt with the following questions: 
 
1. What is the effect of sub-curative drug treatment on the within-host ecology of 
resistant parasites in a two-clone mixed infection? Following up on an experiment 
conducted in the lab previously (Wargo et al. 2007), can reduced drug treatment 
reduce the extent of competitive release of resistant parasites? The rationale being 
that decreasing the amount of drugs given to a mixed infection of resistant and 
susceptible parasites leaves more susceptible parasites in the mixture to potentially 
suppress the resistant parasites (Chapter 2). 
 
2. What is the effect of the frequency of resistant parasites in a mixed infection on 
competitive suppression and release? From previous work in the lab, we have identified 
strong competitive suppression on drug-resistant parasites in mixed infections of 
equal abundance at the outset. However, in a natural situation, resistant parasites can 
also occur in much lower abundances. Is competitive suppression more severe when 
starting out in the minority? Additionally, are these resistant parasites at low 
abundances being competitively released following drug treatment (Chapter 3)? 
 
3. Is competitive suppression and release seen in genetically similar drug-resistant and 
drug-sensitive clones? While we have gained much knowledge on competitive 
suppression of resistant parasites competing with genetically distinct susceptible 
parasites, competition between genetically similar strains (e.g. a resistant strain and its 
ancestor) remains largely unstudied (Chapter 4). 
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4. What is the effect of the number of co-infecting genotypes on the competitive 
suppression and release of drug-resistant parasites? Previous experimental studies have 
been conducted on competition in a two-clone infection; however, field data have 
shown that malaria infections are frequently found to harbor more than two 
genotypes. Is competitive suppression more intense under these circumstances? Also, 
what effect does drug treatment have on resistant parasites in these multi-clone 
environments (Chapter 5)?  
 
5. Are other drug treatment regimes feasible that perform better at controlling drug-
resistant parasites without compromising other treatment goals? The objective of 
malaria drug treatment is threefold: improvement of patient health, reducing 
transmission intensity and control of drug resistance. The experiment described in 
chapter 2 showed a reduced resistant parasite density when fewer drugs were given. 
How does a range of different treatment regimes compare to conventional treatment 
based on these three treatment objectives (Chapter 6)? 
 
1.8 Thesis arrangement 
This thesis is written as a set of independent papers, with one paper representing one 
data chapter. Therefore, there is some inevitable repetition, particularly in the material 
and methods, but also in background information and the logic of arguments. To 
answer the above proposed questions, the P. chabaudi rodent malaria model was used. 
With this study system, I have used a specific set of parasites, drug regimes and 
diagnostic tools; each of these is explained in the respective chapters. The strengths 
and weaknesses of the rodent malaria model are discussed in the general discussion at 
the end of this thesis. The term ‘virulence’ of an infection is used throughout this 
thesis. Virulence is a bit of an ambiguous term; in this thesis I define virulence as the 
level of morbidity (in terms of anaemia and weight loss) a parasite causes to the host, 
which is usually strongly correlated to parasite growth rate. The drug used for these 
experiments is pyrimethamine. Since the motivation for the choice of this drug and 
background on for instance the mode of action and the molecular basis of resistance is 
not covered in the separate chapters, it is given below. Also, specific choices for data 
analysis were made. These analyses were used throughout the thesis and are therefore 
introduced below.  
 





Pyrimethamine is an antifolate drug. Malaria parasites are dependent on de novo folate 
biosynthesis. Pyrimethamine, and other folate inhibitors, exploits this dependency as a 
drug target. Folate is necessary for the conversion of dUMP to dTMP, which is, among 
other things, needed for DNA replication. Without this conversion, the cell cycle arrests 
and the parasite dies. One of the critical steps in the process is the conversion of 
dihydrofolate (H2-folate) into tetrahydrofolate (H4-folate) by the enzyme dihydrofolate 
reductase (DHFR, Figure 1.10). Pyrimethamine inhibits the DHFR enzyme by binding to 
the active site and thus blocking the binding of dihydrofolate, resulting in cell cycle 
arrest for the parasite (Foote and Cowman 1994). Therefore, following pyrimethamine 
treatment, all replicating parasites are killed, while the non-replicating parasites 
(gametocytes) are left unharmed. 
 
 
Figure 1.10 Simplified schematic version of the folate pathway. The arrow at DHFR shows the 
target site for pyrimethamine. By blocking the DHFR enzyme, the folate pathway arrests and the 
replicating parasites die (source: 
http://www.tulane.edu/~wiser/protozoology/notes/drugs.html). 
 
Resistance against pyrimethamine arises by a mutation in the DHFR gene that results 
in a decreased binding affinity of the enzyme to the drug (Bustamante et al. 2009). The 
critical mutation in P. falciparum is a serine to asparagine change at position 108 
(Gregson and Plowe 2005), which is the same mutation observed in the 
pyrimethamine-resistant P. chabaudi clone at position 106 (Cheng and Saul 1994) used 
in the experiments described in this thesis. In SP-resistant P. falciparum in the field, 
more mutations are found, but the 108 mutation is always present. Most SP-resistant 
parasites in Africa have one or two additional mutations in the DHFR gene, while SP-
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resistant parasites in Southeast Asia have an additional third mutation (Hyde 2008). 
Each additional mutation results in an increased resistance towards the drug.  
 
Pyrimethamine-resistance is used in these studies because it is a well-established 
resistant parasite strain in the lab. The resistant parasites have a fully resistant 
phenotype: they grow just as well under drug pressure as without (e.g. de Roode et al. 
2004; Wargo et al. 2007). Furthermore, the molecular basis of pyrimethamine 
resistance in P. chabaudi is largely understood. Since I am interested in the effect of 
drug treatment (that is, the removal of susceptible parasites from a mixed infection) on 
the dynamics of resistant parasites when they are already present in the population, 
the conclusions I obtain about this within-host ecology should qualitatively pertain to 
all drugs. I return to this question in the general discussion. 
 
1.10 Data analysis 
Asexual parasite densities range over 6 orders of magnitude throughout the infection; 
therefore, asexual parasite densities were summarized using the geometric mean over 




Ideally, the outcome of within-host selection would be directly measured in terms of 
parasite frequencies in mosquitoes (e.g. Hallett et al. 2006). To perform this in an 
empirical model system requires logistically complex experiments that involve 
repeated mosquito feeds through time on the same mouse, or greatly increased 
number of mice in the study, were not conducted here. Instead, we inferred 
infectiousness of both clones to new hosts from the gametocyte dynamics of each 
clone. In earlier work, we typically used cumulative gametocyte densities over the 
course of infection as a measure of potential transmission (e.g. Wargo et al. 2007). 
However, infectiousness (proportion of mosquitoes infected) is unlikely to be a simple 
linear function of gametocyte density, not least because there must be a saturation 
effect at high gametocyte densities and less efficient transmission at low densities 
because of mate limitation in gametocyte reproduction (Barnes and White 2005; Paul 
et al. 2007; Sinden et al. 2007). Therefore, we used a density-infectivity function (or q-
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function) to estimate the number of mosquitoes potentially infected with each clone of 




,        (3) 
with gametocyte density denoted as N and probability of infection by q. The exact 
shape of the q-function is not well resolved and it may vary with epidemiological 
settings (Stepniewska et al. 2008). We used two different curves (Figure 1.11) both 
derived from experimental studies with P. falciparum. One comes from data compiled 
by Barnes and White (2005), and is based on feeding experiments on artificial P. 
falciparum infections of 88 neurosyphilitic patients using two different strains, one 
from South Carolina, the other from Panama (Jeffery and Eyles 1955). The other 
dataset comes from 6 different studies on natural P. falciparum infections from West 
Africa, summarised by Carter and Graves (1988). Ideally, we would also be able to 
include a curve estimated from experimental work on P. chabaudi (Buckling et al. 
1997; Taylor et al. 1997b; Mackinnon and Read 1999). However, since most relevant 
data on P. chabaudi come from experiments designed to maximise transmission, there 
are too few data to estimate transmission success at gametocyte densities relevant 
here (post-treatment). The sensitivity of the conclusions to the choice of q-curve is 
considered in the general discussion.  
 
Gametocyte abundances were used to calculate probability of infection through time 
using the q-curves. To translate these dynamical probabilities into a single 
transmission potential parameter, the number of infected mosquitoes from a potential 
of n=100 equally distributed across time was calculated for of each mouse. These 
calculations assume that there is no subsequent interaction between clones in 
mosquitoes which is negatively correlated with relative fitness in the vertebrate host, 
and that infectivity per gametocyte remains equal over the course of infection. Again, 
these assumptions are discussed in the general discussion. 
 





































Figure 1.11 Density-infectivity q-functions used in the analysis: probability of a single 
mosquito becoming infectious based on gametocyte density. Function q1 (black dashed line) is 
based on data from Barnes and White (2005), q2 (red solid line) is based on data from Carter 
and Graves (1988). Probability of infection was calculated using equation (3) and parameters α 
= 0.03, β = 0.6, α/γ = 0.85 for q1 and α = 1∙10-5, β = 2, α/γ = 1 for q2. Infectivity saturates at α/γ. 
Gametocyte density is plotted on a log scale. 
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2.1 Abstract 
Drug resistance is a major problem in malaria control. The rate with which resistant 
parasites spread through a population is dependent on the within-host ecology of 
drug-resistant and drug-sensitive parasites. Drug treatment significantly shapes the 
within-host ecology, with drugs greatly increasing the relative fitness of resistant 
parasites because they have a survival advantage and an additional gain by means of 
reduced competitive suppression. Here we test the hypothesis that the spread of 
resistance can be slowed down by reducing drug treatment and thus restricting 
competitive release. Using the rodent malaria model Plasmodium chabaudi, we found 
that competitive release of resistant parasites was more restricted following low dose 
therapy compared to high dose treatment. Importantly, the lower dose improved host 
health to the same level as high dose treatment. In other words, high dose treatment 
exerted strong positive selection on resistant parasites for little clinical gain. 
Therefore, depending on the epidemiological context such as the frequency of mixed 
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infections in a particular region, our data raise the question whether the currently 




Drug-resistance management is one of the major challenges in modern health care. 
Current management tools are primarily targeted at reducing the likelihood of de novo 
resistant mutants to arise in a treated patient (Arrow et al. 2004; WHO 2006). This 
may be a sensible approach for diseases with highly mutable pathogens such as the 
HIV/AIDS virus. Yet, in diseases where widespread drug resistance is predominantly 
caused by spread of resistant strains as opposed to frequently arising de novo mutants 
such as appear to be the case in malaria (Cortese et al. 2002; Wootton et al. 2002; Nair 
et al. 2003; Hastings 2004; Roper et al. 2004) and perhaps also tuberculosis (Luciani et 
al. 2009), other resistance management tools may be more effective. In this latter case, 
the useful lifespan of a drug, which is the time from introduction of a new drug to a 
treatment failure rate exceeding 10% (WHO 2006), is dependent on the strength of 
selection for drug-resistant parasite strains (Hastings 2003). The strength of selection 
is a function of the relative fitness among resistant and susceptible parasites, and 
depends among other things on the within-host ecology of drug-resistant and drug-
sensitive parasites. The within-host ecology of resistant and sensitive parasites is 
affected by a multitude of factors, most importantly drug pressure. 
  
High level drug resistance has evolved against most classes of first-line antimalarial 
drugs, making the evolution of drug resistance a major obstacle in malaria control 
(Greenwood et al. 2008). Two widely used drugs, chloroquine and sulphadoxine-
pyrimethamine (SP), have become useless in most parts of the world (Hyde 2005). 
Interestingly, the vast majority of strains resistant to chloroquine and SP that are 
currently circulating in Africa have not arisen in Africa itself, but instead originated 
from resistant strains from Southeast Asia (Cortese et al. 2002; Wootton et al. 2002; 
Nair et al. 2003; Roper et al. 2003; Hastings 2004), although there is some discussion 
that a few highly resistant SP strains may have their origin in Africa (Mita et al. 2009). 
In any event, repeated de novo origin of resistant mutants appears to be rare, which 
means that most people who harbour a drug-resistant infection have received these 
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resistant parasites from someone else. Hence, by controlling the spread of resistant 
parasites, the useful lifespan of the drug could be increased. 
 
Multiple genotype infections are common in malaria patients (e.g. Arnot 1998; Babiker 
et al. 1999; Smith et al. 1999; Bruce et al. 2000; Jafari et al. 2004; A-Elbasit et al. 2007; 
Nwakanma et al. 2008; Vafa et al. 2008; Baruah et al. 2009; Soulama et al. 2009). This 
means, especially when resistance is rare, that co-infections of resistant and 
susceptible parasites are very common. When mixed infections of drug-resistant and 
drug-sensitive parasites are drug-treated, the relative fitness of resistant parasites 
increases simply because of a survival advantage resistant parasites have over drug-
sensitive ones. Additionally, diminished competitive suppression by the susceptible 
parasites following drug treatment has been found to increase the relative frequency 
of the resistant parasites even further (Hastings 2003; de Roode et al. 2004; Wargo et 
al. 2007). This competitive release allows the resistant parasites to fill up the 
ecological space left by susceptible parasites. Direct experimental evidence on 
competition between co-infecting P. falciparum genotypes, particularly with drug-
resistant parasites, cannot be ethically obtained from human infections. However, field 
data showing suppressed population densities of a genotype when other genotypes are 
present strongly supports the presence of between-genotype competition within 
malaria-infected hosts (Daubersies et al. 1996; Mercereau-Puijalon 1996; Smith et al. 
1999; Bruce et al. 2000; Hastings 2003; Talisuna et al. 2006; Bousema et al. 2008; 
Harrington et al. 2009). Additionally, there is substantial experimental evidence for 
crowding in rodent malaria models (e.g. Jarra and Brown 1985; Taylor et al. 1997; de 
Roode et al. 2004; de Roode et al. 2005b; Bell et al. 2006; Wargo et al. 2007). 
Competitive suppression and competitive release have also been demonstrated in 
mixed infections of drug-resistant and drug-sensitive P. chabaudi parasites. Drug-
resistant parasites were competitively suppressed in the absence of drug treatment 
and competitive release was subsequently seen following prophylactic (de Roode et al. 
2004) and therapeutic (Wargo et al. 2007) drug treatment. Additionally, competitive 
facilitation was observed, whereby resistant parasites had higher parasite abundance 
than in the absence of competition (Wargo et al. 2007).  
 
This theory suggests that the spread of drug resistance can be slowed by any drug 
treatment that limits competitive release (Wargo et al. 2007). The logic is as follows. 
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Current drug treatment is aimed at eliminating all susceptible parasites from the 
infection. Less aggressive treatment, involving for instance shorter the treatment 
courses or lower drug doses, would result in a partial clearance of susceptible 
parasites, leaving these remaining susceptible parasites to, at least partially, suppress 
the co-infecting resistant parasites and hence reduce competitive release of resistant 
parasites. This hypothesis was tested by treating acute infections with either one, two 
or four days of drug treatment (Wargo et al. 2007). Both incomplete drug regimes of 
one or two days did not fully clear the infection of drug-sensitive parasites, however, 
all treatments still resulted in competitive release of the resistant parasites. The 
release of resistant parasites was significantly reduced in the one day treatment group 
compared to longer treatment durations.  
 
Here we test the hypothesis that the extent of competitive release (absolute fitness 
gain for resistant parasites) can be restricted still further by even lower or shorter 
regimens while still alleviating the clinical symptoms of disease. We were interested to 
see the fitness outcome for drug-resistant genotypes over the full course of infection 
and thus monitored infections for a longer duration than our previous studies. Greater 
sensitivity in malaria transmission stage (gametocyte) quantification and higher 
infected host replication enabled us to quantify more accurately than was previously 
possible the variable and low level dynamics that are known to occur in late stage 
infections. We also introduce two new analytical methods. First, to more precisely 
describe relative transmission success of resistant parasites, we made use of functions 
relating gametocyte density to infectivity (e.g. Stepniewska et al. 2008). Second, to 
better define the evolutionary consequences of drug treatment, we estimated the 
duration and strength of selection through the course of infection.  
 
We found that competitive release occurred after a single high drug dose. Resistant 
parasites were also released following low dose treatment, but the extent of release 
was more restricted. Host health was improved to the same level for both treatments, 
so that high dose treatment led to stronger positive selection on resistant parasites for 
little clinical gain.  
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2.3 Material and methods 
2.3.1 Parasites and hosts 
Two genetically distinct P. chabaudi clonal lineages were used to inoculate the hosts: 
drug-resistant AS12265(pyr-1A) (hereafter referred to as clone R) and drug-sensitive AJ5154 
(hereafter referred to as clone S). Clone R was made resistant to pyrimethamine after 
isolation by a single passage with high dose treatment (Walliker et al. 1975) and has 
been exposed to pyrimethamine in two later passages as well. Clone S has not been 
exposed to pyrimethamine since isolation (Beale et al. 1978). Hosts were six to eight 
week old female C57Bl/6J mice (Harlan, UK) maintained on a 41B maintenance diet 
(Harlan, UK), with their drinking water supplemented with 0.05% para-amino benzoic 
acid (PABA) to enhance parasite growth (Jacobs 1964).  
2.3.2 Experimental design and infections 
Mice were inoculated with one or both clones, with an intra-peritoneal injection of 106 
parasites of each clone. In mixed infections, two separate inoculations were given so 
that mixed infections received twice the parasite dose of single-clone infections. We 
did this because analysing competition requires comparison of the performance of an 
individual clone in the presence and absence of competition, starting from the same 
initial parasite dose. A two fold dose of 106 parasites has a negligible effect on parasite 
dynamics or host health (Timms et al. 2001). Drug treatment was given on day 6 post-
infection (PI), when parasite induced weight loss and anaemia became pronounced. 
Drug treatment consisted of either 8 mg pyrimethamine/kg bodyweight (high dose), 3 
mg/kg body weight (low dose), or no drugs (negative control). Note that both these 
drug treatments were expected not to fully clear the susceptible parasites and fall well 
short of 8 mg/kg pyrimethamine for four successive days, which is the standard drug 
treatment regimen in this model system to fully clear susceptible parasites (e.g. de 
Roode et al. 2004; Wargo et al. 2007). Pyrimethamine was dissolved in dimethyl 
sulfoxide (DMSO) and an inoculum of 50 μl was given intra-peritoneal to each mouse. 
Untreated mice were inoculated with 50 μl of DMSO only. Each treatment group 
consisted of six mice, totalling to 54 mice (Table 2.1).  
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Table 2.1 Experimental set-up of the study. Each treatment group consisted of six mice at the 
start of the experiment.  
 
 No drugs Low dose High dose 
Single-clone infection R 6 6†* 6 
Single-clone infection S 6††† 6 6 
Mixed infection R+S 6 6 6* 
 
† denotes a dead or euthanized mouse, * represents a mouse excluded because of a 
substantially low parasite dose.  
 
2.3.3 Monitoring of infections 
Mice were monitored daily from day three to 21 PI and thereafter on days 24, 26 and 
28 PI. Host health was monitored by measuring mouse body mass (to the nearest 0.01 
gram) and red blood cell density using flow-cytometry (Beckman Coulter) of a 2 μl 
sample of blood from a tail snip (Taylor et al. 1998; Mackinnon et al. 2002a). 
Quantitative real-time PCR was used to determine asexual parasite and gametocyte 
densities for each clone using clone-specific assays, for which an additional 5 μl and 10 
μl of tail snip blood was taken respectively.  
 
DNA was extracted from 5 µl blood using the BloodPrep kit (Applied Biosystems, 
Foster City, CA) on the ABI Prism 6100 Nucleic Acid PrepStation according to 
manufacturer’s instructions. DNA was eluted in a total volume of 200 μl and stored at -
80°C until quantification (Bell et al. 2006). RNA was extracted from 10 µl of blood, 
using the ‘RNA Blood-DNA’ method (Applied Biosystems) on the ABI Prism®6100 
Nucleic Acid PrepStation, following the manufacturer’s protocol, and eluted in 100 µl 
elution solution. Following RNA extraction, single stranded cDNA was synthesized 
using the High-Capacity cDNA Archive Kit (Applied Biosystems) and stored at -80°C 
until quantification (Wargo et al. 2006; Wargo et al. 2007). 
 
PCR was performed on DNA to quantify the respective total parasite densities, and 
subsequently also on cDNA-converted RNA to quantify the number of gametocytes 
(Drew and Reece 2007). Asexual parasite densities were calculated by subtracting 
gametocyte counts from total parasite counts. The PCR reaction was identical for both 
clone-specific assays. Each reaction, with a final volume of 25 µl, consisted of 7 µl of 
DNA or cDNA, 900 nM forward and reverse primers, 250 nM probe and 1X 
concentration TaqMan® Universal PCR Master Mix (Applied Biosystems). All reactions 
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were run on the ABI Prism® 7000 Sequence Detection System using the assay: 50°C for 
2 minutes, 95°C for 10 minutes, then 45 cycles of: 95°C for 15 seconds and 60°C for 1 
min. For primer and probe sequences, see Drew and Reece (2007). Quantification was 
based on serial dilutions of DNA and cDNA standards of known parasite and 
gametocyte density respectively, determined beforehand by microscopy.  
2.3.4 Data analysis 
Selection coefficients 
To estimate the temporal pattern of the strength and direction of within-host selection, 
the coefficient of selection on the resistant clone was estimated. In a two-clone 
infection, the selection coefficient is the difference in the per-capita growth rate of each 
clone. This strength of selection, denoted by si(t), can be calculated from the frequency 






,      (1) 
 where )(tpi is the relative abundance of competitor i at time t (Nelson et al. 2005). 
Essentially, selection reflects how quickly competitor proportions are changing, 
modified by how close they are to loss or fixation. The approach is to fit a time-series 
model to the parasite dynamics, which allows a statistical representation of the 
dynamics in relative abundance and, by using equation (1), a statistical description of 
the selection dynamics. A time-series model was fitted to the asexual parasite and 
gametocyte dynamics for each clone in each mouse. This resulted in four time-series 
models from each mouse, and two estimates of selection dynamics—one for selection 
between the strains in the asexual stage, and one for selection between strains in the 
gametocyte stage. The time-series model was a Generalized Additive Model (GAM) 
with a quasi-likelihood distribution (McCullagh 1983).  
y i(t) = si(t)
Yi(t) ~ Q(y i(t),V (y))
 
where s(t) is a smoothing cubic spline that will represent the fit parasite dynamics. The 
GAM is setup with the standard modified objective function that includes a likelihood 
term that measures how well the model fits the data, as well as a wiggliness term that 
adds a penalty for excessive curvature (Wood 2006). The tradeoff parameter for the 
modified objective function was estimated generalized cross validation. The expected 
parasite dynamics are denoted by y(t), and the observed parasite dynamics by Y(t). 
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The observed parasite dynamics are distributed as Q(y(t),V(y)), which has a quasi-
likelihood distribution with an expectation y(t) and a mean-variance relationship 
denoted by V(y).  
 
Since parasite dynamics span twelve orders of magnitude in natural log units (6 in 
log10 units), we need to pay particular attention to the mean-variance function V(y). To 
estimate this relationship, we conducted a series of additional mouse trials where 
replicate samples were taken on days 3-15 PI from mice infected with clone R (see 
appendix to this chapter). These data suggest a power relationship between the mean 
(y) and variance (V(y)) of both asexual parasite and gametocyte densities. The function 
has the form 
V (y) = ay b          (2) 
which is the general form for Tweedie distributions where a is the dispersion 
parameter, and b determines the specific class of distribution (Jorgensen 1987). For 
asexual parasites, b = 1.59, which falls within the range of compound Poisson 
distributions. For gametocytes, b = 2.206, which falls into the Gamma distribution 
class. Non-integer values of b>2 yield compound distributions that are difficult to 
implement in a GAM framework. To accommodate the implementation, we assumed 
b=2 for both asexual and gametocyte distributions, which still provides a good fit to the 
raw data (see appendix to this chapter). With b=2, the dispersion parameter (a) was 
refit, resulting in a = 0.01415 for asexuals and a = 0.0582 for gametocytes. For all fits, 
we used this observed value of dispersion rather than estimating it from the time-
series data during the fitting process.  
 
Parametric bootstrapping was used to estimate the confidence bands around the 
estimated selection dynamics for the asexual parasites and gametocytes in each 
mouse. The upper and lower 95% confidence bands for selection dynamics were 
calculated from 5000 bootstraps replicates.  
 
Statistical analysis  
Analyses were performed in R 2.9.0 (R Development Core Team 2009). Host health 
was summarized as arithmetic mean mouse body mass and arithmetic mean red blood 
cell density, with minimum red blood cell density and minimum body mass taken as a 
measurement of morbidity during the acute infection. The arithmetic mean of these 
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virulence measures and the geometric mean asexual parasite density were calculated 
for each mouse over the post-treatment infection period (day 7-28 PI). To ensure 
treatment groups with the same clonal infections did not differ prior to drug 
treatment, day 6 values on asexual parasite density, body mass and red blood cell 
density were evaluated for statistical differences. No statistical differences were found. 
The predicted infectiousness was calculated on the post-treatment (day 7-28 PI) 
gametocyte abundances as described in the general introduction. 
 
General linear modeling was used with the following factors: competition 
(single/mixed) and drugs (no drugs/low dose/high dose). Maximal models with the 
interaction terms were fitted first and subsequently removed if not significant. When 
comparing the effect of drugs on single or mixed infections only, a one-way ANOVA 
was performed. To test for differences among drug treatment groups, Tukey HSD 
(Honestly Significant Difference) post-hoc multiple comparison tests were carried out 
and the adjusted p-values are reported. The analysis on the predicted number of 
infected mosquitoes was done separately for single and mixed infections using factors 
drugs (no drugs/low dose/high dose) and clone (R/S). Gametocyte densities did differ 
significantly between treatment groups with the same clonal infections prior to 
treatment on day 6, therefore, day 6 gametocyte densities were included in the model 
as a covariate. 
 
Six mice were excluded from the analysis (Table 2.1). Four mice died or were 
euthanized during the acute phase of the infection and two evidently received a 
substantially lower parasite dose (parasite density at time of treatment two orders of 
magnitude lower than expected; Table 2.1). Note that we deliberately chose a mouse 
strain, sex and size which we know minimizes risk of death; the infection kinetics of 
both clones in the four mice that did die were qualitatively identical to those in mice 
that did not die. 
 
 




2.4.1 Asexual parasite dynamics  
As expected from previous studies (de Roode et al. 2004; Wargo et al. 2007), parasites 
from clone R and S were indeed respectively resistant and susceptible to treatment 
with pyrimethamine. In single clone infections, the densities of asexual parasites of 
clone R were unaffected by drug treatment (Figure 2.1a, drugs: F2,13=0.2, p=0.78), 
whereas clone S densities were reduced (Figure 2.1b, drugs: F2,12=26, p<0.001). The 
high drug dose killed more S parasites than the low drug dose (Single-clone infections - 
Tukey HSD, high dose vs. low dose: padj<0001). The low drug dose resulted in an initial 
kill of S parasites, but over the period following drug treatment, an equal amount of S 



















































Figure 2.1 Parasite densities of the drug-resistant clone R (left panels) and the drug-sensitive 
clone S (right panels) in single (top panels) and mixed (bottom panels) infections that were 
either left untreated (dashed red line), received a low drug dose (solid blue line) or high dose 
(solid black line). Black diamonds indicate the timing of drug-treatment at day 6 post-infection. 
Data are geometric means (± standard error) for up to six mice (Table 2.1). 
 
 
Chapter 2 –Chemotherapy, within-host ecology and relative fitness 
 
42 
In untreated mixed infections, densities of clones R and S increased similarly to peak 
parasitaemia, after which clone R parasite densities declined more rapidly than 
parasite densities of clone S (Figure 2.2, left column). This was due to competitive 
suppression, whereby fewer R parasites were produced when susceptible parasites 
were present (Figure 2.1c, competition: F1,27=15.6, p<0.001). The performance of clone 
S was unaffected by the presence of clone R, with as many susceptible parasites 
persisting for as long in single and mixed infections in the absence of drug treatment 
(Figure 2.1d, competition: F1,28<0.1, p=0.94).  
 
As in single-clone infections, densities of clone S parasites in mixed infections were 
greatly reduced by drug treatment. The two drug dosages had similar rates initially, 
but after two days the decline of S parasites was greater following high dose treatment 
(Figure 2.1bd, 2.2).  
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Figure 2.2 Asexual parasite dynamics of individual mice that were infected with a mixed 
infection of clone R (dashed red line) and clone S (solid black line), which received no drug 
treatment (left column), a low dose of pyrimethamine (middle column) or a high dose of 
pyrimethamine (right column). Each group consisted of 6 mice at the outset of the experiment; 
however, one mouse in the high dose treatment group received a much lower parasite dose 
than intended and was excluded (Table 2.1). Drug treatment was given on day 6 post-infection, 
as indicated by the black diamonds. 
 
 




Three days after treatment, there were as many or more resistant parasites in drug-
treated mixed infections than in single-clone infections (competitive facilitation; 
Figure 2.1c, 2.2, 2.3a, competition x drugs: F2,27=5.8, p=0.008). The higher drug dose 
resulted in more than half as many resistant parasites post-treatment than in 
untreated infections and almost a quarter more than low dose treatment (mixed 





































Figure 2.3 Geometric mean asexual parasite density (± standard error) of clone R (left plot) 
and clone S (right plot) in single and mixed infections that were either left untreated (dashed 
red line), received a low drug dose (solid blue line) or high dose (solid black line). Data are the 
arithmetic means of the geometric mean density per day over the course of post-treatment 
infection for up to six mice (Table 2.1).  
 
Together, these data show that densities of resistant parasite were suppressed when 
drug-sensitive parasites were present. Removing those sensitive parasites with drug 
treatment led to competitive release, and subsequently greatly increased densities of 
resistant parasites compared to untreated mixed infections. 
 
2.4.2 Transmission potential 
Gametocytes of both clone R and S peaked on or around day 6 and subsequently again 
around day 13 in untreated single-clone infections (Figure 2.4, 2.5). Clone S peaked at 
higher gametocyte densities than clone R and typically had an additional gametocyte 
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peak after day 20 post-infection (Figure 2.4ab). As with the asexual dynamics, 
gametocyte densities for clone R were, in the absence of drug treatment, suppressed 
when sensitive parasites were present (Figure 2.4c), while clone S achieved similar 
gametocyte densities in untreated single-clone and mixed infections (Figure 2.4d). The 
day after high dose drug treatment, clone S had higher gametocyte densities, both in 
single and mixed infections (Figure 2.4bd). On subsequent days however, gametocyte 
densities from the sensitive clone were dramatically reduced. Following low dose 
treatment, gametocyte densities a day later were not elevated. Clone S in mixed 
infections did not produce the second gametocyte peak around day 13 following high 
dose treatment but they did following a low dose. All mixed infections demonstrated a 
third S gametocyte peak (Figure 2.4d, 2.5). In line with the competitive release of 
asexual densities following chemotherapy, resistant gametocyte densities in mixed 




















































Figure 2.4 Gametocyte densities of the drug-resistant clone R (left panels) and the drug-
sensitive clone S (right panels) in single (top panels) and mixed (bottom panels) infections that 
were either left untreated (dashed red line), received a low drug dose (solid blue line) or high 
dose (solid black line). Black diamonds indicate the timing of drug-treatment at day 6 post-
infection. Data are geometric means (± standard error) for up to six mice (Table 2.1). 
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Figure 2.5 Gametocyte dynamics of individual mice that were infected with a mixed infection of 
clone R (dashed red line) and clone S (solid black line), which were either left untreated (left 
column), received a low drug dose (middle column) or high dose (right column). Each group 
consisted of 6 mice at the outset of the experiment; however, one mouse in the high dose 
treatment group received a much lower parasite dose than intended and was excluded (Table 
2.1). Drug treatment was given on day 6 post-infection, as indicated by the black diamonds. 
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With high drug dose, the number of mosquitoes predicted to be infected from mixed 
infections was increased for R parasites and decreased for S parasites (Figure 2.6a; 
Table 2.2, drug x dose interaction). Using the q2 function based on data from Barns and 
White (2005), high dose drug treatment converted a more than three-fold advantage 
for clone S in untreated infections into parity (Figure 2.6a), thus losing the advantage 
clone S had over clone R. In single-clone infections, drug treatment did not affect 
predicted infectivity of clone R, but it did for clone S (Figure 2.6b; Table 2.2, drug x dose 
interaction). Surprisingly, a clear downward trend for gametocyte densities of clone S 
was not observed, which is a result of elevated gametocyte densities the day after high 
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Figure 2.6 Least square mean (± standard error) predicted number of infected mosquitoes (out 
of n=100) with clone R (solid line) and clone S (dashed line) from mixed (a) and single (b) 
infections that were either left untreated, received a low drug dose or high drug dose. Predicted 
infectivity is based on the post-treatment gametocyte densities using density-infectivity 
function q2 (Figure 1.11); a similar picture was seen using function q3. Least square means and 
standard errors were calculated from the statistical model whereby covariate gametocyte 
density on day 6 was kept constant.  
 
 
Together, these data show that the relative fitness of resistant parasites in mixed 
infections was increased by drug treatment in two ways. First, susceptible parasite 
fitness decreased, particularly at the high dose treatment. Second, the absolute fitness 
of resistant parasites increased as a consequence of competitive release (Figure 2.6a). 
In single-clone infections, relative fitness of resistant parasites was only increased by 
the survival advantage, and this was only observed in the high dose treatment (Figure 
2.6b). The transmission potential of the resistant parasites never exceeded that of the 
 
Chapter 2 –Chemotherapy, within-host ecology and relative fitness 
 
48 
susceptible parasites, which was the aim of the drug treatments chosen in this 
experiment. 
 
Table 2.2 Analysis of variance table of mixed and single-clone infections to test for an effect of 
drug treatment (drugs: no drugs/low dose/high dose), parasite clone (clone: R/S) and the 
interaction between them, on predicted number of infected mosquitoes based on two density-
infectivity functions (Figure 1.11; q1 and q2) using the post-treatment gametocyte densities 
(day 7-28). Gametocyte densities on day 6 were included as a covariate. 
 
 q1 q2 
mixed infections   
drugs F2,27=1.7, p=0.20 F2,27=1.8, p=0.19 
clone F1,27=90, p<0.001 F1,27=100,p<0.001 
drugs x clone F2,27=22, p<0.001 F2,27=11, p<0.001 




drugs F2,24=14, p<0.001 F2,24=28, p<0.001 
clone F1,24=47, p<0.001 F1,24=53, p<0.001 
drugs x clone F2,24=7.2, p=0.004 F2,24=9.3, p=0.001 
day 6 gametocytes F1,24=7.1, p=0.014 F1,24=11, p=0.002  
 
2.4.3 Total parasite dynamics 
The total parasite burden (clone R + clone S) of the mixed infections was unaffected by 
drug treatment (Figure 2.7a, drugs: F2,14=0.1, p=0.90). This is because the susceptible 
parasites, which dominate in the absence of treatment, are replaced by resistant 
parasites if treatment is given. Similar dynamics were seen for total gametocyte 
densities in mixed infections (Figure 2.7b). Drug treatment also did not affect overall 
predicted infectiousness, again because resistant gametocytes dominate in drug-
treated infections while susceptible gametocyte dominate in untreated infections 
(drugs, q1: F2,13=1.3, p=0.30; q2: F2,13=1.6, p=0.23).  
2.4.4 Host health  
Unsurprisingly, drug treatment of infections consisting of only resistant parasites did 
not improve host health, since clone R was resistant to treatment (Figure 2.8ab, drugs- 
maximum RBC loss: F2,13=0.2, p=0.84; maximum weight loss: F2,13=0.1, p=0.90). In 
contrast, drug treatment alleviated morbidity in all infections containing S parasites 
(Figure 2.8c-f, drugs: maximum RBC loss: F2,29=15, p<0.001; maximum weight loss: 
F2,29=2.9, p=0.073). Following drug treatment, mice with mixed infections were less 
anaemic than untreated infections (drugs: mean RBC density: F2,14=6.9, p=0.008). 
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Importantly, this was independent of drug dose (Tukey HSD, low dose vs. high dose- 
mean RBC density: padj=0.46), so that mice given the low dose treatment were no more 
anaemic than those given the high dose. Drug treatment had no impact on mean body 
mass of mice (drugs: mean body mass: F2,14=0.7, p=0.53). 
 
2.4.5 Selection dynamics 
Drug treatment had a pronounced effect on the kinetics of selection on drug-resistant 
parasites throughout the infection. The rate of selection on clone R through time for  
each mouse is shown in figure 2.9a-c (selection on asexual parasite densities) and 
figure 2.9d-f (selection on gametocyte densities).  
 
In the absence of treatment, the resistant parasites in 5 out of 6 mice were under 
negative selection on asexual parasite densities from approximately day 7 to day 12, 
after which selection became positive in half of the mice. When infections were treated 
with a single high dose of pyrimethamine, the opposite occurred: resistant parasites 
were under positive selection for the first period following drug treatment, and 
negative selection later on. Under low dose treatment, there was no indication of 
positive selection, with the exception of a few short periods in two mice. Later on in 
the infection, resistant parasites in this treatment group were also selected against. 
Positive selection of resistant gametocytes was very strong in all infections that 
received a high drug dose. In untreated and low dose treatment infections, little 
positive or negative selection on R gametocytes was observed. 
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Figure 2.7 Total asexual parasite (left graph) and gametocyte (right graph) dynamics of mixed 
infections that were either left untreated (dashed red line), received a low drug dose (solid blue 
line) or high dose (solid black line). Black diamonds indicate the timing of drug-treatment at 


















































































































Figure 2.8 Body mass (± standard error, left panels) and red blood cell density (± standard 
error, right panels) of mice infected with drug-resistant clone R (top panels), drug-sensitive 
clone S (middle panels) and mixed infections of both clones (bottom panels) for untreated 
infections (dashed red line), low dose treatment (solid blue line) and high dose treatment (solid 
black line). Black diamonds indicate timing of drug treatment at day 6 post-infection. The inset 
bar charts show the mean body mass and mean red blood cell density post-treatment (± 
standard error) for untreated infections (red bars - “N”), low dose treatments (blue bars - “L”) 











































































































































































































































































































































































































































Figure 2.9 Asexual (left panels) and gametocyte (right panels) selection dynamics of clone R 
for each mouse in mixed infections that were either untreated (upper panels), received low 
dose treatment (middle panels) or high dose treatment (bottom panels). Lines are the mean 
selection dynamics with blue segments denoting times when selection is not statistically 
different from zero, red segments times when selection is statistically less than zero, and green 
segments times when selection is greater than zero. Selection could be calculated up to the last 
day that both clones were detectable, which varied between mice.  
 
2.5 Discussion 
This study showed that, in the absence of drug treatment, drug-sensitive parasites 
competitively suppressed resistant parasites, as has been found in previous studies (de 
Roode et al. 2004; Wargo et al. 2007). Drug treatment led to competitive release of the 
drug-resistant clone, seen as increased asexual parasite densities. Importantly, 
competitive release of drug-resistant parasites was more restricted following low dose 
therapy than high dose treatment, even though the lower dose treatment improved 
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host health to the same level as high dose treatment. The high dose treatment thus 
exerted strong positive selection on resistant parasites for little clinical gain. Most 
importantly, resistant parasites in mixed infections that received high dose drug 
treatment had the highest transmission potential. Of note is that the drug treatments in 
this experiment were given on a single day only, while full curative treatment consists 
of high dose treatment given for four days in a row. Selection under such a treatment 
regime will be much more extensive than the treatments used in this experiment. Our 
results confirm the findings in Wargo et al. (2007) and provide proof of principle that 
less aggressive treatment than is currently recommended could help slow the spread 
of drug-resistant malaria parasites. Therefore, compared to the treatment regimes 
currently employed in the field (WHO 2006), milder drug dosages may result in better 
resistance management without clinical compromise. 
 
However, there need be no simple generality when it comes to drug treatment 
regimes. Rational treatment design involves taking the within-host ecology into 
account, which differs greatly between malarious areas. Areas with a low clone 
multiplicity may require a different approach from highly endemic areas which have 
high level of multi-genotype infections. In predominantly single-clone infections, 
competitive release will not play a role in the spread of resistance and low dose drug 
treatment will thus not have an impact on the spread of resistance, with the exception 
of selection for de novo resistant mutants, which has been demonstrated to be a rare 
event (Cortese et al. 2002; Wootton et al. 2002; Nair et al. 2003; Hastings 2004; Roper 
et al. 2004). Similarly, the rationale of reduced drug treatment may apply to a wide 
range of infectious diseases; however, the ecology of the disease determines whether 
reduced treatment is a good resistance management tool. In HIV/AIDS infections for 
instance, de novo resistance arises often within the host and transmission is a less 
important route of acquiring resistance (Wainberg and Friedland 1998). Bacterial 
infections have an additional complexity that involves lateral gene transfer of 
resistance genes across bacterial strains and species (Ochman et al. 2000). Therefore, 
selection for resistance in non-target bacteria within the host may influence the 
acquisition of resistance in the pathogenic bacteria by means of transfer of resistance 
genes selected in the non-target bacteria. Thus, while the logic of arguments presented 
in this study applies to a wide range of diseases, the optimal resistance management 
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strategy depends on the social context of the disease and may vary for different 
diseases. Key in all cases is empirical evaluation of treatment regimens.  
 
A new type of analysis for mixed infections of pathogens was introduced here. The 
selection coefficient analysis makes it possible to directly estimate the strength of 
selection for resistance imposed by different drug regimes. It also makes it possible to 
analyse the duration of drug-imposed selection effect. Positive selection for resistance 
following a high dose treatment lasted for approximately 5 days. Interestingly, the half-
life of pyrimethamine in a mouse is estimated to be approximately 4.5 hours (Coleman 
et al. 1986). If that half-life estimate is correct, our data suggest that positive selection 
for resistant parasites continued for several days after drug concentrations dropped 
below 0.001 mg/kg just 2.5 days after drug treatment. Similar effects have been 
observed in the drug effectiveness of artemisinin derivatives whereby it is suggested 
that “the biological effects of the artemisinin compounds extend beyond their presence at 
therapeutic concentrations in plasma” (White 1997, pg 1416). What factors drive this 
positive selection even after drug clearance is unknown. One possibility is that the 
more abundant resistant clone is capable of temporarily suppressing the less abundant 
susceptible parasites. Another possibility is that a genotype-specific immune system is 
inadvertently favouring the resistant parasites by more actively suppressing the 
previously abundant susceptible parasites (discussed in Wargo et al. 2007). Whatever 
the explanation, susceptible parasites are not increasing in frequency as soon as drug 
pressure wears off (Figure 2.1d), which provides an extended fitness advantage to the 
resistant parasites.  
 
Over the course of infection, both positive and negative selection was exerted on drug-
resistant parasites following drug treatment. While resistant parasites experienced 
positive selection following drug treatment, resistant parasites are selected against 
after drug effectiveness wears off with the treatment regimes used here. It is 
interesting that similar selection dynamics as observed in this experiment are seen 
over the course of a year in P. falciparum dynamics in areas with seasonal malaria. In 
these regions, for instance eastern Sudan, the frequency of resistance genes rises 
during the rainy season when malaria intensity and hence drug usage is high. When 
malaria transmission declines, so does the frequency of resistance genes in the 
parasite population (Abdel-Muhsin et al. 2004; Ord et al. 2007; Babiker 2009).  
 




To our knowledge, this is the first time the kinetics of selection coefficients have been 
estimated during the course of an infection. The selection coefficients presented here 
are conservative estimates of the strength of selection. A selection coefficient cannot 
be calculated on time points when one of the parasite clones is below detection 
threshold, since selection is a function of the abundance of both clones. However, if 
parasites of one clone were not detected at an earlier time point, but observed later on 
in the infection, then these parasites were present earlier on in the infection but below 
detection threshold. Positive selection on the more abundant clone is very strong on 
these particular time points, but is not captured in the model. Therefore, the selection 
coefficients shown in figure 2.5, both positive and negative, may in reality be more 
extreme.  
 
Estimating the transmission potential of both clones was done based on the 
gametocyte densities using a density-infectivity function. The exact form of the q-
function is not well-established. We used two functions based on different datasets 
(Carter and Graves 1988; Barnes and White 2005) and our results were qualitatively 
similar for both q-functions. We also analysed a variety of other hypothetical q-
functions (data not shown) and our conclusions were unaffected, unless there was a 
much higher threshold for infectivity, in which case the resistant clone almost never 
got transmitted. However, there is a lack of detailed information on the competitive 
interactions between strains within the mosquito and the impact strain-specific 
transmission blocking immunity has on strain kinetics. There is evidence that 
competition between different parasite species within mosquitoes exists (Paul et al. 
2002) and so it is likely that there will be competition between presumably 
ecologically more similar genotypes of the same species. Also, gametocyte infectivity is 
known to vary through time (Drakeley et al. 2006), not least in response to 
transmission-blocking immunity. Yet, this analysis is an improvement of the somewhat 
arbitrary cumulative gametocyte densities through time, and provides a tool to 
qualitatively compare of the fitness of resistant parasites following different drug 
treatments.  
 
The susceptible parasite clone in this study showed increased gametocyte densities on 
the day following high dose drug treatment. On subsequent days, however, gametocyte 
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densities rapidly dropped. Such effect was not observed following low dose treatment 
and not clearly seen in the resistant parasite clone. This observation could be the 
result of so-called drug-induced gametocytogenesis as a response to conditions 
unfavorable for asexual replication. However, increased gametocyte densities 
immediately following treatment are not necessarily a result of gametocytogenesis, 
since gametocyte maturation in P. chabaudi is thought to take more than 24 hours 
(Carter and Graves 1988). An alternative explanation could be reduced gametocyte 
clearance rates following drug treatment. Increased gametocyte densities following 
drug treatment have been observed before with pyrimethamine use in P. chabaudi in 
vivo (Buckling et al. 1999a), in P. falciparum following chloroquine treatment in vitro 
(Buckling et al. 1999b) and has been suggested multiple times in falciparum malaria in 
the field following SP drug treatment (Puta and Manyando 1997; Robert et al. 2000; 
Osorio et al. 2002; Sowunmi and Fateye 2003; Talman et al. 2004; Ali et al. 2006; 
Sowunmi et al. 2006), although these field data are in the absence of untreated 
controls difficult to interpret. This facultative response, which interestingly is only 
seen in response to our high dose drug treatment, could affect the spread of drug 
resistance since it reduces the relative fitness of drug-resistant parasites; however, it is 
only observed for a brief period of time and is thus unlikely to have a large overall 
impact. 
 
Taken together, current treatment regimes may not be the best resistance 
management strategy. A few recent studies from other disease models come to the 
same conclusion. In the treatment of both cancer (Gatenby et al. 2009) and 
Staphylococcus aureus infections (Drusano et al. 2009), it appears that reduced 
treatment eases the proliferation of resistant agents and in the former even reduces 
mortality. However, at least in the case of malaria, more studies regarding the effects of 
drug regimes on the competitive interactions between susceptible and resistant 
parasites and their effect on disease epidemiology are needed, both theoretical and 
experimental, before such drug regimens can go into clinical trials. Our results are 
based on rodent malaria parasites. Clearly, mice are not people, therefore these results 
have to be interpreted with caution. However, in the absence of an alternative to study 
the within-host ecology of drug-resistant parasites with untreated controls, it is a 
useful model system to use for proof of concept work as presented here. One study on 
natural P. falciparum infections that does evaluate treated and untreated patients 
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makes use of data on pregnant women who received intermittent preventative 
treatment (IPTp) with SP and compared them with a control group of women who 
elected not to receive IPTp (Harrington et al. 2009). The women who received drug 
treatment during pregnancy had increased parasitaemia, carried a higher proportion 
of resistance alleles and presented with lower parasite diversity. While the control 
group in this study is not truly randomized, it is the best field data on the effect of drug 
treatment we currently have and shows that drug treatment not only selects for 
resistance but also increases parasitaemia. The authors attribute this latter effect on 
competitive facilitation, as described in Wargo et al. (2007). These field data support 
our results derived from a P. chabaudi model that current treatment regimes are not 
necessarily the best. A rational drug regimen design whereby within-host ecology, a 
major driver of resistance evolution, is taken into account, may well be the solution to 
optimal resistance management strategy.  
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The key element of the random component in the statistical model is the mean-
variance relationship (McCullagh 1983). To estimate this relationship for malaria 
parasite and gametocyte densities, we conducted additional experimental infections 
using the resistant clonal parasite lineage on mice that were independent of the 
experiments. Five replicate samples for asexual parasites in one mouse, and three 
replicate samples for gametocytes in two different mice were taken every two days 
during the infection. Due to the amount of blood necessary for conducting DNA and 
RNA extractions (see material and methods), these were the maximum number of 
replicates that could be taken from each mouse without influencing parasite kinetics.  
 
The mean-variance relationship for both asexual and gametocyte densities is shown in 
Figure A1, and suggests a power relationship of the form σ = a μb. This form of a 
variance to mean relationship indicates that the random component is a type of 
Tweedie distribution, which belongs to the exponential dispersion model family of 
distributions. The exact type of distribution is determined by the exponent in the 
power relationship. For asexuals, the power exponent is b = 1.59, which falls within the 
range of compound Poisson distributions. For gametocytes, the exponent is b = 2.206, 
which falls into a different class of distributions based on compound Gamma 
processes. Given that both values are close to a value of two, we assume that b = 2 for 
both and refit the a parameter. The assumed value of b=2 fits the data well (dashed 
line Figure A1), and simplifies the statistical model because it translates into an over-
dispersed Gamma distribution. The power of this data is that we now independently 
estimate the dispersion parameter (a) without having to estimate it from the fitting 








Figure A1 Variance (σ) to mean (μ) relationship for asexual and gametocyte malaria parasites. 
Points are raw data, solid blue line is the best fit assuming a power relationship σ = a μb, and the 
dashed blue line is the fit assuming a slope of b=2. Parameter estimates for the dispersion 
parameter are a = 0.01415 for asexuals and a = 0.0582 for gametocytes assuming a fixed slope 
of b=2. 
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Drug resistance is a major problem in malaria control. Previous research has shown 
that drug treatment provides a great selective advantage to resistant parasites in 
mixed infections with susceptible parasites. Rare resistant parasites in mixed 
infections are likely strongly suppressed by more abundant susceptible parasites and 
for that reason competitive release following drug treatment is expected to be strong. 
In this study, we infected mice with various ratios of drug-resistant and drug-sensitive 
Plasmodium chabaudi malaria parasites (ranging from 1:1 to 1:10-5) and were able to 
track resistant parasites at low frequency through time, at both asexual parasite and 
gametocyte level. We found that resistant parasites were more suppressed when at 
low initial density. Drug treatment caused competitive release of the resistant 
parasites, which was greater for the parasites that started at lower abundance. 
Competitive release resulted in a second parasite peak, which led to a second wave of 
anaemia and greater overall infectiousness compared to untreated infections. These 
results demonstrate that ecological dynamics of mixed malaria infections affect 
treatment outcome and argue for the importance of highly sensitive detection methods 
for rare resistant parasite strains in malaria infections.  
 
 




Drug-resistant malaria parasites are common. For instance, resistance against most 
widely-used antimalarial drugs has spread globally (Plowe 2009) and the efficacy of 
the recently widely-employed artemisinin derivatives class drugs (WHO 2008) is 
declining in South-East Asia (Enserink 2008). Since co-infections are very common in 
malaria (e.g. Arnot 1998; Babiker et al. 1999; Farnert et al. 2001; Jafari et al. 2004; 
Zhong et al. 2007), many patients infected with malaria parasites are likely harboring a 
mixture of parasites of resistant and susceptible to a certain drug. Much work has 
focused on the molecular and genetic background of resistance (for recent reviews, see 
Ekland and Fidock 2007; Hayton and Su 2008; Bustamante et al. 2009), but little work 
has considered the within-host ecological dynamics of resistant parasites in a 
population of susceptible parasites (Read and Huijben 2009). Yet, these dynamics, and 
the way in which they are altered by drug treatment are a primary determinant of the 
rate at which resistant parasites spread through a population (Hastings 2006). 
 
Using a mouse malaria model, previous studies have shown that resistant parasites are 
competitively suppressed by susceptible parasites, and that following treatment, 
competitive release occurs (de Roode et al. 2004; Wargo et al. 2007; Huijben et al. 
submitted). This involves an expansion of resistant parasites once the susceptible 
parasites are removed and can provide great advantage for resistant parasites: not 
only does the relative fitness of the resistant parasites increase simply due to 
susceptible parasites being killed by the drug while the resistant ones remain 
unharmed, it also gives the resistant parasites the opportunity to expand, profiting 
from the resources that were otherwise used by the susceptible parasites.  
 
In these experiments, the resistant and susceptible parasites were introduced to the 
host at equal densities. In reality, the frequency of resistance within a host can range 
from rare (Mookherjee et al. 1999; Bates et al. 2004; Juliano et al. 2007) to near 
saturation (e.g. McCollum et al. 2007; Mlambo et al. 2007; McCollum et al. 2008; Zhong 
et al. 2008). Different frequencies within a host can arise from a simultaneous 
inoculation of different frequencies by the mosquito (coinfection, Nwakanma et al. 
2008; Mohanty et al. 2009) or from two sequential infections (super-infection), 
whereby one parasite strain enters the host when the other strain is already resident 
(de Roode et al. 2005a). Since the relative fitness of resistant parasites will depend 
 
Chapter 3 –Frequency of resistance 
 
62 
qualitatively on the extent of competitive release, which might be greater when 
resistant parasites are rarer, the aim in the work reported here was to study the 
competitive interactions between drug-resistant and drug-sensitive parasites at 
varying inoculation abundances to determine whether the extent of competitive 
release depends on the abundance of resistant parasites. 
  
Furthermore, we were interested in the effect treatment has on the health of hosts that 
harbor resistant parasites at various abundances with susceptible parasites. When 
resistant parasites are present in an infection at the time of treatment, they are, by 
definition, going to cause treatment failure to a certain degree. Treatment failure can 
result in greater morbidity and even mortality. It can also lead to increased 
infectiousness, which, in turn, can lead not only to increased malaria transmission, but 
also to increased transmission of resistant parasites. Therefore, using the P. chabaudi 
mouse model system, we had the following four aims: to establish whether i) 
competitive suppression, ii) competitive release, iii) the morbidity following drug 
failure and iv) infectiousness (both overall infectiousness and resistance 
transmission), is dependent on the abundance of resistant parasites.  
 
3.3 Material and methods 
3.3.1 Parasites and hosts 
Two genetically distinct clones were used in these experiments, drug-sensitive clone 
AJ5p (hereafter referred to as clone S) and drug-resistant clone AS6p(pyr-1A) (hereafter 
referred to as clone R). Both clones were isolated from thicket rats and subsequently 
cloned (Beale et al. 1978). Clone R was made resistant by a single high-dose exposure 
to pyrimethamine (Walliker et al. 1975). Hosts were 15 week old female C57Bl/6 
laboratory mice (Charles River Laboratories). This was our first experiment in a new 
lab, so to test for background variation in mouse health, a group of sham-infected mice 
were monitored contemporaneously. These mice were eight week old female C57Bl/6 
laboratory mice (Charles River Laboratories). All mice were kept on a 12:12 L:D cycle, 
fed Laboratory Rodent Diet 5001 (LabDiet, PMI Nutrition International) and received 
0.05% PABA-supplemented drinking water to enhance parasite growth (Jacobs 1964). 
 
Chapter 3 –Frequency of resistance 
 
63 
3.3.2 Experimental design, infections and drug treatment 
The experiment consisted of either single-clone infections of clone R, or mixed 
infections of clone R with clone S (Table 3.1). The inoculum of clone R consisted of 106, 
105, 103 or 101 parasites. In mixed infections, the inoculum of clone S consisted of 106 
parasites per mouse in all treatment groups, resulting in R:S ratios of 1:1, 1:10, 1:103, 
and 1:105, respectively. Control mice were sham-injected with uninfected blood. Half of 
the mice were drug-treated and the other half left untreated (see below), which totaled 
to 18 different treatment groups. Each treatment group consisted of five mice, except 
for the groups with an inoculum of 101 resistant parasites which consisted of 10 mice 
to allow for the possibility that some mice failed to become infected because of 
stochastic loss due to the low inoculum size (Table 3.1).  
 
Table 3.1 Experimental set-up. Groups were inoculated with clone R in the single-clone 
infections, or clone R and clone S for the mixed infections. The controls were inoculated with 
uninfected red blood cells. The inoculum of clone S was always 106 parasites, the inoculum of 
clone R varied from 106 to 101 parasites. All treatment groups with an inoculum size of 101 
parasites had 10 mice at the start of the experiment. All other treatment groups consisted of 5 
mice. Drug treatment was given on days 6 to 9 post-infection.  
 
Mixed infections Single-clone infections  Ratio 
R:S R parasites S parasites n R parasites n 
1:1 106 106 5* 106 5 
1:10 105 106 5† 105 5 
1:103 103 106 5† 103 5 
1:105 101 106 10 101 10 
No drugs 
Control 0 0 5   
1:1 106 106 5 106 5 
1:10 105 106 5* 105 5 
1:103 103 106 5*† 103 5 
1:105 101 106 10** 101 10 
Drugs 
Control 0 0 5   
* denotes an excluded mouse, † represents a dead or euthanized mouse 
 
Drug treatment started on day 6 post-infection (PI), which is when pronounced 
anaemia and weight loss begin to show (Wargo et al. (2007), and see below), and 
consisted of 8 mg/kg pyrimethamine dissolved in dimethyl sulfoxide (DMSO), 
administrated by intraperitoneal (i.p.) injection of 50 µl on four successive days. 
Untreated controls received i.p. injection of DMSO-only contemporaneously. 
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3.3.3 Monitoring of infections 
Weight and red blood cell density of the mice, plus asexual parasite density and 
gametocyte density of both clones were measured daily (day 3-21 PI) and three times 
a week thereafter (day 23-49 PI).  
 
For each mouse at any time point, 2 µl of blood was taken by tail snip for red blood cell 
density measurements using flow-cytometry (Beckman Coulter). Another 5 µl of blood 
was taken for DNA extraction, which was carried out on the ABI Prism® 6100 Nucleic 
Acid PrepStation according to manufacturer’s instructions. A further 10 µl of blood was 
taken and lysed immediately for RNA extraction, using the ‘RNA Blood-DNA’ method 
on the ABI Prism® 6100 Nucleic Acid PrepStation. Afterwards, RNA was converted to 
single stranded cDNA using the High-Capacity cDNA Archive Kit (Applied Biosystems; 
Wargo et al. 2006). Both DNA and cDNA were stored at -80°C until quantification. 
Additionally, a thin blood smear was made of each mouse on each sampling day.  
 
To measure total parasite density (asexual parasites and gametocytes), quantitative 
PCR was performed on DNA using clone-specific assays. To measure gametocyte 
density, quantitative PCR was performed on cDNA, using the same clone-specific 
assays. Asexual parasite density was estimated by subtracting the gametocyte density 
from the total parasite density. The clone-specific assays have been shown not to 
amplify parasites from the other clone (Drew and Reece 2007). In brief, the PCR 
reaction volume of 25 µl for all assays consisted of 7 µl DNA or cDNA, 900 nM forward 
and reverse clone-specific primers, 250 nM TaqMan® MGB probe (Applied 
Biosystems) and 1x PerfeCTa™ qPCR FastMix™ (Quanta Biosciences). All reactions 
were run on the ABI Prism® 7500 Fast System, using the assay: 95°C for 2 minutes, 
followed by 40 cycles of 95°C for 3 seconds and 60°C for 30 seconds. Quantification 
was based on serial dilutions of DNA and cDNA standards of known total parasite and 
gametocyte density, determined beforehand by microscopy (Cheesman et al. 2003).  
3.3.4 Statistical analysis 
All statistical analyses were performed in R 2.9.0 (R Development Core Team 2009). 
To summarize the asexual densities through time, which fluctuate over six orders of 
magnitude with the highest counts occurring on only a few days, we calculated for each 
mouse the geometric mean asexual parasite density of clone R, or clone S or both for 
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the entire infection course or for the period following drug treatment (day 10-49). The 
rate of decline of asexual parasite density of clone S following drug treatment was 
calculated as the average difference between the log-transformed asexual densities on 
day 7 and day 10 post-infection. Persistence of each clone was estimated for each 
mouse as the last day of detectable asexual parasites in the blood. As a measure of 
transmission potential, the predicted infectiousness was calculated for clone R, clone S 
and both together for the entire infection course and for the period following drug 
treatment (day 10-49) as the number of predicted infected mosquitoes out of n=100, 
using gametocyte densities in the density-infectivity function q1 as described in the 
general introduction of this thesis. As an estimation of morbidity of acute infection, 
which was defined as the initial parasite peak and clinical disease episode, the 
minimum weight and minimum red blood cell densities during this period were used. 
Furthermore, the minimum red blood cell density and minimum weight during 
parasite relapse (after day 12 PI) were used as a measurement of the consequences to 
host health of relapse.  
 
General linear modeling was used with the following factors: competition (S present or 
absent), drugs (treated or not) and R-inoculum (106, 105, 103, 101). Maximal models 
were fitted first and, beginning with higher order interaction, non-significant terms 
were sequentially removed to generate minimal models.  
 
Three mice died or were euthanized during the infection (untreated 1:10 R:S, 
untreated 1:103 R:S, drug-treated 1:103 R:S) and were removed from further analysis. 
Another five were also excluded from the analysis. Two of these failed to become 
infected with resistant parasites from the low inoculum of 101 R parasites (both from 
treated 1:105 R:S) and one (drug-treated 1:103 R:S) failed to completely respond to 
drug pressure for unknown reasons. Furthermore, two mice received an inoculum of 
several orders of magnitude lower than intended, as judged by the kinetics of 
subsequent growth rates which were therefore not representative of their treatment 
group (untreated 1:1 R:S, treated 1:10 R:S, Table 3.1).  
 
 




In R-only infections, lower doses of clone R resulted in a delay in parasitaemia and 
gametocytaemia in single infections of clone R (Figure 3.1ab). This delay was about a 
day for each order of magnitude reduction in dose, as had been observed before in P. 
berghei (Wellde et al. 1966) and P. chabaudi (Timms et al. 2001), but had little impact 
on overall parasite numbers (Table 3.2). Drug treatment had no direct impact on 
parasite densities of clone R (Figure 3.1cd, Table 3.2), as expected for a resistant clone.  
 
In untreated infections, densities of the resistant clone were suppressed when the 
sensitive clone was present (Figure 3.2 - left panels, 3.3ab). In all cases, there were 
lower asexual densities when clone S was present (Figure 3.3a - untreated infections, 
competition: F1,39=349, p<0.001), which translated in a reduced predicted infectivity 
for the resistant parasites (Figure 3.3b – untreated infections, gametocytes, 
competition: F1,39=449, p<0.001). Notably, no gametocytes were produced by the 
resistant clone when it was introduced at the lowest dose in a mixed infection with 
susceptible parasites (Figure 3.2g, 3.3b). 
 
Close inspection of the left panels of figure 3.2 shows that during the resolution of the 
initial wave of parasites, densities of clone R dropped in parallel with clone S. 
Consequently, the fewer R parasites there were in the inoculum, the lower the density 
achieved before suppression, and hence the greater the competitive suppression 
(Figure 3.3a – untreated infections, competition*R-inoculum: F3,39=24, p<0.001).  
 
Table 3.2 Analysis of Variance table of single-clone infections of clone R to test for an effect of 
drug treatment (drugs: treated,untreated), parasite dose (R-inoculum: 101,103,105,106) and the 
interaction between them, on geometric mean asexual parasite production and gametocyte 
production. 
 Asexual parasites Gametocytes 
drugs F1,43=0.1, p=0.75 F1,43=1.4, p=0.25 
R-inoculum F3,43=2.5, p=0.07 F3,43=1.3, p=0.29 
drugs*R-inoculum n.s. n.s. 
n.s. denotes an insignificant term that was excluded from the model 
 
 




















































Figure 3.1 Asexual parasite densities (left panels) and gametocyte densities (right panels) in 
untreated (top panels) and drug-treated (bottom panels) single-clone infections of drug-
resistant clone R. The infections were initiated with an inoculum of 106 (thick solid black line), 
105 (thick dashed blue line), 103 (thin solid green line) and 101 (thin dashed red line) parasites. 
Drug treatment was given on days 6-9 post-infection as indicated by the shaded area. Data are 
log-transformed geometric means (± standard error) of 5 mice (inoculum sizes 106, 105, 103) or 














































































Figure 3.2 Asexual parasite densities (solid lines) and gametocyte densities (dashed lines) of 
drug-sensitive clone S (red lines) and drug-resistant clone R (black lines) in mixed infections 
that were untreated (left panels) or drug-treated (right panels). Drug treatment was given on 
days 6-9 post-infection as indicated by the shaded area. Infections were inoculated with a clone 
R:S relative abundance of 106:106 (top row), 105:106 (second row), 103:106 (third row) and 
101:106 (bottom row). Data are geometric means (± standard error) of up to 5 mice for R:S 
























































































































Figure 3.3 Geometric mean asexual parasite density (left panels) and estimated number of 
infected mosquitoes (from n=100; right panels) of clone R at different initial parasite dosages 
(x-axis) in untreated infections (upper panels) of single-clone (red solid line) and mixed-clone 
(black dashed line) infections, and in mixed-clone infections (bottom panels) with drug-treated 
(blue solid line) and untreated (black dashed line) infections post-treatment (day 10-49). Data 
are means of up to 5 mice (R inoculum sizes 106, 105, 103) or up to 10 mice (inoculum size 101; 
table 3.1). Asexual parasite densities are plotted in a log-scale, note the y-axis varies between 
the right panel plots. 
 
3.4.1 Post-treatment kinetics 
As expected, the density of resistant parasites at the start of treatment was determined 
by the number inoculated, so that the initial inocula of 106, 105, 103, 101 had, by the 
time of treatment (day 6 PI), become 105.4 /μl, 104.6/μl, 102.6/μl, 100.7/μl respectively. 
 
In mixed infections, susceptible parasites were rapidly cleared by drugs (Figure 3.2 – 
right panels). As a result, the initially suppressed populations of resistant parasites 
were able to expand after drug treatment (Figure 3.3cd – mixed infections asexual 
parasites, drugs: F1,36=107, p<0.001), which caused a pronounced second peak of 
parasitaemia (Figure 3.2 – right panels). The extent of this competitive release was 
greater when resistant parasites had started out at lower abundances (Figure 3.3cd - 
mixed infections, asexual parasites, drugs*R-inoculum: F3,36=4.1, p=0.013). Thus, 
resistant parasites had the biggest disadvantage when present at low abundance in 
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untreated infections, and so gained proportionately the most when susceptible 
parasites were removed by drug treatment.  
 
Competitive release translated into large increases in transmission potential, with 
drug treatment greatly increasing the predicted infectivity of the resistant parasites 
(Figure 3.3d – mixed infections, R-infectivity, drugs: F1,36=366, p<0.001; drugs*R-
inoculum: F3.36=6.9, p=<0.001).  
 
Competitive suppression in untreated infections eliminated the resistant parasites on 
average by day 16 (range: day 3-28; Figure 3.2 – left panels), whereas clone R 
persisted for over 2.5 times as long, on average up to day 42, in the absence of 
competition (range: day 18-49; Figure 3.1 – untreated infections, competition: 
F1,42=124, p<0.001). Drug treatment removed the force of suppression, which allowed 
the resistant parasites to persist for twice as long as in the absence of treatment 
(mean: 32 days, range: day 15-49; Figure 3.2, right panels –, drugs: F1,39=27, p<0.001). 
The initial abundance of clone R did not affect its ability to persist in mixed infections 
(R-inoculum: F3,39=1, p=0.40) . 
 
Unexpectedly, the impact of drugs on the kinetics of the susceptible clone was affected 
by the number of resistant parasites at the start of the infection. Even though the rate 
of reduction due to drug treatment was the same for all drug-treated groups (F3,18=0.4, 
p=0.78), the release of resistant parasites resulted in a recrudescence of susceptible 
parasites in the lower abundance groups (Figure 3.2 – right panels). This second peak 
of susceptible parasites resulted in a higher production of asexual S parasites after 
treatment in infections with a low number of R parasites at the outset (drug-treated 
mixed infections, R-inoculum: F3,18=18, p<0.001). However, these recrudesences did 
not translate into a higher predicted infectivity of clone S (Figure 3.2fg, F3,18=0.9, 
p=0.45).  
3.4.2 Overall parasite burden and transmission potential of mixed infections 
The total number of parasites present throughout the entire infections (R+S parasites, 
days 3-49) were reduced by drug administration (Figure 3.4a – mixed infections, 
drugs: F1,36=42, p<0.001), despite the increase in resistant parasites (Figure 3.4c). 
However, drug treatment least effectively reduced total parasite burden when 
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resistant parasites were rare at the time of treatment (drugs*R-inoculum: F3,36=3.5, 
p=0.02), due to a greater abundance of S parasites that occurred during the post-






































































































Figure 3.4 Geometric mean asexual parasite density (left panels) and estimated number of 
infected mosquitoes (from n=100; right panels) of clone R with clone S combined (top panels), 
clone R only (middle panels) or clone S only (bottom panels) in untreated and drug-treated 
mixed infections that were initiated with a clone R inoculum of 106 (thick black solid line), 105 
(thick blue dashed line), 103 (thin green solid line) and 101 (thin red dashed line) parasites. The 
inoculum of clone S was 106 in all cases. Data are means of up to 5 mice (R inoculum sizes 106, 
105, 103) or up to 10 mice (R inoculum size 101; Table 3.1). Asexual parasite densities are 
plotted in a log-scale, note the y-axis varies between plots. 
 
Moreover, drug treatment increased total gametocyte numbers, which translated into 
a higher overall infectivity (Figure 3.4b – mixed infections, drugs: F1,39=32, p<0.001). 
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The magnitude of this increase was not strongly related to the rarity of resistant 
parasites (drugs*R-inoculum: F1,36=2.5, p=0.077), although the more abundant clone R 
was in the initial inoculum, the higher the overall infectivity (R-inoculum: F3,39=19, 
p<0.001). The increase in total infectivity in drug-treated infections was caused by a 
strong increase in predicted transmission for the resistant parasites (Figure 3.4d), 
opposed to a smaller decrease in predicted transmission for the susceptible parasites 
(Figure 3.4f). 
 
The total transmission potential for the resistant parasites over the entire infection 
was dependent on both drug treatment and abundance in a mixed infection. Drug 
treatment greatly increased the transmission potential of the resistant parasites 
(mixed infections, drugs: F1,36=270, p<0.001). While the relative increase in 
transmission potential as a result of drug treatment was greater for low abundance 
parasites than for high abundance parasites (drugs*R-inoculum: F3,36=51, p<0.001), 
more abundant R parasites at the outset had a greater transmission potential overall 
(R-inoculum: F3,36=51, p<0.001). In fact, the transmission potential for these more 
abundant R parasites was as large as it was in the absence of competition. For the R 
parasites that started out at lower abundances however, the overall transmission 
potential was not as high as it would have been in the absence of competition (drug-
treated infections, competition*R-inoculum: F3,37=5.5, p=0.003).  
3.4.3 Host health 
P. chabaudi infections caused significant weight loss and anaemia when comparing 
them to sham-injected controls (Figure 3.5ab). The acute infection was more severe in 
mixed infections of clone R and S than for single-clone infections with clone R only 
(competition: minimum weight, F1,79=78, p<0.001; minimum RBC density, F1,79=39, 
p<0.001), likely driven by the greater virulence of clone S (de Roode et al. 2004; Bell et 
al. 2006; Wargo et al. 2007; Huijben et al. submitted). Drug treatment, as expected, 
significantly reduced the severity of the acute infection (mixed infections, drugs: 
minimum weight, F1,39=23, p<0.001; minimum RBC density, F1,39=73, p<0.001). The 
abundance of clone R did not have an impact on the virulence of acute infection.  
 










































































































Figure 3.5 Change in red blood cell densities (left panels) and weight change (right panels) 
from initial (day -1) values of mixed infections that were left untreated (top panels) or drug-
treated (bottom panels). Drug treatment was given on days 6-9 post-infection as indicated by 
the shaded area. The infections were initiated with an R inoculum of 106 (thick solid black line), 
105 (thick dashed blue line), 103 (thin solid green line) and 101 (thin dashed red line) parasites. 
The inoculum of clone S was 106 in all cases. Sham-injected mice are shown in thin dotdashed 
orange line. The inset graphs show the minimum red blood cell density (x106/µl) (c) and 
minimum weight (gram) (d) reached after drug treatment. Data are means (± standard error) 
of up to 5 mice (R inoculum sizes 106, 105, 103) or up to 10 mice (inoculum size 101; Table 3.1). 
 
However, the drug treatment induced a second wave of anaemia caused by the 
competitive release of resistant parasites (see above and Figure 3.5c). No relapses 
were observed in any of the single clone R infections (data not shown). Drug treatment 
caused more severe anaemia during this period of post treatment relapse than in 
untreated infections, but only in the infections where resistant parasites were at low 
abundance (mixed infections, minimum RBC density during relapse, drugs*R-inoculum: 
F3,36=8.0, p<0.001). The parasite relapse did not significantly affect weight during this 
period (Figure 3.5d). In fact, for all abundances, drug-treated infections had higher 
weights than untreated infections during the post treatment relapses (mixed 
infections, drugs: F1,39=9, p=0.005). The abundance of clone R did not affect the 
minimum weight during relapse (R-inoculum: F3,39=0.7, p=0.55). 
 
 




We found that the fitness of resistant parasites was density-dependent: the more 
abundant the competitor at the start of an infection, the more suppressed the resistant 
clone was. The parasite population appeared to be regulated non-specifically during 
the acute infection; when the more abundant susceptible parasites declined in density, 
the less abundant resistant parasites declined as well. These dynamics are most likely 
regulated by resource abundance (such as red blood cell density, see Mideo et al. 
2008), although innate, non-specific immunity may also play a role (reviewed in Mideo 
2009). Drug treatment released the competitive suppression of the resistant parasites 
with greater expansion following treatment of the infections where resistance was 
rare. Drug treatment of mixed infections did not necessarily benefit the host; even 
though drug treatment alleviated acute phase disease, drug-induced release of the 
minority resistant parasites resulted in a second wave of parasites that caused another 
bout of anaemia. Moreover, the treated mixed infections had a slightly higher 
transmission potential than untreated infections. In conclusion, drug treatment of 
mixed infections gave rise to an increased overall transmission and increased relative 
fitness of resistant parasites, without being much more beneficial to host health.  
 
The within-host dynamics following an inoculum of 101 resistant parasites mixed with 
106 susceptible parasites may resemble the dynamics following a de novo resistance 
mutational event. There is very little understanding of the dynamics between wild-
type and resistant mutants following a mutational event within the host. The actual 
occurrence of de novo mutations is rare, only a handful of times for both chloroquine 
and sulphadoxine-pyrimethamine resistance (reviewed in Plowe 2009). Reasons for 
this rare occurrence of de novo mutations in the field are unknown, but are thought to 
be due to multiple mutations necessary for a viable mutant. Competition will also play 
an important role in determining whether a de novo resistant mutant can rise to 
transmissible densities. This study showed that resistant parasites that started out at a 
101 inoculum did not produce a single detectable gametocyte in the absence of 
treatment. Many infections in Africa are left untreated, as opposed to Southeast Asia, 
where most infections, due to low transmission intensity, are symptomatic and thus 
more often treated (Pongtavornpinyo et al. 2008). This could (partly) explain why 
resistance seems to originate in Southeast Asia rather than Africa for all widely 
employed drugs. In this study, the rarest resistant parasite started in the inoculum at a 
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frequency of 10-5 and was at similar frequency at the time of treatment. Since the 
mutation rate for P. falciparum is though to be around 10-9 (Paget-McNicol and Saul 
2001), the frequency of resistant mutants in an infection is likely much lower than 10-5. 
Further experiments with resistant parasites at lower frequencies, for instance by 
‘seeding’ the resistant parasites later in the infection at high abundance of susceptible 
parasites, could reveal the intensity of suppression at these extremely rare 
abundances. 
 
Due to the design of the study, we are unable to distinguish between parasite density- 
and frequency-dependence, as frequency changed with density. However, our 
conclusions likely apply to both. A previous study by de Roode et al. (2005a) showed 
increased suppression of clone R when it was introduced in the host at the same initial 
density three days after clone S. Although absolute densities were different, at time of 
inoculation there were approximately three orders of magnitude difference between 
clone R and S; a frequency similar to the 103:106 inoculum in this study. The 
subsequent dynamics were very similar in both experiments. These results confirm 
our expectations, though further work should indicate whether the results found in 
this study are indeed frequency dependent. 
 
Drug treatment increased virulence (measured as increased anaemia) in infections 
where resistant parasites were present at low initial abundance, but was actually 
beneficial in infections that started with a higher abundance of resistant parasites. This 
result suggests that the frequency of resistant parasites in a mixed infection is an 
important determinant of clinical outcome and in non-intuitive ways. In particular, it 
may be dangerous for the patient to aggressively treat an infection containing rare, 
possibly undetectable resistant parasites. An example of this is an increased 
parasitaemia in pregnant women taking intermittent preventative treatment (IPTp) of 
SP in an area with widespread SP resistance compared to women opting out of IPTp 
(Harrington et al. 2009). This raises the question of tailoring treatment regimes to the 
presence or absence of resistant parasites in the population. High sensitivity methods 
such as ultradeep pyrosequencing or heteroduplex tracking assays (Kwiek et al. 2007; 
Bushman et al. 2008) in field trials could provide very useful information on the 
presence and dynamics of resistant parasites after drug treatment in field settings. 
Moreover, such highly sensitive diagnostics could be useful in the western world, 
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where such techniques are more readily available and affordable, for examining 
infected travelers returning from malaria endemic areas. Detecting resistant parasites 
that are low in abundance could avoid severe relapses in these non-immune patients. 
 
An increased transmission potential was found for drug-treated mixed infections 
compared to equivalent but untreated infections. This increase was due to the release 
of resistant gametocytes. If this occurs in P. falciparum infections, it has important 
consequences for malaria control: not only would transmission of resistant parasites 
increase as a result of drug failure, but so would overall malaria transmission. These 
argue for a better understanding of the genetic make-up of malaria infections. The 
most dramatic increase in overall gametocyte production was observed in the 
infections that started out with the higher abundance of resistant parasites. Since these 
abundances are above the detection threshold of standard PCR methods that are 
already in use in the tropics today, we argue for the implementation of routine 
screening for resistant parasites in malaria patients as soon as the molecular 
background is known. Such routine screening might prove to be especially valuable in 
areas where malaria eradication is the goal. 
 
Unexpectedly, the drugs worked less efficiently on the susceptible parasites when 
resistant parasites were present at low frequencies. This result means there is an even 
stronger argument for identifying the genetic build-up of the infection prior to drug 
treatment: if resistant parasites are present at low frequencies, not only will resistant 
parasites greatly increase in density in the infection, but so will susceptible parasites. 
We do not understand what caused the relapse of the susceptible clone. The drug 
treatment given was evidently insufficient to fully clear the population of susceptible 
parasites. However, infections with the susceptible clone alone never have such a 
relapse (e.g. Wargo et al. 2007), which therefore strongly suggests that something to 
do with the expanding population of resistant parasites allows the sensitive parasites 
to relapse as well. A possible explanation is that the expanding population secretes 
immune suppressants which facilitate the growth of the susceptible clone. 
Nevertheless, the relapse of susceptible parasites did not translate in a much increased 
gametocyte density; therefore, the relative fitness of the resistant parasites was mostly 
unaffected by this relapse of clone S. 
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The occurrence of a second peak of parasites after treatment, as seen in these 
experimental infections, is frequently observed in the field, often referred to as 
‘recurrence’. These recurrences could be the result of recrudescence from the existing 
infection (i.e. treatment failure), or of re-infections, which especially happens in high 
transmission areas. Therefore, standard practices for antimalarial trials is the use of a 
so-called ‘PCR correction’ (Snounou and Beck 1998), whereby the infection is 
genotyped before and after treatment to conclude whether recurrence is due to 
recrudescence or reinfection. The accuracy of genotyping methods has been debated: 
much of the outcome depends on arbitrary decisions that researchers have to make 
regarding the number of markers used, the statistical analysis, and subjective criteria 
on the exact allele frequencies at which to differentiate between new and recrudescing 
infections (Greenhouse et al. 2007; Ashley et al. 2008; Liu et al. 2008). Also, the visual 
inspections of band sizes appears to be subjective and variable (Rouse et al. 2008) and 
will not differentiate between small amplicon length differences or sequences (Juliano 
et al. 2009). Most importantly, the sensitivity of these methods to pick up minority 
strains is highly doubted (Liu et al. 2008; Juliano et al. 2009). Alleles present in less 
than 20% of the population cannot be reliably demonstrated (Juliano et al. 2009), yet, 
the present study shows a profound recurrence from a minority strain lower than 
0.001% at the time of treatment. PCR correction could thus seriously underestimate 
treatment failure. The use of new methods such as heteroduplex tracking assays and 
ultradeep pyrosequencing could be of great value in significantly increasing our 
understanding of recurrent parasites (Kwiek et al. 2007; Bushman et al. 2008). 
 
The ultimate objective of many malaria policy makers and funding bodies dealing with 
malaria control nowadays is malaria elimination or even eradication. The proposed 
programs to achieve this goal are to a large extent dependent on drug treatment (Roll 
Back Malaria 2008; Feachem and Malaria Elimination Group 2009), yet we know 
surprisingly little about the effect such an extensive drug administration has on the 
spread of resistance. The data that exists on mass drug administration provides 
sometimes conflicting results, though mass drug treatments are generally assumed to 
promote the spread of drug resistance (von Seidlein and Greenwood 2003). We also 
know resistance can spread very fast once it has arisen (Plowe 2009). It is therefore 
important that we better understand the dynamics of resistant parasites. The data in 
this study clearly show that within host dynamics prior to drug treatment can 
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influence treatment outcome, both from a patient-perspective and for the transmission 
of resistance. Highly sensitive techniques assessing parasite population dynamics 
could provide very useful information in clinical trials, giving (i) a better insight in 
competitive interactions between resistant and sensitive P. falciparum strains, (ii) a 
reduction of the spread of drug resistance and overall transmission and (iii) an 
improvement of treatment regimes on a patient-specific level. Failure to incorporate 
resistant parasite dynamics in eradication programs might not only result in a failure 
of malaria eradication, but could also make the health-situation worse than it was 
prior to intervention. 
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4. Competitive release of resistant parasites following 
removal by chemotherapy of susceptible parasites from 
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One of the aims of radical parasitological treatment is to reduce the probability of 
resistant malaria mutants arising de novo within a patient. However, such treatment 
regimes will maximally up-select any resistant mutants that are present. Previous 
research has shown that resistant parasites present at a low frequency in infections 
with unrelated sensitive parasites were greatly advantaged by competitive release 
following drug treatment. De novo resistant mutants would also be at very low 
frequency in a mixed infection with their sensitive progenitors. Using the Plasmodium 
chabaudi malaria model, we test the hypothesis that resistant parasites at low 
frequency in infections of sensitive parasites, both originating from the same ancestral 
lineage, also result in a pronounced parasite relapse following drug treatment. We 
found that drug treatment induced distinct parasite relapses in both genetically related 
and genetically unrelated mixed infections of drug-resistant and drug-sensitive 
parasites. This finding suggests that competitive release following drug treatment may 
play an important role in up selecting de novo resistant mutants once they have arisen 
in the infection. 
 
 




Current antimalarial treatment guidelines advise radical parasitological treatment 
(aimed at rapid elimination of all parasites) to reduce the probability that de novo 
resistant mutations occur in infections (WHO 2006). Yet, much experimental evidence 
shows that resistance in the laboratory is most readily obtained by exposing large 
numbers of malaria parasites to high drug dosages (discussed in Peters 1987). Such a 
selection treatment regime used to select for resistant parasites in the lab is similar to 
radical parasitological treatment in malaria patients. Drug treatment which aims at 
radical parasitological cure, using high drug dosages over a longer time period, 
decreases the likelihood of parasites with the relevant mutations to occur by means of 
reducing absolute parasite numbers. However, if a resistant mutant has arisen in the 
infection, such radical treatment is expected to provide the greatest possible selection 
for these resistant mutants since it will eliminate competition by the susceptible 
progenitor parasites. Therefore, in terms of resistance management, radical 
parasitological treatment is likely a two-edged sword. How these two contrasting 
forces play out has yet to be determined. 
 
Drug-resistant parasites are likely suppressed when in competition with susceptible 
parasites due to a cost of resistance (Walliker et al. 2005; Felger and Beck 2008; 
Babiker et al. 2009). When drug treatment is given to a mixed infection of drug-
resistant and drug-sensitive parasites, the relative fitness of resistant parasites 
increases because of a survival advantage resistant parasites have over susceptible 
ones. Additionally, the resistant parasites can be released by expanding into the 
ecological space that was previously occupied by the susceptible parasites. This 
competitive release could further increase the relative fitness of resistant parasites 
(Hastings 2003; de Roode et al. 2004; Wargo et al. 2007; Huijben et al. submitted). The 
extent of competitive release may be dependent on the strength of competitive 
suppression, which is expected to be much greater between de novo resistant mutants 
and its sensitive progenitor since they will likely occupy identical niches. Such 
competitive suppression may be particularly strong against de novo resistant mutants 
since little evolutionary time has passed to accumulate compensatory mutations 
(Walliker et al. 2005). 
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Understanding the initial selection process for resistant mutants is of critical 
importance for designing treatment regimes that reduce the likelihood of drug 
resistance arising. A previous experiment with resistant parasites at low frequency in 
the infection has shown that pronounced competitive release occurs following drug 
treatment (Chapter 3). However, the resistant parasites in that experiment were 
genetically distinct from the susceptible parasites and therefore differ at many loci. 
This means they can potentially occupy different niches and be differentiated by the 
immune system. Experiments whether competitive release occurs when drug-resistant 
and susceptible parasites are from the same clonal lineage have yet to be conducted. 
Here we report such a test.  
 
Pyrimethamine-resistant and susceptible Plasmodium chabaudi parasites of the same 
clonal lineage differ in only a single nucleotide (Cheng and Saul 1994). So far as we are 
aware, standard PCR techniques are not capable of accurately quantifying single 
nucleotide polymorphisms (SNPs) at a frequency lower than 5% (Hunt et al. 2005; 
Cheesman et al. 2007). A mixed infection of a pyrimethamine-resistant P. chabaudi 
clone with its susceptible ancestral lineage can thus not be quantified for each clone 
separately. However, the experiment described in chapter 3 showed a pronounced 
relapse of resistant parasites following drug treatment of an infection with low-
frequency resistant parasites competing with genetically distinct susceptible parasites. 
Therefore, to test our hypothesis that mixed infections of rare resistant parasites in 
competition with susceptible parasites from the same genetic background also have 
significant relapses of resistant parasites following drug treatment, we studied the 
total parasite kinetics following drug treatment. If competitive release of resistant 
parasites occurs following treatment, we expect to observe a pronounced relapse peak. 
Such distinct parasite relapses were indeed found in both genetically related and 
genetically unrelated mixed infections of drug-resistant and drug-sensitive parasites. 
This suggests that competitive release following drug treatment may play an 
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4.3 Material and Methods 
4.3.1 Parasites and hosts 
Parasites from three clonal lineages were used in these experiments, drug-sensitive 
clone AJ8p (hereafter referred to as clone AJsens1), drug-resistant clone AS8p(pyr-1A) 
(hereafter referred to as clone ASres*) and drug-sensitive ancestral lineage of clone 
ASres, AS13p(sens) (hereafter referred to as clone ASsens). Clones AJsens and ASsens were 
originally isolated from thicket rats and subsequently cloned (Beale et al. 1978). Clone 
ASres was derived from an ancestor of ASsens (AS35) and made resistant by exposing it to 
a high dose of pyrimethamine in a single passage (Walliker et al. 1975). Since the 
splitting of ASres from ASsens, both clones have been passaged 25 times through 
vertebrate hosts (ASres through 16 mice and 9 thicket rats, ASsens through 24 mice and 1 
thicket rat). Clone ASres has been passaged 5 times through a mosquito vector, clone 
ASsens 3 times. Clone ASres has been exposed to pyrimethamine in two additional 
passages following the selection process.  
 
Hosts were 10 week old female C57Bl/6 laboratory mice (Charles River Laboratories). 
All mice were kept on a 12:12 L:D cycle, fed Laboratory Rodent Diet 5001 (LabDiet, 
PMI Nutrition International) and received 0.05% PABA-supplemented drinking water 
to enhance parasite growth (Jacobs 1964). used 
4.3.2 Experimental design, infections and drug treatment 
Mixed infections of ASres + AJsens (treatment groups 1 and 5), and ASres + ASsens 
(treatment groups 2 and 6) were initiated with an inoculum consisting of 106 parasites 
of the susceptible clone (ASsens or AJsens) and approximately 10 parasites of clone ASres 
(Table 4.1). Treatment groups with single-clone infections of clone ASres with an 
inoculum of ~10 parasites were included to establish infection success following the 
seeding event in the absence of competition (treatment groups 3 and 7), and single-
clone infections of clone ASsens, with an inoculum of 106 parasites, to determine the rate 
                                                             
1 Note that clone AJsens is of the same clonal lineage as clone S in other chapters in this thesis 
and clone ASres is of the same clonal lineage as clone R elsewhere in this thesis. For clarity, clone 
annotations other than those used elsewhere in the thesis had to be applied in this chapter 
since the otherwise nonsensical concept of a susceptible clone R had to be used. 
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at which susceptible parasites could relapse, for instance through the generation of de 
novo mutations (treatment groups 4 and 8). Half of the mice received drug treatment 
(treatment groups 5-8), which was given on days 6-9 post-infection (PI) with 8 mg/kg 
pyrimethamine dissolved in 0.05 ml DMSO. The other half was left untreated and 
received 0.05 ml DMSO only (treatment groups 1-4). Both parasites and drugs were 
administered by an intra-peritoneal injection. The treatment groups that received 
clone ASres, either in a mixture or as a single-clone infection, consisted of 9 mice to 
allow for the possibility that some mice would fail to become infected with clone ASres 
due to stochastic loss due as a result of the low inoculum size. Treatment groups with a 
single-clone infection of clone ASsens consisted of 5 mice (Table 4.1). 
 
Table 4.1 Experimental setup. Infections consisted of either single-clone infections of clone 
ASres and clone ASsens, or mixed infections of ASres + AJsens and mixed infections of ASres + ASsens. 
Inoculations with clone ASres consisted of 101 parasites, inoculations of clones ASsens and AJsens 
of 106 parasites. All treatment groups containing ASres parasites consisted of nine mice, the 








(parasite dose: 10) 
n 
 No drugs   
1 AJsens ASres 9
†
 
2 ASsens ASres 9
††
 
3 - ASres 9* 
4 ASsens - 5 
 Drug-treated   
5 AJsens ASres 9
††
* 
6 ASsens ASres 9 
7 - ASres 9 
8 ASsens - 5 
†
 denotes a dead or euthanized mouse, * indicates an uninfected mouse 
 
4.3.3 Monitoring of infections 
Body mass and red blood cell density of the mice, plus total parasite density were 
measured daily from days 3 to 26 PI and subsequently on days 28, 31 and 33. For each 
mouse, body mass was measured (to the nearest 0.1 gram), 2 µl of blood was taken by 
tail snip for red blood cell density measurements using flow-cytometry (Beckman 
Coulter) and a thin blood smear was made for estimating parasitaemia. Parasite 
density was calculated by multiplying parasitaemia with red blood cell density. The 
change in body mass in percentage through time was calculated for each mouse from a 
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baseline value, for which the mean body mass on the day prior to infection and day 3 
post-infection was used. 
 
On days 5-8 and 17-21 PI, another 5 µl of blood was taken from all ASres + AJsens 
infections (treatment groups 1 and 5) for DNA extraction, which was carried out on the 
ABI Prism® 6100 Nucleic Acid PrepStation according to manufacturer’s instructions. 
DNA was stored at -80°C until quantification. DNA was extracted from these mice to 
confirm mixed infections during acute phase and establish the presence of parasite 
clones during the relapse phase. Since clones ASres and ASsens in mixed infection could 
not be distinguished by qPCR, this procedure was not done on mice with ASres+ASsens 
infections. From these mice and the single clone infections, 5 µl of blood was also taken 
but immediately discarded. An AS-specific and AJ-specific qPCR assay was performed 
on the DNA samples, as described elsewhere (Chapters 2,3, 5 and 6), using the primer 
and probe sequences of Drew and Reece (Drew and Reece 2007).  
4.3.4 Statistical analysis 
To summarize the parasite densities through time, which fluctuate over six orders of 
magnitude with the highest counts occurring on only a few days, the geometric mean 
parasite density post-treatment (day 7-33 PI) and during parasite relapse were 
calculated. A relapse was defined as a second peak in parasite densities following a 
period of the parasites being below detection threshold. Additionally, peak parasite 
density and time of the peak of relapse was taken. 
 
As an estimate of virulence of the acute infection (defined as the initial parasite peak 
and clinical disease episode), the maximum loss in body mass and minimum red blood 
cell densities during this period were obtained. Furthermore, the minimum red blood 
cell density and minimum weight during parasite relapse were used as a measurement 
of virulence of relapse.  
 
General linear modeling was used to fit the following factors: clone (ASres, ASsens or 
AJsens) and drugs (treated or untreated). The data were analyzed separately for single 
and mixed infections. Maximal models were fitted first and non-significant interaction 
terms were removed to generate minimal models. All statistical analyses were 
performed in R 2.9.0 (R Development Core Team 2009). 
 




Five mice died or were euthanized during the infection: two in the drug-treated ASres + 
AJsens mixed infection group, one in the untreated ASres + AJsens mixed infection group 
and two in the untreated ASres +ASsens mixed infection group. Additionally, one mouse 
in the drug-treated ASres + AJsens mixed infection group failed to become infected, as 
well as one mouse in the single ASres infections group. These mice were excluded from 
the analysis (Table 4.1). 
 
4.4 Results 
In 17 out of the 18 mice that were inoculated with ~10 ASres parasites, infection was 
successfully established. ASres was also detected by qPCR for at least one day in all 14 
co-infections with clone ASres + AJsens. Thus, despite the low parasite dose, the inoculum 
of ASres was successful at establishing an infection.  
 
As expected from a previous experiment (Chapter 3), a parasite dose of ~10 ASres 
parasites resulted in a later peak parasitaemia compared to the inoculation of 106 
ASsens parasites (Figure 4.1ab). As expected, clone ASres was resistant to 
pyrimethamine: parasite density between drug-treated infections was similar to 
untreated infections (Figure 4.1a). Clone ASsens was susceptible to drugs, showing 
much lower mean parasite density in drug-treated infections compared to untreated 
infections (Figure 4.1b, drugs x clone interaction: F1,23=122, p<0.001). Consequently, 
drug treatment did not have an impact on maximum red blood cell loss in ASres 
infections, whereas it did in ASsens infections (Figure 4.1cd, drugs x clone interaction: 
F1,23=9.1, p=0.006). Drug treatment slightly reduced loss in body mass in ASsens -
infections, while it did not for ASres infections, though no significant interaction was 
observed (Figure 4.1ef, drugs x clone interaction: F1,23=0.8, p=0.38) 
4.4.1 Relapses 
Drug-treated ASres + AJsens infections showed a pronounced relapse (Figure 4.2a), as 
seen in previous experiments (Chapters 2, 3 and 6). This relapse was observed in all 
six infections. PCR analysis of the relapses demonstrated that the large majority of the 
parasites in the relapse were ASres parasites. As observed in previous experiments, 
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clone AJsens was also detected in the relapses in 5 out of 6 infections; though at parasite 
































































































Figure 4.1 Mean (± standard error) asexual parasite density dynamics (upper panels), red 
blood cell densities (middle panels) and change in body mass (bottom panels) of single-clone 
infections of ASres (left panels) and single-clone infections of ASsens (right panels) which were 
either drug-treated (dashed black lines) or untreated (solid red lines). Drug treatments were 
given on days 6-9 post-infection as indicated by the grey shaded area. Inocula of clone ASres 
consisted of 101 parasites, inocula of clone ASsens of 106 parasites. Data are means of up to nine 
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Figure 4.2 Mean (± standard error) parasite dynamics (upper row), red blood cell density 
(middle row) and weight (bottom row) of mixed infections ASres + AJsens (left column) and ASres 
+ ASsens (middle and right columns). The middle column shows ASres + ASsens infections with all 
mice included, the right column shows ASres + ASsens infections where the three mice that did not 
relapse were excluded. Infections were either drug-treated (black dashed lines) or left 
untreated (red solid lines). Drug treatment was given on days 6-9 post-infection, as indicated 
by the gray shaded area. Data are means of up to nine mice (Table 4.1).  
 
Mixed infections of ASres + ASsens also resulted in a pronounced parasite relapse, 
although only observed in 6 out of 9 infections (Figure 4.2bc, 4.3). In those six 
infections, the parasite densities at peak relapse did not differ significantly from the 
relapses seen for ASres + AJsens infections (clone: F1,10=3.5, p=0.092), but it occurred 3.5 
days later (clone: F1,10=45, p<0.001). Overall, more parasites were produced in the 
relapse of ASres + AJsens than in the relapse of ASres + ASsens (Figure 4.4, clone: F1,10=11, 
p=0.008). 
 
Two out of the five drug-treated single-clone infections of clone ASsens also relapsed 
(Figure 4.3a). These relapses were later than the relapse following mixed infections of 
ASres + ASsens (competition: F1,6=19, p=0.005), but had similar peak parasite densities 
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(competition: F1,6=0.7, p=0.43). The total parasite density during the relapse of single-
clone ASsens infections was lower than in ASres + ASsens infections, however, this 
difference was not significantly different (Figure 4.4, competition: F1,6=3.1, p=0.13). 
Untreated single-clone infections of ASsens also relapsed (two out of five infections), 
with the relapses occurring later in the course of infection and at lower peak parasite 
densities (Figure 4.3a). Similarly, single-clone ASres infections relapsed, both in 
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Figure 4.3 Parasite densities during relapse for drug-treated ASres+AJsens (thick solid black 
lines), ASres+ASsens (thick dashed red lines), single-clone ASsens (thin solid blue lines) and 
untreated single-clone ASsens (thin dashed green lines) infections (upper panel), and parasite 
densities during relapse for drug-treated (orange solid line) and untreated (dashed purple line) 
single-clone ASres infections (bottom panel). Each line represents an individual mouse. 
Horizontal error bars represent the lower and upper bounds of the standard error of the mean 
day of peak parasite density during relapse. In drug-treated mixed-clone infections of ASres + 
AJsens, 6 out of 6 infections relapsed, in ASres + ASsens, 6 out of 9 infections relapsed, in drug-
treated single-clone infections of ASsens, 2 out of 5 relapsed and in untreated single-clone 
infections of ASsens, 2 out of 5 infections relapsed. Of the single-clone ASres infections, 4 out of 9 
relapsed in drug-treated infections and 4 out of 8 relapsed in untreated infections. 
 
 



















































































Figure 4.4 Geometric mean parasite density during relapse for drug-treated ASres+AJsens (black), 
ASres+ASsens (red), single-clone ASsens (blue), untreated single-clone ASsens (green), drug-treated 
single ASres (orange) and untreated ASres (purple) infections. Data are geometric means of 
relapsed infections only (see Figure 4.3). 
 
4.4.2 Relapse morbidity 
The relapsing infections caused a second anaemic phase, both in ASres + AJsens and ASres 
+ ASsens infections (Figure 4.2 middle row). There was no difference observed in the 
maximum red blood cell loss during relapse between ASres + AJsens and ASres + ASsens 
infections (clone: F1,10=0.78, p=0.40), nor between ASres + ASsens and single-clone ASsens 
infections (competition: F1,6=2.2, p=0.19). Mice with relapsing infections did not have a 
distinct second period of loss in body weight (Figure 4.2 bottom row). 
 
4.5 Discussion  
This experiment shows that drug treatment of mixed infections, consisting of 
susceptible parasites with a low abundance of resistant parasites, leads to a 
pronounced parasite relapse. Similar parasite relapses have been observed previously 
in mixed infections of genetically distinct parasites (Wargo et al. 2007; Chapters 2,3 
and 6). In this study, parasite relapses peaked at similar densities in mixed infections 
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of resistant and sensitive parasites from a different clonal lineage as in mixed 
infections with parasites from the same clonal lineage, although the peak for the latter 
group was later and parasite abundance during the relapse lower.  
 
These observations are consistent with our hypothesis that drug treatment selects for 
rare resistant parasites in a mixed infection. With current molecular techniques, the 
clone-composition of the relapses in mixed infections with two clones from the same 
clonal lineage could not be accurately quantified; however, quantitative PCR of the 
mixed infections from genetically distinct clonal lineages showed that the majority of 
parasites present in the relapse were drug-resistant parasites. Based on the similarity 
in the observed parasite kinetics between unrelated and related mixed infections, it is 
very likely that the relapses in the mixed infections of genetically similar parasites 
were also predominantly caused by the drug-resistant parasites. Interestingly, 
however, the relapse in mixed infections of genetically related parasites occurred 3.5 
days later in time and had a lower parasite density during relapse than genetically 
related mixed infections (Figure 4.3 and 4.4 respectively). Moreover, only six out of 
nine infections relapsed in the genetically related mixed infection as opposed to all 
infections in the genetically unrelated mixed infection. These observations suggest 
different underlying within-host dynamics in the genetically related versus genetically 
unrelated mixed infections. An explanation for this could be a lower parasite density at 
the time of release (Chapter 3). This is consistent with the theory that resistant 
parasites from the same clonal lineage could be more suppressed than resistant 
parasites competing with genetically distinct parasites due to niche overlap in the 
former. This could also explain why only six out of nine infections relapsed in these 
genetically similar mixed infections, opposed to all of the genetically distinct mixed 
infections: in the cases where resistant parasites did not relapse, competitive exclusion 
could have eliminated the resistant parasites. An alternative hypothesis for the later 
parasite peak is the involvement of the immune system, whereby a clone-specific 
immune system could suppress genetically similar parasites more effectively than 
genetically distinct parasites. However, if such cross-immunity between the genetically 
similar resistant and sensitive parasites exists, relapsed parasites would perhaps be 
expected to have a lower peak parasite, which was not observed. Moreover, similar 
rates of parasite increase during relapse were observed between the genetically 
related and unrelated infections, which does not indicate increased suppression.  
 




All treatment groups had at least two infections that showed relapsing parasites. The 
difficulty in this experiment is to separate these background relapses from relapses 
due to competitive release of resistant parasites. The relapses of untreated ASsens 
parasites are noticeably later and of lower parasite density than the relapses of drug-
treated ASsens parasites and are therefore likely based on different within-host kinetics. 
One explanation, which is in line with our hypothesis, is that the relapses observed in 
drug-treated ASsens infections are initial up-selected de novo resistant mutants: this is 
possible as resistance mutations against pyrimethamine are easily selected for in a 
single mouse (Walliker et al. 1975). The later peak in parasite density could be 
explained by the low number of parasites at the time of release, as would be expected 
if de novo resistant mutants are the cause of the relapse. Under this hypothesis, it is 
possible that the relapse observed in the mixed infections of ASsens and ASres is also 
(partly) made up from resistant mutants, as could be the case for relapsing AJsens 
parasites.  
 
This study makes use of a ‘seeding’ approach by inoculating a low number of parasites 
from the same clonal lineage to mimic de novo resistance mutations. Both parasite 
clones from the same clonal lineages were passaged 25 times since they diverged. 
Serial passage of P. chabaudi in the absence of a mosquito vector increases the 
virulence of the clonal lineage (Mackinnon and Read 1999) and serial passage of drug-
resistant lines will likely generate compensatory mutations for resistant parasites to 
increase their virulence (Walliker et al. 2005). Therefore, the two clonal lineages likely 
have genetic differences other than single resistance-associated mutations.  
 
Given what we know now from this experiment, a more ideal experiment would be to 
make use of pyrosequencing (Cheesman et al. 2007) or proportional-sequencing (Hunt 
et al. 2005) to determine the clone-composition in parasite relapses. These techniques 
can not reliably quantify genotypes lower than 5% in a mixed infection; however, even 
though the resistant parasites started the infection at 0.001%, the relative frequency 
during relapse increased well above this detection threshold of 5%. Pyrosequencing or 
proportional sequencing would thus be an informative tool to determine the genotypic 
composition during relapse. Additionally, next-generation sequencing methods, for 
instance Roche/454 pyrosequencing, can provide increased sensitivity though at 
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greater cost (Mardis 2008). A further recommendation for future work is to alter the 
seeding approach to more closely mimic de novo resistant mutants. While seeding 10 
resistant parasites in the initial inoculum of 106 susceptible parasites represents a 
density of resistant parasites five orders of magnitude lower than susceptible 
parasites, it still results in ~15.000 parasites at the time of treatment. If the seeding 
event takes place just before peak parasitaemia (when, due to high parasite 
abundance, the likelihood of resistant mutants to arise is maximal) as opposed to a 
simultaneous inoculation, the study would better mimic a de novo resistance 
mutational events. Nevertheless, the best way to study the effect of drug treatment on 
the selection for de novo resistant mutants is to study de novo mutations themselves. 
With such an experiment, the effect of different classes of drugs and the importance of 
stepwise resistance can be established, at least in this rodent malaria model. 
Determining the effect of drug treatment on the up-selection of de novo resistance 
mutations is important since at present, antimalarial treatment regimes are based on 
the conventional wisdom that radical, high dose, drug treatment reduces the chances 
of de novo resistance to arise (WHO 2006). If this empirically unverified assumption is 
wrong, current treatment guidelines may need to be revised or, at the very least, the 
resistance management rhetoric surrounding radical parasitological cure be 
abandoned.  
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5. Competitive suppression and release of drug-resistant 
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Multi-genotype malaria infections are common. The within-host dynamics of malaria 
parasites is thought to play an important role in the spread of drug resistance. In the 
absence of treatment, resistant parasites can be competitively suppressed by co-
infecting susceptible parasite strains. However, drug treatment can greatly increase 
the relative fitness of resistant parasites because of (i) a survival advantage and (ii) 
competitive release as a result of reduced competitive suppression. It is thought that in 
the absence of treatment, an increasing number of co-infecting susceptible parasite 
strains results in increased competitive suppression and hence increased competitive 
release following drug treatment. Here, we test this hypothesis using the Plasmodium 
chabaudi mouse malaria model. We found no evidence for increased suppression nor 
increased competitive release with a higher number of co-infecting parasite clones. 
Therefore, clone multiplicity in malaria infections may have less of a significant role in 
the spread of drug resistance then initially assumed. 
 
5.2 Introduction 
Multi-genotype malaria infections are common (e.g. Arnot 1998; Babiker et al. 1999; 
Smith et al. 1999; Bruce et al. 2000; Jafari et al. 2004; A-Elbasit et al. 2007; Nwakanma 
et al. 2008; Vafa et al. 2008; Baruah et al. 2009; Soulama et al. 2009). The within-host 
dynamics of malaria parasites likely plays an important role in the spread of drug 
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resistance (Hastings 2003; Read and Huijben 2009), since crowding of co-infecting 
parasite strains2 can lead to between-genotype competition. Direct experimental 
evidence on competition between co-infecting Plasmodium falciparum genotypes, 
particularly with drug-resistant parasites, cannot be ethically obtained from human 
infections. However, field data showing suppressed population densities of a genotype 
when other genotypes are present strongly supports the presence of between-
genotype competition within malaria-infected hosts (Daubersies et al. 1996; 
Mercereau-Puijalon 1996; Smith et al. 1999; Bruce et al. 2000; Hastings 2003; Talisuna 
et al. 2006; Bousema et al. 2008; Harrington et al. 2009). Additionally, there is 
considerable direct experimental evidence for crowding in rodent malaria models (e.g. 
Jarra and Brown 1985; Taylor et al. 1997; de Roode et al. 2004; de Roode et al. 2005b; 
Bell et al. 2006) and, in particular, competitive suppression of drug-resistant P. 
chabaudi parasites in a mixed infections with drug-sensitive parasites (de Roode et al. 
2004; this thesis; Wargo et al. 2007; Huijben et al. submitted). When mixed infections 
of drug-resistant and sensitive parasites are drug-treated, the relative fitness of the 
resistant parasites increases not only as a result of a survival advantage in the drug 
environment, but also by the removal of the susceptible competitors, which leads to an 
expansion of drug-resistant parasites. Such drug-induced competitive release was 
demonstrated in a two-genotype rodent malaria infection following both prophylactic 
(de Roode et al. 2004) and therapeutic (Wargo et al. 2007; Huijben et al. submitted; 
Chapters 3 and 6) drug treatment, which likely results in a great fitness advantage for 
resistant parasites.  
 
All previous experiments on competitive release were carried out with a resistant 
clone competing with one susceptible genotype. In reality, resistant parasites often 
find themselves in infections with many more susceptible genotypes. Multi-clone 
infections can arise in two different ways: by a multi-clone infection from a single 
mosquito (co-infection;  Nwakanma et al. 2008; Mohanty et al. 2009) or from two 
sequential infections from mosquitoes infected with a single (or multi-) clone (super-
                                                             
2 The terminology of parasite strains, genotype and clone is tricky. When considering 
Plasmodium falciparum infections, parasite strain and genotype are used interchangeably, 
indicating genetically similar parasites derived from the same ancestor. This term is ambiguous 
since recombination within the mosquito results in great genetic variety. When considering P. 
chabaudi parasites, parasite clone is used to describe parasites originating from the same clonal 
lineage. Due to multiple passages within a clonal lineage and mutation accumulation, different 
parasites from the same clone may have some genetic variation and are thus not ‘true’ clones. 
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infection; de Roode et al. 2005a). In highly endemic areas such as large parts of sub-
Saharan Africa, an entomological inoculation rate (EIR) of several hundred infective 
bites per year have been reported (Trape and Rogier 1996; Beier et al. 1999; Smith et 
al. 2005; Gemperli et al. 2006), which leads to high levels of multi-genotype infections. 
The number of parasite strains observed within a person range from one to more than 
five, sometimes exceeding ten strains per infection (e.g. Babiker et al. 1999; Konate et 
al. 1999; Beck et al. 2001; Magesa et al. 2002; Sutherland et al. 2002; Schoepflin et al. 
2009). Competition for resources in such multi-genotype infections is likely strong 
since host resources have to be shared among multiple parasite strains (Hastings and 
D'Alessandro 2000; de Roode et al. 2003). Consider for example a situation whereby 
either two clones or five clones are competing within the host, with one of the clones 
being resistant and the host resources are equally shared among the clones. In the two-
clone example, removal of the susceptible parasites may lead to a doubling of resistant 
parasites, but in the five-clone example the removal of the four susceptible clones may 
lead to a 500% increase in resistant parasites. To the best of our knowledge, there is 
no empirical data on the effect multi-genotype competition has on drug-resistant 
parasites in the absence and presence of drug treatment. We hypothesize that resistant 
clones are increasingly suppressed with an increasing number of susceptible 
genotypes co-infecting the host, while drug treatment likely increases the competitive 
release, with a greater relative release when strong suppression occurs (Hastings and 
D'Alessandro 2000).  
 
The aim of this study was to evaluate the within-host dynamics in multi-genotype 
infections, with a specific focus on resistant parasites in the presence and absence of 
drug treatment. Using a P. chabaudi mouse model, up to four genetically distinct clonal 
lineages in mixed infections were quantified through time. Strong competitive 
suppression was observed for resistant parasites competing with each of three other 
susceptible clonal lineages. However, we found no evidence that the extent of 
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5.3 Material and methods 
5.3.1 Parasites and hosts 
In this experiment, four genetically distinct P. chabaudi clones were used: drug-
resistant clone AS8p(pyr-1A) (hereafter referred to as clone R), and drug-sensitive clones 
AJ8p, AT2p and CB2p (hereafter referred to as clones AJ, AT and CB respectively) . All 
clones were originally isolated from thicket rats and subsequently cloned (Beale et al. 
1978). Clone R was made resistant in the laboratory by exposure to a high dose of 
pyrimethamine in a single passage (Walliker et al. 1975). Female C57Bl/6 laboratory 
mice (Charles River Laboratories), aged approximately 10 weeks, were used as hosts. 
All mice received 0.05% PABA-supplemented drinking water to enhance parasite 
growth (Jacobs 1964). The mice were fed on Laboratory Rodent Diet 5001 (LabDiet, 
PMI Nutrition International) and were kept on a 12:12 L:D cycle. 
5.3.2 Experimental design, infections and drug treatment 
Mice were infected with either a single-clone infection of clone R, or a mixed infection 
with clone R and one, two or all three of the other clones. All possible combinations of 
clones co-infecting clone R were included in the study. Half of the mice were drug-
treated, which came to a total of 16 different treatment groups (Table 5.1). Each 
experimental treatment consisted of 5 mice, except for the untreated infections with 
three and four clones. These groups consisted of respectively 7 and 9 mice, since we 
expected a higher mortality to occur in infections with a higher clone multiplicity. The 
mice of treatment groups of 5 mice were housed in one cage, mice of treatment groups 
of 7 and 9 mice were housed in two cages. 
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Table 5.1 Experimental set-up. All mice in each treatment group were inoculated with clone R 
and none, one, two or all of the clones AJ, AT and CB. An ‘x’ in the column of each of the 
respective clones indicates the inclusion of that clone in the inoculum. The column ‘n’ specifies 
the number of mice that were included in the treatment group at the start of the experiment 
with the number that survived in brackets. Half of the treatment groups received drug 
treatment, which was administered on days 6-9 post-infection. 
 
Treatment R AJ AT CB n 
No drug treatment      
R x    5 (5) 
R-AJ x x   5 (5) 
R-AT x  x  5 (5) 
R-CB x   x 5 (2) 
R-AJ-AT x x x  7 (6) 
R-AJ-CB x x  x 7 (3) 
R-AT-CB x  x x 7 (5) 
R-AJ-AT-CB x x x x 9 (5) 
Drug-treated      
R x    5 (5) 
R-AJ x x   5 (5) 
R-AT x  x  5 (5) 
R-CB x   x 5 (5) 
R-AJ-AT x x x  5 (5) 
R-AJ-CB x x  x 5 (5) 
R-AT-CB x  x x 5 (5) 
R-AJ-AT-CB x x x x 5 (5) 
 
Infections were initiated with an intraperitoneal injection of 106 parasites of each 
clone. Multi-clone infections were established by mixing the different parasite clones 
in the inoculum, so that only a single inoculation was necessary. In multi-clone 
infections, each clone was initiated with 106 parasites, so that the four-clone infection 
received a four fold higher parasite dose than the single-clone R infection. We did this 
because analysing competition requires comparison of the performance of an 
individual clone in the presence and absence of competition, starting from the same 
initial parasite dose. Up to a four fold higher dose of 106 parasites has little effect on 
overall parasite dynamics or host health (Timms et al. 2001).  
 
Drug treatment was initiated on day 6 post-infection (PI), when parasite-induced 
weight loss and anaemia became pronounced, and subsequently repeated on days 7 to 
9. Drug treatment consisted of 8 mg pyrimethamine/kg mouse weight dissolved in 
dimethyl sulfoxide (DMSO) and was administrated by intraperitoneal injection of 50 µl. 
Untreated controls were given DMSO-only. 
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5.3.3 Monitoring of infections 
Mice were monitored daily from day 3 to day 21 PI and three times a week up to day 
35 PI. During sampling, mouse weight (to the nearest 0.1 gram) and red blood cell 
density using flow-cytometry (Beckman Coulter) were measured, and a thin blood 
smear was taken. Additionally, 5 μl of blood was taken for counting the total parasite 
density and 10 μl was taken for counting gametocyte density, both by using 
quantitative PCR.  
 
DNA was extracted from 5 µl of blood, which was performed on the ABI Prism® 6100 
Nucleic Acid PrepStation according to manufacturer’s instructions. RNA was extracted 
from 10 µl of blood, using the ‘RNA Blood-DNA’ method on the ABI Prism® 6100 
Nucleic Acid PrepStation. RNA was converted to single stranded cDNA immediately 
after extraction, using the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems; Wargo et al. 2006). Both DNA and cDNA were stored at -80°C until 
quantification.  
 
To measure parasite density (asexual parasites and gametocytes combined) of each 
clone, quantitative PCR was performed on extracted DNA using clone-specific assays. 
Clone R and AJ were measured using the R-specific and AJ-specific PcCG1 assay 
respectively, as described in Drew and Reece (2007). Clone AT was quantified using 
the msp-1 AT assay and clone CB was quantified using the msp-1 CB assay, both 
described in Bell et al. (2006). We only quantified the gametocyte density of clone R, 
since this was our focal clone and no clone-specific gametocyte qPCR assay is yet 
developed for clones AT and CB. For gametocyte quantification, cDNA was used instead 
of DNA on the R-specific PcCG1 assay. Due to loss of samples, gametocyte data is only 
available from day 3 to day 17. 
 
The PCR reactions for the R-specific and AJ-specific CG1-assays had a total volume of 
25 µl, which consisted of 7 µl DNA or cDNA (clone R only), 900 nM forward and 
reverse clone-specific primers, 250 nM TaqMan® MGB PcCG1 probe (Applied 
Biosystems) and 1x PerfeCTa™ qPCR FastMix™ (Quanta Biosciences). The reactions of 
the msp-1 AT assay and msp-1 CB assay both also had a total volume of 25 µl, these 
consisted of 2 µl DNA, 300 nM forward and reverse clone-specific primers and 200 nM 
TaqMan® MGB msp-1 probe. All reactions were run on the ABI Prism® 7500 Fast 
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System, using the assay: 95°C for 2 minutes, followed by 40 cycles of 95°C for 3 
seconds and 60°C for 30 seconds. Quantification was based on serial dilutions of clone-
specific DNA and cDNA standards of known total parasite and gametocyte density, 
determined beforehand by microscopy (Cheesman et al. 2003). Parasite density for 
clone R was determined for days 3-35, for clones AJ, AT and CB up to day 23. 
5.3.4 Statistical analysis 
Analysis was done using analysis of variance in R 2.9.0 (R Development Core Team 
2009). For analysis of competition in untreated infections, the geometric mean 
parasite density was calculated over days 3-35 PI for clone R and over days 3-23 PI for 
clones AJ, AT and CB, which was the monitoring period of the susceptible clones. For 
analysis of drug-treated infections, geometric mean parasite density of clone R post-
treatment was calculated (day 7-35 PI). The total parasite density of all parasite clones 
combined in the infection was estimated by summing the parasite densities of each 
infecting clone in mixed infections up to day 23. As a measure of transmission 
potential, the predicted infectiousness was calculated for clone R after the start of 
treatment until day 17 using gametocyte densities in the density-infectivity function 
q1 as described in the general introduction of this thesis. As a measurement of 
virulence, the mean weight and mean red blood cell density during the infection was 
calculated, as well as the maximum weight loss and maximum red blood cell loss for a 
measurement of virulence during the acute infection. 
 
As explanatory variables, drug treatment (drug-treated/untreated) and co-infecting 
clones (AJ/AT/CB/AJ-AT/AJ-CB/AT-CB/AJ-AT-CB) or number of co-infecting clones 
(0/1/2/3) were included. Maximal models were fitted first and non-significant 
interactions were removed to obtain minimal models.  
 
Many treatment groups had one or more mice that appeared to have received a lower 
inoculum of parasites than intended, seen as a lag in growth of the parasites of a day or 
more (Chapter 3). Since the different clones were mixed into a single inoculum, the 
mice that received a lower dose of parasites received an overall lower dose of all 
parasite-clones, but the parasite ratio was maintained. Parasite dynamics in individual 
mice are given in figures A1 and A2 in the appendix to this chapter. To account for any 
effect of the lower inocula, the R parasite density at the first sampling day (day 3) was 
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included in the models as a covariate. This factor did not have a significant effect in any 
of the tests was therefore eliminated from the models.  
 
A total of 14 mice died or were euthanized during the course of the infection, all of 
them in untreated groups (Table 5.1). All deaths occurred between days 8 and 13 post-
infection, with a peak on day 10. These 14 mice were excluded from the analyses. 
 
5.4 Results 
5.4.1 Asexual parasite dynamics 
In untreated infections, all parasite clones reached peak parasite density around day 6 
or 7, after which clones AJ, AT and CB persisted at higher parasite densities than clone 
R (Figure 5.1, Figure A1 – appendix to this chapter). When the infections were drug-
treated, the susceptible parasite clones dropped in parasite density and were below or 
around detection threshold around day 12 post-infection, at which time clone R 
increased in parasite abundance with distinct second peaks in R parasite density 
observed when in competition with two or more susceptible clones (Figure 5.2, Figure 
A2 – appendix to this chapter). In the absence of drug treatment, the resistant 
parasites were competitively suppressed by all three clones, which are known to be 
more virulent than clone R (Figure 5.3a, presence of competitors: F1,34=61, p<0.001) 
(Bell et al. 2006), while drug treatment resulted in clone R performing as good or 
better than in the absence of competition (Figure 5.3b). Taking the different clones 
together, no differences were observed in the strength of suppression between the 
number of co-infecting clones (Figure 5.4 – untreated infections, number co-infecting 
clones: F2,28=0.1, p=0.89). In drug-treated infections, the resistant parasites were 
released following treatment. In competition with multiple clonal genotypes, the 
resistant parasites had lower densities before being released, but were released to a 
higher density than the resistant parasites in the absence of competition or when 
competing with one clone (Figure 5.3b). Therefore, over the entire infection period 
following drug treatment, the parasite density of clone R post-treatment was similar 
between treatments with different number of co-infecting susceptible clones (Figure 
5.4, no. of co-infecting clones: F2,32=0.46, p=0.64).  
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Few differences were found in the effect of the different susceptible clones on the 
parasite dynamics of clone R. The strength of competitive suppression in untreated 
infections was less strong with a co-infection with clone CB than with AJ or AT (Figure 
5.5a, clone: F2,9=6.4, p=0.019), similarly, the combination AJ + CB exerted less 
competitive suppression than the other two combinations (Figure 5.5b – F2,11=7.4, 
p=0.009). Clone R in competition with one other clone followed similar parasite 
dynamics following drug treatment as in the absence of treatment. The genotype of the 
co-infecting clone did not affect the extent of competitive release (Figure 5.5, one co-
infecting clone: F2,12=0.04, p=0.97; two co-infecting clones: F2,12=0.55, p=0.59 
respectively).  
 
Since no single-clone infection of the susceptible parasite clones were included in this 
experiment, competitive suppression could not be studied for these clonal lineages. 
However, a comparison could be made between with co-infections with clone R only, 
and with one or two of the other, virulent, clones. A co-infection with clone R only has 
been shown before not to affect the performance of AJ or AT, and only slightly 
suppress CB (Bell et al. 2006). Strikingly, clone AJ performed better in competition 
with one additional virulent clone (AT or CB), or both together (AT plus CB), than with 
just clone R (Figure 5.6a, padj=0.013, padj=0.002 respectively). Clones AT and CB 
performed as well with just clone R as with 1 or 2 of the other clones (Figure 5.6bc, 
p=0.28, p=0.08 respectively). Thus, each of the susceptible clones had similar or more 
parasite densities when sharing the host with only clone R or with one or two 
additional virulent parasite clones. 
 
As a consequence, in untreated infections with an increasing number of co-infecting 
clones, the total parasite density increased as well (Figure 5.7, number of infecting 
clones: F3,32=50, p<0.001). Overall, drug-treated infections had a lower total parasite 
density than untreated infections (drugs: F1,68=117, p<0.001). The total parasite 
densities in drug-treated infections were the same for double, triple or quadruple 
infected mice (no. of co-infecting clones: F2,32=2.5, p=0.10).  
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Figure 5.1 Parasite dynamics of untreated infections of clone(s): R alone (a), R with AJ (b), R 
with AT (c), R with CB (d), R with AJ and AT (e), R with AJ and CB (f), R with AT and CB (g), R 
with AJ, AT and CB (h). The total parasite densities for clone R are shown in solid red line, for 
clone AJ in solid black line, for clone AT in dashed blue line and for clone CB in dotted green 
line. Data are means (± standard error) of up to 6 mice (table 5.1). The mixed infection of R with 
CB consisted of only two surviving mice. 
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Figure 5.2 Parasite dynamics of drug-treated infections of clone(s): R alone (a), R with AJ (b), R 
with AT (c), R with CB (d), R with AJ and AT (e), R with AJ and CB (f), R with AT and CB (g), R 
with AJ, AT and CB (h). The total parasite densities for clone R are shown in solid red line, for 
clone AJ in solid black line, for clone AT in dashed blue line and for clone CB in dotted green 
line. Data are means (± standard error) of 5 mice (table 5.1). Drug treatment was given on days 
6-9 post-infection, as indicated by the shaded area. 
 
 


















































Figure 5.3 Parasite dynamics of clone R in untreated (a) and drug-treated (b) infections of 
clone R alone (solid thick red line), R with AJ (solid black line), R with AT (dashed black line), R 
with CB (dotted black line), R with AJ and AT (solid blue line), R with AJ and CB (dashed blue 
line), R with AT and CB (dotted blue line) and R with AJ, AT and CB (thick dashed green line). 
Drug treatment was given on days 6-9 post-infection, as indicated by the shaded area. Data are 
means (± standard error) of up to six mice (Table 5.1). The mixed infection of R with CB 
consisted of only two surviving mice. 
 














































Figure 5.4 Geometric mean daily parasite density of clone R in drug-treated (solid black line) 
and untreated (dashed red line) infections of either clone R alone (0 competing clones) or in a 
co-infection with 1, 2 or 3 other clones. Data are means (± standard error). The means for 1 and 
2 competing clones have been derived by combining the data from these respective treatments. 
 




















































Figure 5.5 Geometric mean daily parasite density of clone R in drug-treated (solid black line) 
and untreated (dashed red line) infections, when competing with one other clone (AJ, AT, or CB, 
upper graph), or two other clones (AJ and AT, AJ and CB, or AT and CB; lower graph). Data are 
means (± standard error) of up to six mice. The mixed infection with CB only consisted of only 


























































Figure 5.6 Geometric mean daily parasite density for non-focal clones AJ (a), AT (b) and CB (c) 
in drug-treated (solid black line) and untreated (dashed red line) infections, when competing 
with only one clone (less virulent clone R), with two clones (clone R with one of the other 
virulent clones) or with three clones (clone R with both other virulent clones). Data are means 
(± standard error). The means for 2 co-infecting clones have been derived by combining the 
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Figure 5.7 Geometric mean daily total parasite density of all clones combined in drug-treated 
(solid black line) and untreated (dashed red line) infections of either clone R alone (0 
competing clones) or in a co-infection with 1, 2 or 3 other clones from day 3 to 23 PI. Data are 
means (± standard error). The means for 1 and 2 competing clones have derived by combining 
the data from these respective treatments. 
 
5.4.2 Transmission potential 
The gametocytes of clone R peaked around day 6 in untreated infections, after which 
densities dropped and peaked again around day 13. Clone R produced higher 
gametocyte densities throughout the infection in the absence of competition. Of note is 
that clone R did not produce a distinct second gametocyte peak when in competition 
with one or more of the other parasite clones (Figure 5.8a). When drug treatment was 
given, all infections showed a second peak in gametocyte production (Figure 5.8b), 
which was similar to or higher than clone R in the absence of competition. 
 
The predicted number of mosquitoes infected with resistant parasites was reduced 
when in competition (untreated infections, presence of competitors: F1,34=37, p<0.001). 
An increasing number of co-infecting genotypes did not decrease the transmission 
potential of resistant parasites in untreated infections (Figure 5.9, no. of co-infecting 
clones: F2,28=1.7, p=0.20). As in asexual parasite dynamics, drug treatment resulted in a 
release of resistant gametocytes which doubled their transmission potential (Figure 
5.9, drugs: F1,68=214, p<0.001). The number of co-infecting clones did not affect the 
competitive release of resistant gametocytes, such that the estimated infectivity of 
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clone R was comparable between infections with one, two or three co-infecting 





















































Figure 5.8 Gametocyte dynamics of clone R (day 3-17) in untreated (a) and drug-treated (b) 
infections of clone R alone (solid thick red line), R with AJ (solid black line), R with AT (dashed 
black line), R with CB (dotted black line), R with AJ and AT (solid blue line), R with AJ and CB 
(dashed blue line), R with AT and CB (dotted blue line) and R with AJ, AT and CB (thick dashed 
green line). Drug treatment was given on days 6-9 post-infection. Data are means (± standard 
error) of up to six mice (Table 5.1). The mixed infection of R with CB consisted of only two 
surviving mice. 
 
The co-infecting genotypes seemed to affect the estimated infectiousness of clone R, 
with competition with clone CB resulting in slightly less competitive suppression than 
the other clones (Figure 5.10a, co-infecting clone(s): F2,9=4.4, p=0.047). For three-clone 
co-infections, the susceptible clone combination did not affect the predicted infectivity 
of the resistant parasites (Figure 5.10b, co-infecting clone(s): F2,11=2.0, p=0.18). In 
drug-treated infections, the predicted infectivity was similar between the different co-
infecting clones, both in double infections (drug-treated infections, co-infecting clone: 
F2,12=0.5, p=0.62) and triple infections (co-infecting clone: F2,12=1.3, p=0.32).  
 
 









































Figure 5.9 Estimated number of infected mosquitoes (out of n=100) clone R post-infection (day 
7-17) in drug-treated (solid black line) and untreated (dashed red line) infections of either 
clone R alone (0 competing clones) or in a co-infection with 1, 2 or 3 other clones. Data are 
means (± standard error). The means for 1 and 2 competing clones have been derived by 















































Figure 5.10 Estimated number of infected mosquitoes (out of n=100) of clone R in drug-
treated (solid black line) and untreated (dashed red line) infections, when competing with one 
other clone (AJ, AT, or CB, upper graph), or two other clones (AJ and AT, AJ and CB, or AT and 
CB; lower graph). Data are means (± standard error) of up to six mice. The mixed infection with 
CB only consisted of only two surviving mice. 
 




5.4.3 Host health 
Untreated infections of clone R in combination with other susceptible clones caused a 
higher degree of anaemia during the infection than clone R in a single-clone infection 
(Figure 5.11a, mean red blood cell density: F1,34=39, p<0.001). No differences were 
found in mean body mass of the mice (Figure 5.11b, F1,34=0.01, p=0.92). The number of 
additional susceptible parasite clones in the infection did not have an effect on the 
mean mouse body mass (Figure 5.11b – untreated infections, F2,28=0.24, p=0.79), nor 
on the maximum weight loss during the acute infection (F2,28=0.60, p=0.56). However, 
mice with more clones in the infection were more anaemic on average during the 
infection (Figure 5.11a – untreated infections, F2,28=12, p<0.001). This result could not 
be explained by the inclusion of the presence of any of the three clones as a co-variate. 
Increased maximum red blood cell loss during the acute infection with more additional 
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Figure 5.11 Mean daily red blood cell density (a) and body mass (b) in drug-treated (solid 
black line) and untreated (dashed red line) infections of either clone R alone (0 competing 
clones) or in a co-infection with 1, 2 or 3 other clones. Data are means (± standard error). The 
means for 1 and 2 competing clones have been derived by combining the data from these 
respective treatments.  
 




The different susceptible genotypes of the co-infecting clonal lineages did not have a 
different impact on host health (co-infecting clone, body mass: F2,9=0.72, p=0.51; red 
blood cell density: F2,9=1.56, p=0.26). Also in triple infections, the different clone 
combinations did not affect host health differently (body mass: F2,11=0.48, p=0.63; red 
blood cell density: F2,11=0.31, p=0.74). The same results were found when using the 
maximum loss in body mass and maximum red blood cell loss during the acute 
infections.  
 
Drug treatment significantly reduced disease-related morbidity, with a higher mean 
body mass (drugs: F1,71=7.1, p=0.009) and higher mean red blood cell density (F1,68=91, 
p<0.001). The same was true for maximum weight and red blood cell density loss. 
While drug treatment relieved the symptoms of the infection, infections with more 
clones were still more anaemic than infections with only clone R or clone R with one 
other clone (Figure 5.11a – drug-treated infections, no. of co-infecting clones: F2,32=4.1, 




Multi-clone infections are common in patients with malaria in endemic areas and could 
result in both a reduction of the fitness of drug-resistant parasites (in the absence of 
treatment) and an increase of fitness by means of competitive release following drug 
treatment (de Roode et al. 2004; Wargo et al. 2007; Huijben et al. submitted). This 
study shows strong competitive suppression for drug-resistant parasites in untreated 
multi-genotype infections and competitive release when these infections were drug-
treated. Unexpectedly, we found that the number of co-infecting susceptible genotypes 
did not affect competitive suppression, or the extent of competitive release, which 
suggests that resistant parasites in multi-clonal environments are not worse off than 
resistant parasites sharing their host with only one susceptible genotype. 
 
Why was competition not affected by the number of co-infecting parasite clones? 
Competition between co-infecting malaria parasites is thought to arise from 
competition for resources, most dominantly red blood cell densities (Yap and 
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Stevenson 1994; Mideo et al. 2008; Mideo 2009), though other resources such as 
glucose may also play a role (de Roode et al. 2003). Immune-mediated competition, 
whereby antibodies produced against one parasite genotype are cross-reactive against 
other genotypes, is likely also a factor in competition between different malaria 
genotypes (Mota et al. 2001). In this latter case, the immune response provoked by one 
strain negatively affects a co-infecting strain.  
 
No competitive interactions between the different drug-sensitive genotypes were 
observed in this experiment. Consequently, a higher total parasite density and a higher 
degree of anaemia during the acute infection were observed with an increasing 
number of parasite clones. In other words, the carrying capacity of the infection 
appeared to increase with increasing genotypic diversity. Since the carrying capacity of 
the infection increased with an increasing number of co-infecting susceptible clones, 
no additional competitive suppression was exerted on the drug-resistant parasites. 
One possible explanation for the increasing carrying capacity is that the different drug-
sensitive genotypes inhabit a slightly different niche, for example by having a different 
red blood cell age preference (Mideo et al. 2008), which results in enhanced resource 
exploitation. We would expect that there is a limit to this enhanced exploitation of the 
host; however, with the combination of four clones in this experiment, we did not seem 
to have reached that limit.  
 
Our results suggest that resistant parasites experienced no additional cost to being in 
an infection with more than one susceptible parasite strain and could persist in multi-
genotype environments. Studies in areas of seasonal malaria have shown that resistant 
parasites can persist during the long dry season in mixed infections with susceptible 
parasites (Abdel-Muhsin et al. 2004; Ord et al. 2007; Babiker 2009) and are not 
competitively excluded. Such infections, however, are chronic and asymptomatic, 
whereas predominantly the acute phase of the infection is studied in this experiment. 
Competition during the chronic phase of an infection may be mediated through a 
different mechanism since red blood cells are less of a limiting factor. However, 
previous research has shown that parasite dynamics of co-infecting clones during the 
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The infections in this study were initiated with a simultaneous inoculum of different 
parasite genotypes, mimicking a co-infection by a multi-genotype infected mosquito. 
However, infections that arise from multiple infectious bites, several days or weeks 
apart are very common as well. A turn-over of different parasite clones has been 
frequently observed in the field (Daubersies et al. 1996; Farnert 2008). The dynamics 
following such super-infections may result in different competitive outcomes, whereby 
competition may be more intense for genotypes that infect later on in the infection (de 
Roode et al. 2005a). Similarly, the experiments presented in chapters 3, 4 and 6 of this 
thesis show that competitive suppression and competitive release are pronounced 
when resistant parasites are at low frequency in the infection. It could well be that 
resistant parasites at low frequency in the infection experience more pronounced 
competitive suppression with increasing multiplicity of infection. 
 
The within-host dynamics of resistant and susceptible parasites may be utilized as a 
resistance management tool by adjusting drug treatment regimes such that 
competitive suppression of drug-resistant parasites remains maintained (Wargo et al. 
2007; Read and Huijben 2009; this thesis). For this, a thorough understanding of the 
within-host dynamics of resistant and susceptible parasites is necessary. These results 
suggest that clone multiplicity does not influence within-host dynamics. The 
generalizability of these findings needs to be studied, however, if these ecological 
dynamics are true for natural P. falciparum infections, at least one potential complexity 
in designing rational patient treatment regimes can be crossed off the list.  
 



















































































Figure A1 Parasite dynamics of individual mice in untreated infections with clone R alone (top 
row), or mixed clone infections of clone R + AJ (second row), clone R + AT (third row), clone R + 
CB (fourth row), clone R + AJ + AT (fifth row), clone R + AJ + CB (sixth row), clone R + AT + CB 
(seventh row) and clone R + AJ + AT + CB (bottom row). Parasite densities for clone R are 
shown in solid red, for clone AJ in solid black, for clone AT in dashed blue and for clone CB in 
dotted green. Single- and double-clone infections started out with 5 mice, three-clone infections 
started with 7 mice and four-clone infections with 9 mice; only surviving mice are shown 
(Table 5.1). 
 
















































































































Figure A2 Parasite dynamics of individual mice in drug-treated infections with clone R alone 
(top row), or mixed clone infections of clone R + AJ (second row), clone R + AT (third row), 
clone R + CB (fourth row), clone R + AJ + AT (fifth row), clone R + AJ + CB (sixth row), clone R + 
AT + CB (seventh row) and clone R + AJ + AT + CB (bottom row). Parasite densities for clone R 
are shown in solid red, for clone AJ in solid black, for clone AT in dashed blue and for clone CB 
in dotted green. Drug treatment was given on days 6-9 post-infection, as indicated by the 
shaded area. Each treatment group consisted of 5 mice (Table 5.1). 
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6. The strength of within-host selection for drug resistance 
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6.1 Abstract 
Antimalarial drug treatment is aimed at improving patient health, reducing overall 
infectiousness, and resistance management. The current approach to achieve these 
objectives is radical parasitological cure, intended at killing every parasite in the 
infection. This approach is not obviously a resistance management strategy, as it 
provides the greatest possible selective advantage for any resistant parasites that are 
present. We hypothesize that treatment regimes which involve lower drug dosages or 
shorter duration of drug treatment impose weaker selection for resistant parasites 
while at the same time also improving patient health and reducing overall infectivity. 
Using a Plasmodium chabaudi malaria model, we found such treatment regimes are 
achievable. These findings raise the prospect of a different, rational, approach to 
developing patient treatment regimes for antimalarial resistance management.  
 
6.2 Introduction 
Drug treatment regimes of most infectious diseases have three goals: (i) improvement 
of patient health, (ii) reductions in transmission intensity as a public health goal and 
(iii) control of the emergence and spread of resistant pathogens (e.g. WHO 2006). The 
best treatment strategy maximizes all three of these objectives. 
 
 
Chapter 6 –Treatment regimes 
 
117 
In the case of malaria, conventional patient treatment regimens are aimed at ‘radical 
parasitological cure’, that is drug treatment intended to kill every parasite in the 
infection (WHO 2006). This approach drastically reduces parasite numbers, resulting 
in a rapid improvement of patient health and a reduced patient infectiousness. The 
reduced parasite density also lowers the probability of resistance mutations appearing 
and minimizes the number of parasites exposed to low levels of drugs in the drug-
elimination phase; in other words, reducing the selection for low level resistance 
(tolerance).  
 
While this conventional patient treatment regimen may be successful at reducing the 
probability of new resistant mutants arising, it provides a great selective advantage to 
any drug-resistant parasite already present in the host, either by de novo mutation or 
by a newly derived resistant infection. The logic is as follows. When mixed infections of 
resistant and susceptible parasites are drug-treated, the relative fitness of resistant 
parasites increases due to the survival advantage they have over drug-sensitive 
parasites. In addition, competitive suppression of the resistant parasites by the 
susceptible parasites is alleviated or even fully removed following drug treatment, 
allowing the resistant parasites to fill up the ecological space left by susceptible 
parasites (Hastings 2003; Read and Huijben 2009). This competitive release has been 
demonstrated in Plasmodium chabaudi infections following both prophylactic (de 
Roode et al. 2004) and therapeutic (Wargo 2006; Huijben et al. submitted) drug 
treatment. Direct evidence of competitive release can not be ethically obtained for P. 
falciparum infections in humans as it requires an untreated control group, but 
suggestive evidence for this has been observed in P. falciparum infections in women 
receiving intermittent preventative treatment during pregnancy (IPTp; Harrington et 
al. 2009). Thus, from a resistance management perspective, ‘radical parasitological 
cure’ approach is a two-edged sword: it reduces the probability of resistant mutants 
arising, but at the same time maximally selects for the resistant parasites already 
present (Hastings 2003; Read and Huijben 2009). In the case of malaria, de novo 
resistance mutational events are extremely rare; for most drugs, global resistance is 
the result of a few resistant strains that have swept across most parts of the malaria 
endemic world (reviewed in Plowe 2009). Therefore, conventional patient treatment 
regimes may be obstructing the third objective of patient treatment, namely resistance 
management. 
 




Since we know competitive release provides a great advantage to resistant parasites, 
and that shorter treatment regimens (Wargo et al. 2007) and reduced drug dosages 
(Huijben et al. submitted) reduce the extent of competitive release, we wanted to test 
the hypothesis that treatment regimens other than radical parasitological cure may be 
better at simultaneously maximizing the three treatment goals when resistance is 
already present in the population. Here our aim is not, of course, to find the best 
treatment regimen for falciparum malaria infections, but rather to test a proof of 
principle: compared to radical parasitological cure, are there treatment regimens that 
better maximize simultaneously host health, reductions in infectiousness and 
resistance management? We found that there are.  
 
6.3 Material and methods 
A mathematical model was utilized in the decision process for choosing drug regimes 
to test experimentally. For details on this model, see appendix to this chapter. 
6.3.1 Parasites and hosts 
Two genetically distinct clonal lineages were used in the experiments, drug-sensitive 
AJ5p (hereafter referred to as clone S) and drug-resistant clone AS6p(pyr1A) (hereafter 
referred to as clone R), both clones were isolated from thicket rats and subsequently 
cloned (Beale et al. 1978). Clone R was made resistant by exposing it to a high dose of 
pyrimethamine in a single passage (Walliker et al. 1975). Hosts were nine week old 
female C57Bl/6 laboratory mice (Charles River Laboratories). All mice were kept on a 
12:12 L:D cycle, fed Laboratory Rodent Diet 5001 (LabDiet, PMI Nutrition 
International) and received 0.05% PABA-supplemented drinking water to enhance 
parasite growth (Jacobs 1964). 
6.3.2 Experimental design, infections and drug treatment 
Mice were randomly assigned to one of eight treatment groups. Each group consisted 
of eight mice, randomly allocated to two cages with four mice in each cage. All mice 
were inoculated at day zero with a mixed infection of both clone R and clone S, so as to 
establish an infection with 106 parasites of clone S and ~10 parasites of clone R, 
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representing a situation where resistance is rare in the population. On day 6 post-
infection (PI), at the onset of disease symptoms, mice received: 
i) no drug treatment,  
ii) 8 mg/kg pyrimethamine (“high dose”), given 5 days in a row 
(“conventional treatment”),  
or one of six alternative treatment regimes:  
iii) 4 mg/kg pyrimethamine (“low dose”), given only once,  
iv) 4 mg/kg pyrimethamine, given every 7 days,  
v) 4 mg/kg pyrimethamine, given every 4 days,  
vi) 8 mg/kg pyrimethamine, given only once, 
vii) 8 mg/kg pyrimethamine, given every 7 days, or 
viii) 8 mg/kg pyrimethamine, given every 4 days.  
Pyrimethamine was dissolved in dimethyl sulfoxide (DMSO) and inoculated intra 
peritoneal with 50 µl of the solution. The untreated control group did not receive any 
treatment during the entire infection to mimic the situation of untreated patients. 
6.3.3 Monitoring of infections 
Weight, red blood cell density, asexual parasite density and gametocyte density of both 
clones were measured daily (day 3-22 PI) and three times a week thereafter (day 24-
49 PI). Weight was determined to the nearest 0.1 gram. Red blood cell density was 
measured using flow-cytometry (Beckman Coulter), for which two µl of tail snip blood 
was diluted in 80 ml isotonic saline. A subsequent 5 µl and 10 μl of tail snip blood was 
taken for respectively asexual parasite and gametocyte quantification.  
 
DNA was extracted from 5 μl of blood on the ABI Prism® 6100 Nucleic Acid 
PrepStation according to manufacturer’s instructions. RNA was extracted from 10 μl of 
blood using the ‘RNA Blood-DNA’ method on the ABI Prism® 6100 Nucleic Acid 
PrepStation. RNA was subsequently converted to single stranded cDNA using the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems; Wargo et al. 2006). 
Both DNA and cDNA were stored at -80°C until quantification. 
 
To measure total parasite density (asexual parasites and gametocytes combined), 
quantitative PCR was performed on DNA using clone-specific assays. To measure 
gametocyte density, the same clone-specific quantitative PCR assays were performed 
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on cDNA (Drew and Reece 2007). Asexual parasite density was estimated by 
subtracting the gametocyte density from the total parasite density. Each reaction, with 
a final volume of 25 µl consisted of 7 µl DNA or cDNA, 900 nM forward and reverse 
clone-specific primers, 250 nM TaqMan® MGB probe (Applied Biosystems) and 1x 
PerfeCTa™ qPCR FastMix™ (Quanta Biosciences). Primer and probe sequences are 
those used by Drew and Reece (2007). All reactions were run on the ABI Prism® 7500 
Fast System, using the assay: 95°C for 2 minutes, followed by 40 cycles of 95°C for 3 
seconds and 60°C for 30 seconds. Quantification was based on serial dilutions of DNA 
and cDNA standards of known parasite and gametocyte density respectively, 
determined beforehand by microscopy.  
6.3.4 Statistical analysis 
Analyses were performed in R 2.9.0 (R Development Core Team 2009). The geometric 
mean asexual parasite densities of clone R and S separately and combined were 
calculated for the period after the initiation of drug treatment (day 7-49 PI). Since 
asexual parasite densities range over 6 orders of magnitude during the course of the 
infection, mean asexual densities were summarized as the geometric mean. As a 
measure of transmission potential, the predicted infectiousness was calculated for 
both clones separately and combined after the start of treatment (day 7-49 PI) using 
gametocyte densities in the density-infectivity function q1 as described in the general 
introduction of this thesis. The rate of decline of asexual S parasites after the first day 
of treatment was calculated as the difference in the log-transformed densities of day 6 
and 7. Additionally, gametocyte density following 8 mg/kg, 4 mg/kg treatment and no 
drug treatment was compared, for which the proportion of the gametocyte density on 
day 6 (prior to treatment) compared to the gametocyte density on day 7 (first day 
post-treatment) was estimated and subsequently square root transformed to meet 
normality assumptions. The change in mouse body mass, as a percentage from the 
baseline value of the mean body mass of day -1 and day 3 for each mouse, was 
calculated through time. As measurements of host health, the mean body mass change 
and mean red blood cell (RBC) density post-treatment (day 7-49 PI) were calculated. 
Furthermore, the maximum loss in body mass and minimum RBC density during the 
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Analysis of variance (ANOVA) was used to test for a difference between drug-treated 
and untreated infections. A subsequent ANOVA was applied to test for an effect of drug 
treatment regime among treated infections. Post-hoc Tukey Honestly Significant 
Differences (HSD) tests were carried out for pair-wise comparisons of treatment 
regimes, in which case the adjusted p-values are reported. Lastly, a fully cross-factored 
ANOVA was done on the alternative treatments with drug dose (low: 4 mg/kg, or high: 
8 mg/kg) and treatment frequency (once/ every 7 days/ every 4 days). To ensure 
treatment groups did not differ prior to drug treatment, day 6 values on asexual 
parasite density, gametocyte density, proportional change in body mass and RBC 
density were evaluated for statistical differences. Significant differences between 
treatment groups were found in gametocyte densities of clone S and R+S combined 
and in RBC densities, therefore, day 6 values of these variables were included in their 
respective models as a covariate. 
 
A total of 15 mice failed to become infected with clone R (determined by the absence of 
detection by qPCR during the entire course of infection), presumably as a result of 
stochastic loss due to the low inoculum size. These mice had therefore to be removed 
from the analysis. Another mouse received a substantially lower inoculum of clone S 
than intended (treatment group 4 mg/kg every 4 days), as judged from much lower 
parasite densities the first 6 days post-infection than is expected for a 106 parasite 
dose (Chapter 3), and was therefore also removed from the analysis (Table 6.1). 
 
Table 6.1 Treatment regimes used in the experiment with number of mice at the start of each 
treatment. The number in brackets indicates the number of mice used in the analysis (see 
material and methods). 
 
Pyrimethamine dose 1 day only every 4 days every 7 days 
5 days in a 
row 
none 
4 mg/kg 8 (7) 8 (6) 8 (5)   
8 mg/kg 8 (7) 8 (5) 8 (6) 8 (5)  
untreated     8 (7) 
 
6.4 Results 
6.4.1 Asexual parasite dynamics 
In untreated infections, resistant parasites, which were inoculated at five orders of 
magnitude lower than the susceptible parasites, barely reached densities above 
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detection (Figure 6.1a). In the absence of competition, this parasite dose results in 
similar levels of peak parasite density as a parasite dose five orders of magnitude 
larger (Chapter 3). Drug treatment of these mixed infections resulted in a release of 
resistant parasites, though the level of release varied greatly with drug treatment 
regime (Figure 6.1b-h). 
 
Drug treatment significantly reduced susceptible parasite densities (F1,46=7.6, 
p=0.009), the extent of which varied among treatment regimes (Figure 6.1, 6.2a; 
F6,34=5.8, p<0.001). Conventional treatment led to the greatest suppression of 
susceptible parasites, with a significantly lower mean asexual parasite density than all 
other treatments, except for the 8 mg/kg dose every 7 days treatment (Figure 6.3a). 
This enhanced suppression of susceptible parasites following conventional treatment 
resulted in a greater release of resistant parasites. A similar or higher resistant 
parasite density was produced in this treatment group than in other treatment groups 
(Figure 6.1, 6.2b, 6.3b; F6,34=5.0, p<0.001). Analysis of the proposed alternative 
treatment regimes showed that drug dose had a significant effect on the release of 
resistant parasites (dose: F1,32=8.0, p=0.008), while the frequency of treatment did not 
(frequency: F2,32=2.3, p=0.12).  
 
Resistant parasites typically showed only a single parasite peak following competitive 
release, while the susceptible parasites rebounded after drug pressure wore off and 
subsequently had a third parasite peak after day 20 PI (Figure 6.1). The rate of decline 
of susceptible parasites following drug treatment was similar following a low dose (4 
mg/kg) and high dose (8 mg/kg) treatment (Tukey HSD, padj=0.27), in both cases much 
more rapidly than in untreated control mice (Figure 6.2a, F2,45=18, p<0.001) . However, 
the drug-induced decline persisted for longer in high dose treatments. Drug treatment 
with a high dose for 5 days in a row (conventional treatment) resulted in a prolonged 
decline, which resulted in the susceptible parasites in all mice being below detection 
level by day 11. However, also these susceptible parasites relapsed after drug pressure 
wore off, coinciding with the relapse of resistant parasites. 
 
Taken together, drug-treated infections had a slightly lower total asexual parasite 
density than untreated infections (Figure 6.3c; F1,46=5.1, p=0.029). However, among 
the different treatment regimes, no differences were observed in total parasite density 
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(F6,34=0.7, p=0.69). These similar parasite densities among treatment groups are the 
result of high numbers of susceptible parasites and low numbers of resistant parasites 
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Figure 6.1 Asexual parasite dynamics of drug-resistant clone R (red line) and drug-sensitive 
clone S (black line). Infections were either left untreated (a), treated with 8 mg/kg 
pyrimethamine for 5 days in a row (“Conventional”) (b), or received one of the alternative 
treatments: 4 mg/kg only once (c), 8 mg/kg only once (d), 4 mg/kg every 7 days (e), 8 mg/kg 
every 7 days (f), 4 mg/kg every 4 days (g) or 8 mg/kg every 4 days (h). Days of drug treatment 
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Figure 6.2 Asexual parasite dynamics of clone S (upper panel), clone R (middle panel) and 
clone R+S combined (bottom panel) of untreated infections (solid thin red line), infections 
treated with a low dose of drugs (4 mg/kg) given only once (dashed thin orange line), every 7 
days (dotted thin pink line), or every 4 days (dotdashed thin green line) and infections treated 
with a high dose of drugs (8 mg/kg) given only once (dashed thick cyan line), every 7 days 
(dotted thick blue line), every 4 days (dotdashed thick purple line) or for 5 days in a row only 
(“Conventional treatment”, solid thick black line). Drug treatment was in all cases initiated on 
day 6 PI, as indicated by the dashed grey line. Data are geometric means (± standard error) of 
5-7 mice (Table 6.1). 
 
















































































































































































Figure 6.3 Geometric mean (± standard error) asexual parasite density per day after start of 
treatment (left panels) and arithmetic mean (± standard error) predicted number of infected 
mosquitoes from a total of n=100 after start of treatment (right panels) of clone R (upper 
panels), clone S (middle panels) and clone R+S combined (bottom panels) for each treatment 
group. Treatment groups (x-axis) were no treatment (left hand bar in gray), 8 mg/kg for 5 days 
in a row (“conventional treatment”, right hand bar in dark red and dark green), or one of the 
alternative treatments: 4mg/kg given only once (“4mg once”), 4 mg/kg given every 7 days 
(“4mg e7d”), 4 mg/kg given every 4 days (“4mg e4d”), 8 mg/kg given only once (“8mg once), 8 
mg/kg given every 7 days (“8mg e7d”) and 8 mg/kg given every 4 days (“8mg e4d”). Data are 
means of 5-7 mice (Table 6.1). The p-values indicate the level of significance of the difference 
between untreated and all drug-treated groups together. The asterisks point out the alternative 
treatment groups which differ from conventional treatment (based on post-hoc Tukey HSD 
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6.4.2 Transmission potential 
Clone R did not produce gametocytes in untreated infections, while clone S typically 
produced three distinct gametocyte peaks throughout the infection: the first coinciding 
with peak asexual parasite densities, a second around day 12 and a third after day 20 
post-infection (Figure 6.4a, 6.5a). As a result of competitive release of resistant 
parasites, clone R produced a single gametocyte peak following drug treatment, 
coinciding with the asexual parasite relapse and the level of release of gametocytes 
dependent on the drug regime (Figure 6.4b-h, 6.5b). 
 
Importantly, drug treatment with a high dose resulted in increased gametocyte density 
the day following drug treatment, whereas untreated infections showed a drop in 
gametocyte density (padj<0.001). A difference between untreated and low dose 
treatment was also found (padj=0.005), with the latter having similar gametocyte 
densities before and after treatment (inset graph figure 6.5a). Also, the single low dose 
treatment resulted in a greatly increased second gametocyte peak of susceptible 
parasites compared to all other treatment regimes (Figure 6.5a). 
 
Large differences between different treatment regimes were thus found in the 
predicted transmission of clone S (Figure 6.3d), with all low dose treatments resulting 
in higher predicted transmission than conventional treatment. Among the alternative 
treatments, drug dose had the greatest impact on transmission of susceptible parasites 
(dose: F1,29=33, p<0.001), whereas frequency of treatment did not make a difference 
(frequency: F2,29=1.7, p=0.20). 
 
Drug treatment greatly increased the transmission potential of drug-resistant 
parasites (F1,46=7.3, p=0.010). Conventional treatment provided the greatest predicted 
infectivity for resistant parasites than all other treatments, with the exception of 8 
mg/kg given every four days (Figure 6.3e). Among the different alternative treatment 
regimes, a higher drug dose was the biggest determinant for increased transmission 
potential for resistant parasites (F1,32=7.0, p=0.012). A higher frequency of treatment 
did not increase the predicted infectivity of clone R (F2,32=1.1, p=0.33).  
 
Altogether, drug treatment tended to increase the overall infectiousness of the mixed 
infections (F1,45=4.0, p=0.053). No differences were found in the overall infectiousness 
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between conventional treatment and the alternative treatments (Figure 6.3f), which, 
as in the asexual densities, is the result of the balance between high transmission 
potential of susceptible parasites and low transmission of resistant parasites or vice 
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Figure 6.4 Gametocyte dynamics of drug-resistant clone R (red line) and drug-sensitive clone S 
(black line). Infections were either left untreated (a), treated with 8 mg/kg pyrimethamine for 5 
days in a row (“Conventional”) (b), or received one of the alternative treatments: 4 mg/kg only 
once (c), 8 mg/kg only once (d), 4 mg/kg every 7 days (e), 8 mg/kg every 7 days (f), 4 mg/kg 
every 4 days (g) or 8 mg/kg every 4 days (h). Days of drug treatment are indicated by asterisks. 
Data are geometric means (± standard error) of 5-7 mice (Table 6.1). 
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Figure 6.5 Gametocyte dynamics of clone S (upper panel), clone R (middle panel) and clones 
R+S combined (bottom panel) of untreated infections (solid thin red line), infections treated 
with a low dose of drugs (4 mg/kg) given only once (dashed thin orange line), every 7 days 
(dotted thin pink line), or every 4 days (dotdashed thin green line) and infections treated with a 
high dose of drugs (8 mg/kg) given only once (dashed thick cyan line), every 7 days (dotted 
thick blue line), every 4 days (dotdashed thick purple line) or for 5 days in a row only 
(“Conventional treatment”, solid thick black line). The inset graph in the upper panel is an 
enlargement of day 6 and 7 PI. Drug treatment was in all cases initiated on day 6 PI, as indicated 
by the dashed grey line. Data are geometric means (± standard error) of 5-7 mice (Table 6.1).  
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6.4.3 Host health 
Drug treatment led to earlier recovery from anaemia and body mass loss during the 
acute phase of the infection compared to untreated infections, which resulted in less 
weight loss and anaemia in drug-treated than in untreated infections (Figure 6.6, 
6.7ab, minimum red blood cell density: F1,45=66, p<0.001; maximum proportional body 
mass loss: F1,46=4.2, p=0.045;). However, drug-induced parasite relapses also affected 
host-health, with a relapse in anaemia coinciding with parasite relapse (Figure 6.6b, 
6.7c). Parasite relapses did not affect mouse body mass (Figure 6.6a, 6.7d). The 
anaemia relapses were most severe following conventional treatment, though no 
significant differences were observed with the alternative treatments, with the 
exception of high dose treatment given every 4 days (Figure 6.7C). Importantly, 
frequency of drug treatment had a significant impact on the severity of the anaemic 
relapse; more frequent treatment resulted in reduced red blood cell loss (frequency: 
F2,31=3.7, p=0.037), while treatment dose did not have an impact on the severity of the 
anaemic relapse (dose: F1,31=0.1, p=0.78). Overall, no differences were observed 
between conventional treatment and alternative treatments on the average red blood 
cell density and change in body mass after the start of treatment regimes.  
 
Of note is that mice which were treated less frequently throughout the infection (no 
treatment, treatment given only once and conventional treatment given 5 days in a 
row early in the infection), increased in body mass at a slightly higher rate than mice 
that were treated more frequently (Figure 6.6a). This observation is likely a result of 
treatment stress. We deliberately chose not to include control mice for each treatment 
or impose treatment stress on all mice for each treatment to reduce the number of 
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Figure 6.6 Mean change in body mass (upper panel) and red blood cell densities (lower panel) 
through time of untreated infections (solid thin red line), infections treated with a low dose of 
drugs (4 mg/kg) given only once (dashed thin orange line), every 7 days (dotted thin pink line), 
or every 4 days (dotdashed thin green line) and infections treated with a high dose of drugs (8 
mg/kg) given only once (dashed thick cyan line), every 7 days (dotted thick blue line), every 4 
days (dotdashed thick purple line) or for 5 days in a row only (“Conventional treatment”, solid 
thick black line). Drug treatment was in all cases initiated on day 6 PI, as indicated by the 
dashed grey line. Data are means (± standard error) of 5-7 mice (Table 6.1). 
 
 













































































































































































Figure 6.7 Red blood cell density (left panels) and change in body mass (right panels) per 
treatment group. The upper panels show the mean minima reached during the acute phase (day 
3 to 11), the middle panels show the mean minima reached during relapse (day 12 to 25), and 
the bottom panels show the mean values over the course of infection after the start of 
treatment (day 7-49 PI). Treatment groups were no treatment, 8 mg/kg for 5 days in a row 
(“conventional treatment”), or one of the alternative treatments: 4mg/kg given only once (“4mg 
once”), 4 mg/kg given every 7 days (“4mg e7d”), 4 mg/kg given every 4 days (“4mg e4d”), 8 
mg/kg given only once (“8mg once), 8 mg/kg given every 7 days (“8mg e7d”) and 8 mg/kg 
given every 4 days (“8mg e4d”). Data are arithmetic means of 5-7 mice (Table 6.1). The p-values 
indicate the level of significance of the difference between untreated and all drug-treated 
groups together. The asterisks point out the alternative treatment groups which differ from 
conventional treatment. Note the y-axis varies between plots.  
 
 




In this experiment, we tested the hypothesis that drug treatment regimes other than 
the conventional approach of radical parasitological cure could perform better at 
simultaneously maximizing all three treatment goals: (i) improvement of patient 
health, (ii) reduction in infectiousness, and (iii) resistance management. The data 
presented here provide proof of principle that there are other treatment strategies 
which do this. Reduced drug dosages resulted in less competitive release of resistant 
parasites, which furthermore resulted in a lower predicted transmission potential for 
resistant parasites (resistance management). High dose treatment reduced 
transmission potential of susceptible parasites but increased the transmission 
potential of resistant parasites. The reverse was observed in low dose treatment. 
Therefore, the overall predicted infectivity of both clones combined was comparable 
across the diverse treatment regimes. All treatment regimes reduced host morbidity as 
well as conventional treatment, though conventional treatment caused pronounced 
anaemia during relapse. Together, these data show that, in principle, there are 
treatment regimes other than radical parasite cure, which perform equally well or 
even better at improving host health and reducing transmission, while more effectively 
reducing the predicted infectivity of the resistant parasites. 
 
Thus, our data suggest that current treatment regimes may not be the best approach to 
treat patients with malaria if these results generalize to natural human infections. In 
our experiment, reduced treatment was enough because host immune system rapidly 
controlled the infection. This might take longer in P. falciparum infections. 
Additionally, the ‘best’ treatment likely depends on a variety of factors. The infections 
in this study were seeded with a low abundance of drug-resistant parasites. Hence, 
resistance was already present. If resistance had not been present in the infection, 
conventional treatment would have likely been the best treatment at controlling 
parasite populations and reducing overall infectivity (Figures 3ad). The best rational 
treatment regime may thus depend on the presence of resistant mutants, whereby for 
instance a change in treatment practice from conventional treatment to a reduced 
treatment regime is advised once resistant parasites have been observed in a region. 
The dramatic effect of continuing drug treatment in an area with high level drug 
resistance was demonstrated using the effect of IPTp. These intermittent treatments 
work very well in areas with low levels of resistance (ter Kuile et al. 2007), however, 
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when resistance is wide spread, IPTp seems to exacerbate malaria infections in 
pregnant women (Harrington et al. 2009).  
  
Reducing drug dose or shortening the length of treatment to avoid the elimination of 
all susceptible parasites from an infection and therefore reducing the selection for 
resistance contradicts with medical orthodoxy. However, this orthodoxy is being 
challenged in different areas of research. In cancer treatment for instance, a recent 
study has shown that low but frequent drug dosages are the best way of controlling 
resistant cells from growing. This type of treatment resulted in 100% survival of mice 
infected with a human ovarian cancer, whereas all untreated and conventionally (high-
dose) treated mice died (Gatenby 2009; Gatenby et al. 2009). An in vitro study using 
the Staphylococcus aureus bacteria showed that a short course of antibacterial drugs 
performed better at controlling the resistant bacterial population than the 
conventional longer course (Drusano et al. 2009).  
 
Despite these recent studies questioning orthodox belief that the causal agent should 
be hit as hard as possible, the translation of the findings presented in this experiment 
to refinement of current treatment protocols for malaria is many steps away. The 
mouse malaria model system is, like any model of a human disease, an approximation 
of the reality and may not capture certain relevant factors. The findings in this study 
should therefore be interpreted with caution and merely be seen as a proof of 
principle, which, in due course, may lead to clinical trials. Before then, more empirical 
testing is necessary to establish the generality of these findings among a variety of 
parasite strains in both animal and in vitro P. falciparum models.  
 
Of note is that increased gametocyte densities following the first day of drug treatment 
were observed for susceptible parasites, with the highest densities following high dose 
treatment (Figure 6.5a). Such effect was also observed in the experiment described in 
chapter 2 of this thesis. This observation could be the result of so-called drug-induced 
gametocytogenesis as a response to conditions unfavorable for asexual replication. 
However, increased gametocyte densities immediately following treatment are not 
necessarily a result of gametocytogenesis, since gametocyte maturation in P. chabaudi 
is thought to take more than 24 hours (Carter and Graves 1988). An alternative 
explanation could be reduced gametocyte clearance rates following drug treatment. 
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Increased gametocyte densities following drug treatment have been observed before 
with pyrimethamine treatment in P. chabaudi in vivo (Buckling et al. 1999a), in P. 
falciparum following chloroquine treatment in vitro (Buckling et al. 1999b) and has 
been suggested multiple times in falciparum malaria in the field following 
sulphadoxine-pyrimethamine drug treatment (Puta and Manyando 1997; Robert et al. 
2000; Osorio et al. 2002; Sowunmi and Fateye 2003; Talman et al. 2004; Ali et al. 2006; 
Sowunmi et al. 2006), although these field data are difficult to interpret due to the 
absence of untreated controls. This facultative response, which appears to be dose 
dependent, can be important for the spread of drug resistance, since it reduces the 
relative fitness of drug-resistant parasites. The specificity of these findings to 
pyrimethamine should be further studied. 
 
An unexpected observation in this study was the low impact of drug treatment on 
susceptible parasites later on in the infection (Figure 6.1: susceptible parasite densities 
were increasing despite administered drug treatments). There are several possible 
explanations for this observation. First, the parasites from the susceptible strain could 
(partly) consist of drug-resistant mutants. Selection for resistance against 
pyrimethamine is very likely to occur after only a single exposure to this drug 
(Walliker et al. 1975). However, de novo resistant mutants are unlikely to be present at 
high densities early in the infection and are thus unlikely the cause for reduced 
sensitivity to high dose drug treatment as early as for instance 10 days post-infection 
(Figure 6.1h). Another explanation could be an enhanced drug detoxification by the 
mouse after multiple exposures, though we are unaware of any evidence for this 
mechanism. A specific characteristic of pyrimethamine is that it only kills replicating 
parasites (Foote and Cowman 1994). Therefore, a further explanation could be a 
persistence of temporarily growth-arrested intra-erythrocytic parasites (White 2008), 
or reduced growth rate or burst size later on in the infection resulting in reduced 
susceptibility. Furthermore, the synchronicity of P. chabaudi parasites is known to 
break down somewhat as the infection progresses (Mackinnon et al. 2002b). 
Therefore, a shift in the time of day of parasite replication could result in lower drug 
concentrations at the time of replication, since the half-life of pyrimethamine is 
estimated to be only 4.5 hours (Coleman et al. 1986). Finally, there could be a density-
dependent drug-efficacy effect, since the drug-efficacy was high at peak parasite 
density and evidently less effective at lower densities. 
 




Clearly, this is an issue that needs to be resolved. Further studies could demonstrate 
drug efficacy at different time points in an infection and the effect of multiple 
exposures on parasite reduction. Additional studies using different classes of drugs 
could show whether this is a pyrimethamine-specific effect. Understanding the 
mechanism behind reduced drug-efficacy later on in the infection is important, since it 
may also affect treatment efficacy of super-infecting parasite strains, depending on the 
mechanism. Nevertheless, even though the frequency of drug treatment did not have 
an impact on parasite densities, drug treatment with a low and high dose on a single 
day provides support for our hypothesis and shows that reduced drug treatment 
enhances resistance management while being equally good or better at improving 
patient health and overall infectiousness. 
 
From an evolutionary point of view, current treatment regimes do not a priori make 
sense as a resistance management strategy. The data presented here confirm this 
hypothesis. We are not advocating a direct change in malaria patient treatment 
regimens based solely on these data; more research is needed to this end. However, 
our data show the importance of evolutionary principles such as competition and 
selection for the potential spread of resistance and, furthermore, the different impact 
that various drug treatment regimes exert on resistant parasites. Such principles 
should not be ignored in policy making. To improve the useful life span of current and 
future antimalarial drugs, it is key to have an empirically-tested basis for rationally 
developing patient treatment regimens. Unfortunately, this is currently not the case. 
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A mathematical model was utilized in the decision process for choosing drug regimes 
to test experimentally. The basic model, derived from Mideo et al. (2008), is of the 
following generalized form:  
 
PS (t +1)= fS PS ( (t),R(t)) 
PR (t +1)= fR PR ( (t),R(t)) 
R(t +1)= g(R(t −τ ))− hS PS ( (t),R(t))− hR PR ( (t),R(t)) 
where PS, PR and R track the daily densities of drug-sensitive parasites, drug-resistant 
parasites and host red blood cells. The functions fS and fD describe the process of red 
blood cell invasion by parasites as well as the production of progeny parasites within 
an infected cell. The functions hS and hR account for the loss of red blood cells due to 
infection. In both cases, the subscripts denote the fact that while the functions are the 
same, they take on unique parameter values for each parasite strain (estimated by 
maximum likelihood procedures described in Mideo et al. (2008)). The function g 
describes the daily production of new red blood cells which depends on red blood cell 
density τ days earlier to account for the maturation time of blood cell precursors. 
Details of model assumptions, derivations and functional forms are in Mideo et al. 
(2008). 
 
Drug activity was superimposed on the model described above. Phenomenologically, 
anti-malarial drug action can be described as operating via a threshold mechanism – 
above a threshold drug concentration, a given proportion of susceptible parasites are 
killed and below the threshold, there is no effect of drugs (e.g. White 2008). The length 
of time that the within-host drug concentration is above this threshold and thus how 
long the drug-induced parasite decline continues depends on dose, dosing interval and 
duration of treatment. This was shown to be true for pyrimethamine against P. 
chabaudi in mice (Schneider et al. 2008). Using those data we estimated how drug dose 
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affects the duration of ‘drug activity’. The number of additional days (beyond the 







557.3 , where b is the drug dose in mg/kg. We also 
estimated that each day of drug activity results in a 94% decline in susceptible parasite 
numbers. 
Incorporating this description of drug action into the model of competition required no 
change to the model structure.  
 
In the absence of drug treatment, the dynamics of the two parasite strains and the host 
red blood cells are governed by the basic competition model. In the presence of drugs 
(on days drugs are administered + a days after), the density of drug-sensitive parasites 
on the next day is a simple linear function of the current density. Thus, PS (t +1) = 
0.06PS (t), while the rest of the system remains unaltered. Using this approach, we 
were able to qualitatively capture the outcome of competition experiments between 
drug-sensitive and drug-resistant malaria parasite clones in the presence of drugs, 
with conventional drug treatment (a dose of 8mg/kg for 4 days starting at the onset of 
disease symptoms) and with different initial ratios of sensitive to resistant parasites. 
This model was used to predict the effects of different drug regimens on the success of 
the drug-resistant parasite clone within a host. The treatment regimens which were 
predicted to give the most interesting dynamics and the best potential for suppressing 
the resistant parasites were included in the experiment. 
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7. General discussion 
A discussion on the specific findings of each experiment is given in the individual 
chapters. Here, I discuss the general findings of this thesis and the strengths and 
weaknesses of my experimental approach. Subsequently, I discuss the generalizability 
and significance of the conclusions drawn in this thesis. I finish by giving 
recommendations for future work which could improve our understanding of within-




The overall aim of this thesis was to increase our understanding of the within-host 
dynamics of drug-resistant and drug-sensitive parasites in the presence of drug 
treatment. A better understanding of the within-host dynamics is important to 
understand the spread of drug-resistant malaria strains (Hastings 2003; Read and 
Huijben 2009). The first steps towards this aim were made by studying the 
competition in untreated and prophylactic drug-treated infections (de Roode et al. 
2004). Additional complexity was added through drug treatment at peak parasitaemia 
when symptoms are occurring (therapeutic treatment) and shortening the treatment 
course (Wargo et al. 2007). In this thesis, I expanded on these early steps and added 
more complexity by studying multi-genotype infections, competition at different clone 
frequencies and competition between resistant and susceptible parasites from the 
same clonal lineage. Finally, I looked at a variety of different drug treatment regimes.  
 
I observed within-host competitive interactions between drug-resistant and drug-
sensitive parasites, with the resistant genotype having a competitive disadvantage in 
the absence of drug treatment. The frequency of resistant parasites at the start of the 
infection was an important determinant of the strength of selection: the lower their 
frequency, the stronger the competitive suppression in non-treated hosts and the 
greater their competitive release when drugs were given. Resistant and sensitive 
parasites derived from the same clonal lineage showed similar dynamics following 
drug treatment as genetically distinct resistant and susceptible parasites. Multiplicity 
of infection did not have an effect on the within-host dynamics: a larger number of co-
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infecting susceptible genotypes did not lead to greater competitive suppression or 
release of resistant parasites. Lastly, various drug treatment regimes were compared. 
Conventional drug treatment resulted in the greatest selective advantage for drug-
resistant parasites, while less aggressive treatments were equally as effective, or even 
better, at improving host health and reducing overall infectiousness.  
 
These experiments demonstrate that altering the within-host ecology of drug-resistant 
parasites by administering drugs and hence removing drug-sensitive competitors 
results in a positive selection for drug-resistant parasites in various ecological 
contexts. Together, these data provide proof of principle that drug treatment regimes 
which are less aggressive than conventional treatment could control drug-resistant 
parasites to a higher degree than conventional drug treatment, without compromising 
on other treatment goals.  
 
7.2 Experimental approach 
To study the within-host dynamics of resistant parasites and address the questions on 
optimal treatment regimes, the use of an experimental model system is unavoidable 
since my objectives cannot be addressed in clinical trials or with human volunteers as 
we need untreated control groups. Certain choices were made in selecting the 
experimental approach for this thesis. I will discuss the specificity of my findings 
towards these choices below. 
7.2.1 Plasmodium chabaudi model 
Although no animal model can fully capture the characteristics and dynamics of P. 
falciparum malaria in humans, the mouse malaria model has proven useful to gain 
insight in many areas of malaria research, such as malaria immune responses, vaccine 
development, genetics of drug-resistance and infection dynamics (Wykes and Good 
2009). P. falciparum and P. chabaudi parasites have various features in common. Both 
species prefer to infect mature red blood cells, as opposed to reticulocytes, and 
undergo rosetting and sequestration to endothelial cells. P. falciparum shows 
recrudescent asexual peaks after the acute peak, which is also observed in P. chabaudi 
infections. Both species produce similar gametocyte densities in these hosts. 
Additionally, both infections are normally resolved by the human or mouse hosts 
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(Taylor-Robinson 1995; Carlton et al. 2001). However, the P. chabaudi model does not, 
of course, capture every biological detail of human malaria.  
 
Mice are not the natural hosts of P. chabaudi. In this artificial laboratory model system, 
P. chabaudi is more virulent in mice than P. falciparum is in humans. In mice, mortality 
rates of P. chabaudi infections are much higher (5-20%) than P. falciparum infections 
in humans (0.1-1%). Also parasitaemia levels higher than 30% are common among P. 
chabaudi infections, whereas P. falciparum infections rarely have a parasitaemia higher 
than 10%. Since mice are much smaller, total parasite density in mice at peak 
parasitaemia is around 109 parasites (based on a blood volume of 1.5 ml) and in 
humans 1010-1012 (e.g. Hastings and D'Alessandro 2000; Arrow et al. 2004), leading to 
potentially more mutational variation in P. falciparum infections. Mice develop 
sterilizing immunity against P. chabaudi infections, with infections below detection 
threshold after approximately 50 days, whereas P. falciparum infections are usually 
detected for over 100 days. However, another fundamental difference between P. 
falciparum and P. chabaudi parasites is that the former has a life cycle of 48 hours, 
opposed to 24 hours for P. chabaudi. Therefore, in terms of generation time, 
persistence in the host could be comparable between both species (Taylor-Robinson 
1995; Carlton et al. 2001).  
 
Thus, there are several differences between this mouse malaria model and P. 
falciparum in humans. The relative importance of these differences is unknown and 
depends on the question asked. In this thesis, I am interested in the within-host 
kinetics of parasites. There are no obvious reasons that these differences should affect 
my conclusions, with the possible the exception of a higher parasitaemia in P. chabaudi 
infections that could enhance competitive interactions. However, a large body of field 
data suggests competitive interaction between P. falciparum genotypes occurs 
(Daubersies et al. 1996; Mercereau-Puijalon 1996; Smith et al. 1999; Bruce et al. 2000; 
Hastings 2003; Talisuna et al. 2006; Bousema et al. 2008; Harrington et al. 2009). 
Overall, I consider the mouse model system a useful model to study these general 
principles, though drug treatment policy will not be changed based solely on these 
data. Nevertheless, these data, along with additional data as described in the future 
directions section (§ 7.5), could strongly argue for empirical testing in human field 
trials. 
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7.2.2 Choice of drug 
The antimalarial drug used in these experiments is pyrimethamine. Since I am 
interested in the effect of drug treatment (that is, the removal of susceptible parasites 
from a mixed infection) on the relative and absolute fitness of resistant parasites, my 
conclusions should qualitatively pertain to all drugs. However, some differences 
between drugs could have a quantitative influence on the questions posed here.  
 
First, the rate at which susceptible parasites are removed can vary for different classes 
of drugs. Artemisinin-based drugs, for instance, cause a much higher rate of parasite 
clearance than pyrimethamine (104 parasites/cycle and 102 parasites/cycle 
respectively; White 2008), which may have a more immediate effect on the dynamics 
of drug-resistant parasites. Second, the half-life of antimalarial drugs varies 
significantly between different drug classes. Pyrimethamine has a relatively long half-
life in humans (~ 4 days), compared to artemisinin derivatives which have a very short 
half-life (~ half an hour; White 1985). Drug half-lives in mice are much shorter: the 
half-life of pyrimethamine is estimated to be 4.5 hours (Coleman et al. 1986) and that 
of artemisinin derivatives 19 minutes (Batty et al. 2008). Treatment with a drug that 
has a long half-life results in an extended period of susceptible parasites being killed 
compared to drugs that have a short half-life. This will thus result in an extended 
positive selection on the drug-resistant population. Finally, the genetics of resistance 
may be of influence on the experimental results since the likelihood of susceptible 
parasites developing resistance in the course of an experiment may differ per drug. 
Pyrimethamine resistance develops rather easily in the lab (Walliker et al. 1975), while 
de novo resistance mutations against artemisinins seem to be much rarer (Afonso et al. 
2006; Puri and Chandra 2006). Therefore, for some drugs, the possibility of developing 
resistance in the susceptible parasite population as the experiment progresses has to 
be taken into account. However, the above differences between drugs should not 
qualitatively affect the results as described in this thesis. Since the aim here is to study 
the general principles of removal of drug-susceptible parasites in mixed infections of 
resistant and susceptible parasites, I do consider it unlikely that the conclusions drawn 
in this thesis to be specific for pyrimethamine, but clearly other drugs have to be 
studied. 
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7.2.3 Density-infectivity analysis 
In this thesis, I studied the effects of drug treatment on the relative and absolute 
fitness of resistant parasites in different ecological contexts. In reality, however, ‘true’ 
fitness of the resistant parasites was not studied in these experiments, since the full life 
cycle of a Plasmodium parasite involves a vertebrate and mosquito host. The 
experiments presented here do not include transmission from mice to mosquitoes 
because of the additional complexity and number of mice involved. Instead, the fitness 
of the resistant parasites was inferred by analyzing the gametocyte densities using a 
density-infectivity function. Such analysis is an improvement of the somewhat 
arbitrary cumulative gametocyte densities through time, which has been used 
previously (e.g. Wargo et al. 2007), since mosquito infectivity and hence parasite 
fitness is not a simple linear function.  
 
This approach, however, is not a perfect alternative for parasite fitness either, because 
there are many gaps in our knowledge on mosquito infectivity. Apart from the lack of 
data to determine the exact relationship between gametocyte densities and infectivity 
as discussed in chapter 2, there are some additional caveats in this type of analysis. 
The density-infectivity analysis assumes an equal infectiousness through time, 
whereas in reality, the shape of the density-infectivity function likely changes through 
time. Much variability in gametocyte infectivity is observed, with for instance 
gametocytes produced during the acute phase of the infection appearing to be less 
infectious than gametocytes produced later on (Jeffery and Eyles 1955; Drakeley et al. 
2006; Hallett et al. 2006; Wargo 2006 - chapter 3). This initial gametocyte peak, 
however, is often the highest during the course of infection and weighs heavily 
towards determining the predicted infectivity of the parasites. Later on in the 
infection, transmission blocking immunity can also result in reduced infectivity of 
gametocytes (Beier 1998), while there is also evidence of enhanced gametocyte 
infectivity of chronic infections (Nedelman 1989; Boudin et al. 1993). Furthermore, the 
analysis used assumes no interaction between parasites in the mosquito vector, 
something that is likely to occur in reality (Paul et al. 2002). 
 
Thus, more direct transmission data on gametocyte infectivity is required to refine the 
density-infectivity analysis, such logistically complex experiments were beyond the 
scope of this thesis. I do not expect that the conclusions in this thesis are biased due to 
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the choice of analysis, as the observation is that competitive release of asexual 
parasites translated into a release of gametocytes which must result in a fitness 
advantage for resistant parasites, all else being equal. The aim of this analysis was to 
give a more biological meaningful comparison of predicted infectivity between 
different treatment groups, not to quantitatively predict actual transmission. 
 
7.3 Generalizability of findings 
The general aim of this thesis is to study the effect of drug treatment on the within-
host ecology of drug-resistant and drug-sensitive malaria parasites. This aim is based 
on the main evolutionary principle that the removal of susceptible competitors will 
lead to a competitive release of drug-resistant parasites (Hastings 2003; de Roode et 
al. 2004; Wargo et al. 2007; Read and Huijben 2009). This evolutionary principle 
should be relevant for all diseases where genetically diverse infections are common 
and resistant pathogens are present and spread through the population.  
 
However, different diseases have different ecological characteristics and may have 
different treatment goals. Therefore, the optimal treatment regime may vary greatly 
between diseases. For instance, in the case of cancer, the aim of treatment is not to 
reduce infectiousness, since it is not an infectious disease. In the case of HIV/AIDS 
infections, de novo resistance mutations, which can threaten the life of the treated 
patient, are more of a concern than the spread of resistant viruses. Bacterial infections 
have an additional complexity of lateral transfer of resistance genes for other bacteria. 
Here, drug treatment increases overall selection for resistance genes, including in the 
non-target bacterial population, and these resistance genes can subsequently be 
transferred to the target population.  
 
Thus, while the general evolutionary principles that are demonstrated in this thesis 
may be applicable to a wide variety of diseases, the application to inform drug 
treatment regimes may differ considerably between diseases, depending on the social 
context. Currently, however, the same approach of high-level, long-duration drug 
treatment is applied to virtually every disease. More empirical data are needed to 
design disease-specific rational treatment regimes. The current ‘kill-them-all approach’ 
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that is used for nearly all diseases is unlikely to be the best resistance management 
strategy in every specific situation.  
 
7.4 Significance of findings 
The translation of these findings to refinement of current treatment protocols for 
malaria is many steps away. There are some obvious objections to reduce current 
advised treatment dosages, which I will discuss below. 
 
The first and foremost concern is that anything less than full course chemotherapy 
could endanger patient health. Yet, the current aim is to kill every single parasite 
(parasitological cure), which usually involves the continuance of treatment beyond the 
improvement of patient health (therapeutic cure). The use of therapeutic cure, as 
opposed to parasitological cure, need not compromise patient health. Further studies 
need to examine whether reduction in drug dosage from parasitological to therapeutic 
cure would be enough to control the release of resistant parasites. The implementation 
of such a treatment regime could be a simple ‘take drugs until you feel better’ advice, 
with treatment repeated when symptoms reoccur. Another approach would be a 
frequent (for instance once a week) low dose of drug treatment to keep parasite 
growth under control. A further concern to reduced treatment regimes is that lower 
drug dosages may result in chronic asymptomatic parasitaemia, which can increase the 
risk of anaemia and other diseases such as chronic hepatosplenomegaly (enlargement 
of spleen and liver), nephrotic syndrome (kidney damage) and Burkitt’s Lymphoma 
(childhood lymphatic cancer) (Gilles 1986; Greenwood 1987; Wilson et al. 2007). 
Finally, chronic infections may result in increased gametocyte carriage (Drakeley et al. 
2006) and thus increased malaria transmission. On the other hand, chronic malaria 
infections are known for their generation of protective immunity; removing the 
majority of the infections from a population could potentially increase malaria 
morbidity and mortality (Smith et al. 1999; Males et al. 2008).  
 
The above concerns arise from the distinction and possibly the trade-off between 
resistance management and the other treatment goals: patient health and overall 
infectiousness. Without a full (empirical) understanding on the effect of various 
treatment regimes on these three treatment goals (WHO 2006), a conclusion on the 
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existence of a trade-off between them cannot be drawn. In the best case scenario, the 
work presented in this thesis, combined with future work leading from this thesis, will 
lead, through appropriate clinical trials, to the implementation of empirically validated 
rational treatment design, which will hopefully lead to extending the therapeutically 
useful life spans of current or future drugs. If future work, either empirically or 
through clinical trials, demonstrates that current treatment practices are indeed the 
best practice (based on the three treatment goals), this would still be a valuable 
outcome: there is a need for an empirically-proven foundation of treatment regimens 
which are supported by evolutionary principles. If the future teaches us that radical 
parasitological cure of malaria patients is indeed the best resistance management 
strategy by strongly reducing the probability of resistance mutations, with selection on 
pre-existing resistant parasites being an unavoidable side-effect of this treatment 
strategy, different approaches to slow the spread of resistance, once it has arisen, 
should be studied. The dramatic effect of increased parasitaemia in pregnant women 
drug-treated with SP in an area with widespread SP drug resistance was demonstrated 
in the study by Harrington et al. (2009). Therefore, the best rational treatment regime 
may depend on the presence of resistant mutants: a reduced treatment regime can be 
advised to control the spread of these resistant parasites once they have been 
observed.  
 
7.5 Future directions 
Clearly, treatment practices cannot be based solely on the data presented here; more 
research is needed. First, more experiments are needed to establish the generality of 
our findings within the P. chabaudi model. The conclusions presented in this thesis are 
based on (i) few clonal parasite lineages in (ii) one inbred host genotype using (iii) one 
specific drug. While the evolutionary principles are expected to be similar across a 
wide variety of parasite clones, mice genotypes and immune status, and different 
classes and combinations of drugs, this hypothesis should be tested empirically before 
the principles presented here can be tested in clinical trials. Second, experiments using 
P. falciparum in vitro should be conducted to confirm the findings from the P. chabaudi 
experiments. Furthermore, this model can be used to test the various treatment 
regimes on their ability to reduce the probability of de novo mutations, but also 
selection for resistance. Moreover, resistant mutants from the field could be tested in 
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this in vitro model on their response to different treatment regimes. Third, 
mathematical models could provide a good insight in the dynamics of resistant and 
susceptible parasites following treatment and will reduce the number of experimental 
mice needed. The model used in chapter 6 of this thesis demonstrated the usefulness 
of such a mathematical model by providing an informed choice of treatment regimes to 
include in the experiment based on predictions from the model. Such a model, specific 
for P. falciparum would be particularly useful. Additionally, mathematical models could 
provide insight in the spread of drug-resistance on a population level following various 
treatment regimes. Fourth, if this thesis, combined with the above proposed future 
studies, provides enough convincing empirical evidence, the proposed principles could 
be tested in controlled field trials. During these field trials, much research will need to 
be done not only on the ecology of resistant parasites but also on the short-term and 
long-term effects of reduced treatment regimes on patient health and overall 
transmission.  
 
7.6 Concluding remarks 
The conclusions drawn in this thesis are highly controversial because they challenge 
conventional wisdom. I also recognize that the mouse model, like most other animal 
models of human disease, fails to capture some aspects of human malaria and I am 
therefore not advocating an alteration of malaria patient treatment regimens based 
solely on these data. However, I hope to start a dialogue between policy makers and 
evolutionary biologists to critically revisit treatment practices and determine what 
data are needed to lead to better-informed treatment designs. I believe this thesis is a 
first step on the route towards evolutionary-informed rational patient treatment 
regimes.  
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Introduction
Drug resistance causes immense human suffering globally
and is one of the best documented examples of evolution
in real time. No self-respecting introductory evolution
text fails to mention this, and several professional evolu-
tion societies give this as a major practical argument for
the teaching of evolution and continued investment in
evolutionary science (Meagher and Futuyma 2001). Yet
the drug resistance field is – with a few outstanding
exceptions – dominated by people with no training in
evolutionary biology. Indeed, the microbiologists, clini-
cians and public health practitioners who publish on drug
resistance do not even much use the word ‘evolve’– they
more naturally use ‘emerge’, ‘spread’ or ‘arise’ (Antonovics
et al. 2007). The vast majority of publications on the
evolution of antibiotic resistance are in the medical field
and not in academic evolutionary biology or genetics
journals (Antonovics et al. 2007).
Why do so few professional evolutionary biologists
work on drug resistance evolution, particularly given the
commercial and grant money involved? This is certainly a
specific instance of the remarkable antipathy of most
evolutionary biologists to utilitarian science (the journal
Evolutionary Applications appeared 17 years after the first
issue of Ecological Applications), an antipathy historians of
science have yet to explain. But in the case of drug
resistance, the overwhelming volume of data does make
assimilating the relevant natural history a challenge,
especially as the data are elucidated by physicians, veteri-
narians, microbiologists and public health specialists, so
that a foreign, often pathogen-specific jargon and intellec-
tual culture dominates. Moreover, drug resistance, like
many biomedical problems, is perhaps not so interesting
to those attracted to evolutionary biology by a passion for
‘natural’ natural history.
But we think it goes deeper than this. Based on an
entirely ad hoc, nonrandom sample of our colleagues (lar-
gely the evolutionary biologists we meet at conferences),
we believe the main reason evolutionary biologists avoid
drug resistance is that evolutionary biologists consider
drug resistance to be conceptually uninteresting. And at
one level it is. As Antonovics et al. (2007) point out, ‘the
evolution of antibiotic resistance, while critically impor-
tant from a medical view point, is no longer in and of
itself a novel finding in evolutionary biology’. This is true
of course, but the evolutionary processes which determine
patterns of drug resistance are a different issue. Our straw
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Abstract
Evolutionary biologists have largely left the search for solutions to the drug
resistance crisis to biomedical scientists, physicians, veterinarians and public
health specialists. We believe this is because the vast majority of professional
evolutionary biologists consider the evolutionary science of drug resistance to
be conceptually uninteresting. Using malaria as case study, we argue that it is
not. We review examples of evolutionary thinking that challenge various falla-
cies dominating antimalarial therapy, and discuss open problems that need
evolutionary insight. These problems are unlikely to be resolved by biomedical
scientists ungrounded in evolutionary biology. Involvement by evolutionary
biologists in the science of drug resistance requires no intellectual compro-
mises: the problems are as conceptually challenging as they are important.
Evolutionary Applications ISSN 1752-4571
ª 2009 The Authors
40 Journal compilation ª 2009 Blackwell Publishing Ltd 2 (2009) 40–51
poll reveals that most professional evolutionary biologists
consider these processes conceptually simple (mutation,
selection, fixation), and any solutions largely obvious
(combination therapy, reduced drug use). The general
feeling seems to be that drug resistance provides excellent
examples with which to begin evolution classes and intro-
ductory textbooks, and an excellent vehicle to get across
basic population genetics. But it is not believed to be an
intellectually challenging pursuit around which to struc-
ture an interesting evolutionary research program.
Here we attempt to counter this view. We believe there
is a strong case for advanced classes in drug resistance
evolution, and also that there are numerous conceptually
challenging problems in drug resistance evolution to
which evolutionary biologists can make unique contribu-
tions. The solution of these problems would both be
intellectually rewarding and could reduce human suffer-
ing. We make this case using malaria, with which we are
most familiar, but we believe similar arguments can be
made for almost any infectious disease.
We illustrate our case by reviewing a series of fallacies
which were, or still are, held by the malaria community
(albeit here translated into evolutionary language), and
we finish with a number of very open evolutionary
research questions. Throughout, we have picked examples
which we think are both interesting and challenging, and
which demonstrate the practical contribution evolutionary
biology is making, or could make, to help alleviate the
medical problems caused by drug resistance. By way of an
aside, we emphasize that none of this is intended as an
argument against fundamental evolutionary research
(clearly everything we discuss here builds on that founda-
tion), or a critique of those biologists – evolutionary or
otherwise – currently engaging with drug resistance. Our
point is that the proportion of evolutionary biologists
working on drug resistance is tiny compared with the
importance and size of the problem – and the conceptual
interest of the issues involved.
The malaria drug resistance problem
Malaria parasites have evolved resistance to all classes of
antimalarials that have gone into widespread use, except
for the recently deployed artemisinin derivatives (Roll
Back Malaria 2008). Resistance was first reported from
the field between 1 and 15 years after introduction,
depending on the drug (Fig. 1; Peters 1987, Hyde 2005)
with drugs failing (i.e. being withdrawn from use by
national authorities) years or even decades after that. For
instance, chloroquine was widely deployed after the Sec-
ond World War, with resistance first seen in the field in
1957 in Thailand (Talisuna et al. 2004). Molecular evolu-
tion studies show that chloroquine resistance arose only a
handful of times, from which it spread world wide
(Fig. 2A). It never arose in Africa. Chloroquine was first
withdrawn as a first line drug from Thailand in 1973
(Talisuna et al. 2004) and is now recommended only for
central America, where parasites are still susceptible
(WHO 2008). High level sulphadoxine–pyrimethamine
(SP) resistance was observed within the same year as it
was introduced in Thailand in 1967 (Talisuna et al.
2004), but replaced chloroquine as first line treatment in
most African countries in the early 1990s. Resistance
against SP is now widespread. Similar to chloroquine
resistance, the major cause of SP resistance in Africa is
thought to be a consequence of a selective sweep from a
single introduction from southeast Asia (Fig. 2B) (Roper
et al. 2004). There may also have been an African origin
Figure 1 History of the introduction of antimalarial drugs and the first detection of resistance in the field. The following abbreviations are used:
CQ, chloroquine; PG, proguanil; Pyr, pyrimethamine; SP, sulphadoxine–pyrimethamine; Mef, mefloquine; Hal, halofantrine; ACTs, artemisinin com-
bination therapies; Ato, atovaquone; Ato-PG, atovaquone–proguanil combination (malarone); LD, LapDap (chlorproguanil–dapsone). R as suffix
denotes resistance. Figure redrawn from Hyde (2005).
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in Kenya (McCollum et al. 2006) which seems not to
have spread far. Current hopes rest on artemisinin and its
derivatives, which have become the key element in cur-
rent malaria control plans (Roll Back Malaria 2008). Ar-
temisinins are used in co-formulations with other
antimalarial agents (artemisinin combination therapy,
ACT) in an attempt to minimize the chances of resistance
arising. So far this seems to be working, although there
are recent reports of parasites with reduced sensitivity to
some ACTs (White 2008) and artemisinin resistance can
be readily generated in the laboratory (Afonso et al. 2006;
Puri and Chandra 2006).
The evolution of drug resistance by malaria parasites is
now accepted as inevitable by the World Health Organi-
zation (WHO 2006), and a key component of the recently
released global malaria action plan (GMAP) is an explicit
plan for a drug delivery pipeline – intended as open-
ended so long as malaria parasites still exist (Roll Back
Malaria 2008). This is the so called ‘drug treadmill’, the
rolling-out of new drugs which will inevitably fail in the
face of parasite evolution. The GMAP estimates of the
cost of this pipeline are as follows. The basic research
budget is estimated as $US34 million per year, and the
development cost of bringing a new compound to market
at $US250 million over 10 years. The budget for reformu-
lation of compounds already in use (new combinations
for instance) is put at $US25 million over 2–6 years.
Given the rate at which existing drugs are rendered use-
less by evolution (in many cases, faster than the speed
with which new compounds can go through regulatory
processes), and the few useful compounds currently avail-
able, GMAP estimates that two new active ingredients for
(A)
(B)
Figure 2 The history of chloroquine and high level pyrimethamine–sulphadoxine (SP) resistance inferred from molecular evolution studies.
Chloroquine resistance has spread globally from selective sweeps from five independent origins, none of them in Africa where the health burden
of drug resistance is greatest. Resistance to SP is tracked by analyses of the dhfr gene which primarily confers resistance to the pyrimethamine
component. The timing of two of the independent origins is unclear. SP resistance may have several local origins in Kenya (denoted by ‘????’),
but the majority of SP-resistant infections are a consequence of a selective sweep from a single origin in South East Asia. Figure 2A is redrawn
from Wellems (2004), Fig. 2B is a summary of data from Cortese et al. (2002), Nair et al. (2003), Roper et al. (2003, 2004), McCollum et al.
(2006, 2007, 2008), Maiga et al. (2007), Mita et al. (2007), Hayton and Su (2008), Saito-Nakano et al. (2008).
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preventive therapy and six new ingredients for therapeutic
use will need to be discovered and brought to market in
the coming decade. Over the same period, 14 reformula-
tions of existing and new compounds will need to be
developed. Thus, the costs of the pipeline for R&D alone
(i.e. excluding the production and deployment costs) will
be in excess of $US2.5 billion for the coming decade to
get things up to speed. Once the currently inadequate
drug arsenal is rebuilt, $US1.5 billion will be required
every decade that follows. These are incredible amounts
of money for a disease affecting some of the poorest peo-
ple on the planet.
The challenge for evolutionary biologists is to devise
ways to slow the drug treadmill. This includes the demo-
lition of any evolutionarily-naı̈ve medical orthodoxies
which drive the treadmill faster. The speed of the tread-
mill is set primarily by the rate at which mutations con-
ferring resistance escape the clutches of stochastic loss
and establish in a population, and then the rate at which
they subsequently spread. The WHO considers a drug
ineffective once 10% of the parasites in a population have
become resistant (WHO 2006, p. 15). Reviews of malaria
drug resistance from a population genetics perspective are
provided by Hastings and D’Alessandro (2000), Hastings
(2001), Koella and Antia (2003), Barnes and White
(2005) and Mackinnon (2005), and from the more domi-
nant drug discovery, biochemistry or pharmacokinetic
perspective by Hastings et al. (2002), White (2004), Hyde
(2005), Barnes et al. (2008), Hayton and Su (2008) and
Stepniewska and White (2008). The current WHO guide-
lines for drug use at national and individual patient levels
are published by the WHO (2006).
Fallacy 1: Drugs active against transmission stages
slow the spread of resistance
It is apparently conventional wisdom among malariolo-
gists that the spread of resistance can be slowed by drugs
which target the parasite stages responsible for infecting
mosquitoes (sexual stages called gametocytes). For
instance Mendez et al. (2002, p. 237) state that ‘Antima-
larial drugs and drug combinations designed to eliminate
both asexual and sexual parasites may deserve priority
[…] because they will reduce the spread of drug resis-
tance in its earliest stages’. Similarly, the WHO (2006, p.
141) says that ‘Reducing transmission is fundamental to
the curtailment of drug resistance’, and Barnes and White
(2005, p. 230) state that ‘...reducing the carriage of
gametocytes […] is necessary to limit the transmission of
malaria parasites and the spread of antimalarial resis-
tance’. The intuition behind this orthodoxy is that attack-
ing transmission stages reduces the chances of
transmitting a resistant mutant.
But as Hastings (2006a) has pointed out, this argument
makes little evolutionary sense. It is true that gametocyto-
cidal drugs will reduce transmission, but they will do so
most strongly for sensitive parasites. The relative fitness
of resistant and sensitive strains determines the rate of
spread of resistance, and this will be increased by drugs
targeting transmission stages. Imagine an individual
infected with susceptible parasites and a few resistant
mutants. If drug treatment kills all susceptible gameto-
cytes, only the few resistant gametocytes will remain.
Now imagine treatment with a drug which kills only the
replicative (asexual) stages. Susceptible gametocytes
remain viable in the blood for weeks, and so will
co-occur with the resistant gametocytes. The relative
fitness of the resistant mutants is lower in the second
scenario compared to the first one. All else being equal,
gametocytocidal drugs will enhance the rate at which
resistant parasites rise in frequency in a population.
This can turn into a significant effect because small rel-
ative fitness differences compound through time. Using a
population genetics model, Hastings (2006a) has shown
that where drug use is common in a population, the
enhanced fitness advantage conferred by gametocytocidal
drugs on resistant strains can reduce the useful therapeu-
tic lifespan of a drug by about a year (15%) compared to
nongametocytocidal therapy. There may still be sound
reasons for using drugs which target transmission stages
(e.g. reductions in infectiousness, reducing case incidence,
or an incidental side-effect of high lethality against blood
stages), but resistance management is not one of them.
Indeed, these other reasons need to be weighed against
the enhanced resistance evolution that such drugs will
prompt.
Fallacy 2: Drugs with long half lives are
preferable
Drugs that are slowly eliminated from the body after
treatment have several clinical advantages. Clearly, they
provide longer term protection against re-infection. For
SP, this can be up to 2 months, which in a high transmis-
sion region can help prevent novel infections interfering
with recovery or generating new symptoms. Slowly elimi-
nated drugs also require fewer administrations to achieve
clearance, reducing problems of patient compliance.
However, as Watkins and Mosobo (1993) pointed out,
drugs with long clearance times also impose stronger
selection for drug resistance. This is because, for similar
treatment rates, parasites are substantially more likely to
encounter drugs with long half lives. If a course of artesu-
nate persists for 5 days, the drug pressure exerted by SP
is 10 times greater (Hastings et al. 2002). Drug half life is
typically left out of models of drug resistance, yet it may
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be one of the most powerful determinants of the useful
lifespan of a drug (Hastings et al. 2002). From the resis-
tance management perspective, drugs which are rapidly
eliminated from the body are preferable.
An important corollary of this argument is that half
lives of drugs used for combination therapy should be
similar (Hastings et al. 2002; Hastings and Watkins
2006). The more dissimilar the elimination rates, the
greater the chances that resistance to one of the compo-
nent compounds can become established in a population,
thus effectively reducing combination therapy to mono-
therapy. To achieve clearance with artemisinins alone
takes a 7-day treatment regime. Because adherence to a 7-
day course is typically poor, the current WHO policy is
to combine it with a slowly eliminated antimalarial drug
(WHO 2006; White 2008). Recent reports of the failure
of these combinations seem to be due to the failure
of the partner compound (e.g. Wongsrichanalai and
Meshnick 2008). This is likely to continue whenever the
partner is a slowly cleared compound. If so, rapid reform-
ulation of ACTs is going to be an open-ended necessity,
or there will need to be an abandonment of the aim of
complete clearance following ACT.
Fallacy 3: De novo resistance mutations are the
main enemy
Current malaria treatment guidelines for uncomplicated
malaria are radical parasitologic cure (WHO 2006). This
is achieved by the administration of sufficiently high
and repetitive drug dosages to ensure a kill of every par-
asite in an infection, and recommended patient treat-
ment regimes are explicitly designed to do this. A major
motivator behind this is that ‘[r]esistance can be pre-
vented, or its onset slowed considerably, by […] ensur-
ing very high cure rates through full adherence to
correct dose regimens’ (WHO 2006, p. 12). The under-
lying reasoning is that complete parasitologic cure (i)
reduces parasite biomass and thus the chances of resis-
tance mutations occurring (e.g. White 2004; WHO 2006,
p. 165), and (ii) minimizes the number of parasites
exposed to sub-curative drug dosages which favor ‘toler-
ant’ parasites (e.g. Hastings and Watkins 2006). Tolerant
parasites are mutants which are not fully resistant but
are able to survive subcurative doses and so are a muta-
tional step towards full resistance (Hastings and Watkins
2006).
However, there are very few data demonstrating that
resistance arising de novo within a patient is a clinically
relevant source of drug failure in malaria patients. Indeed,
as we summarized above, the evolutionary history of
resistance to two of the major antimalarials, chloroquine
and SP, argues that it is effectively zero. Resistance to
both drugs arose just a handful of times and spread
worldwide (Fig. 2). Indeed, chloroquine resistance seems
never to have arisen de novo in Africa: it was imported
from Asia. So far as is known, every patient in Africa with
chloroquine-resistant parasites got them from other peo-
ple, never from mutational processes within their own
infections. Most high-level SP resistance in Africa was
similarly due to a single selective sweep of resistance
introduced from SE Asia (Fig. 2).
Given this, the widespread conventional wisdom that
patients should take a full course of chloroquine to slow
resistance evolution makes little sense. Indeed, chloro-
quine resistance clearly failed to arise in Africa despite
widespread underdosing as a consequence of the eco-
nomically driven noncompliance and low quality drugs
(Djimde et al. 1998; Goodman et al. 2007; Bate et al.
2008). Moreover, the recommended patient treatment
regimes of overwhelming drug treatment, way beyond
what is needed on clinical grounds, imposes the strongest
possible selection in favor of resistance, possibly for little
clinical gain. Indeed, there is an inconsistency at the heart
of the current WHO (2006) guidelines. Correctly, there
is a strong argument for reducing unnecessary use of
antimalarials at a population level, so as to minimize
selection for resistance. In contrast, the recommendation
at the single patient level is overwhelming drug use even
when there is no clinical need. This maximizes selection
for resistance.
De novo resistance may not be irrelevant for all anti-
malarials, and where single point mutations confer high
level resistance as, for example against atovaquone
(White 2004), de novo mutations may be a serious issue
clinically. But for at least high level chloroquine and SP
resistance, for which there is the best data on the evolu-
tionary history, resistance arose so rarely that the de novo
origin of resistance can be ignored as a clinical concern.
The explanation for the rare origins is almost certainly
because complete resistance with high viability involves
multiple mutations (Hastings and Watkins 2006), and so
requires a highly unlikely series of mutational events to
occur simultaneously. Current combination therapy rec-
ommendations are – rightly – designed to make artemisi-
nin resistance similarly unlikely (WHO 2006). When
resistance against artemisinins does arise, as it inevitably
will, WHO will need to consider patient treatment
regimes that will minimize the spread of resistance – not
to continue to manage individual malaria patients against
the extraordinarily unlikely possibility that every patient
will be the source of a second origin. There is no strong
argument for treating malaria as if it were a highly
mutable pathogen like HIV, and nor is it a bacterium
which can easily acquire resistance by lateral gene
transfer.
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Fallacy 4: Genetic trade-offs alone determine the
magnitude of the costs of resistance
Much circumstantial evidence suggests that resistant
malaria parasites have a lower fitness than sensitive para-
sites in the absence of chemotherapy (Walliker et al.
2005; Felger and Beck 2008). Suggestive evidence for a
cost of resistance comes from progressive increases in
drug sensitivity in populations where drug use has been
discontinued. This has been seen in Malawi (Kublin et al.
2003; Mita et al. 2003; Laufer et al. 2006), Tanzania
(Temu et al. 2006), South-Africa (Raman et al. 2008),
Thailand (Thaithong et al. 1988), and China (Liu et al.
1995), although there are also areas where a decrease of
resistance has not been observed (e.g. McCollum et al.
2007; Yang et al. 2007). Seasonal variation in the fre-
quency of resistant alleles in eastern Sudan and The
Gambia is also consistent with costs of resistance. When
there is low to no transmission during the dry season,
and hence few new malaria cases and essentially no drug
use, resistance alleles drop in frequency among the chron-
ically infected patients who source the next outbreak.
During the wet season, when high transmission ensures
many new disease cases and hence high drug usage, resis-
tance alleles rise in frequency (Abdel-Muhsin et al. 2004;
Ord et al. 2007).
As in other pathogens, costs of resistance in malaria
presumably arise from the metabolic costs of efflux or
detoxification, or reduced biochemical efficiency associ-
ated with target site mutations (Hastings and Donnelly
2005); in other words, genetic trade-offs. Most models of
malaria drug resistance evolution recognize these costs of
resistance, but, if included at all, they are typically taken
as a fixed and relatively modest parameter (e.g. a selective
disadvantage s, so that the fitness of resistant mutant is
1 ) s, where s in the order of 0.1 or less). Although not
much discussed, we believe there is a widely held assump-
tion that these costs can be mitigated by compensatory
mutations, as they can be in bacteria and HIV (Levin
et al. 2000), so that s can drop further through time.
Such selection processes might explain some of the
sequential mutational steps associated with chloroquine
and SP resistance (Hastings and Donnelly 2005; Hastings
and Watkins 2006).
Yet the natural history of malaria makes it highly unli-
kely that the costs of resistance can be captured by a fixed
parameter like ‘s’, and moreover suggests that the costs
can often be much larger under some ecologic circum-
stances. This is because the costs of resistance are a func-
tion of the interactions between coinfecting strains within
the host. Indeed, this in-host ecology maybe the primary
determinant of the magnitude of the costs of resistance.
The natural history is as follows.
Human malaria infections frequently consist of more
than one Plasmodium genotype (Arnot 1998; Babiker
et al. 1999; Smith et al. 1999; Bruce et al. 2000; Jafari
et al. 2004), so that coexistence of sensitive and resistant
parasites is common – and indeed may even be the rule,
especially when resistance is beginning to spread through
a population. Mixed infections arise from inoculations of
genetically diverse parasites by a single mosquito, or con-
temporaneous bites by multiple mosquitoes infected with
different parasites.
A substantial body of correlational epidemiologic evi-
dence is consistent with crowding effects within infec-
tions, where population densities of individual genotypes
are suppressed when other genotypes are present (Dau-
bersies et al. 1996; Mercereau-Puijalon 1996; Smith et al.
1999; Bruce et al. 2000; Hastings 2003; Talisuna et al.
2006). Direct experimental evidence of crowding cannot
be ethically obtained from human infections, but in the
rodent malaria model Plasmodium chabaudi in laboratory
mice, we and others have experimentally demonstrated
that strong crowding effects occur. Replicative and trans-
mission stage densities of individual clones within an
infection are severely suppressed when coinfecting
strains are present (e.g. Jarra and Brown 1985; Taylor
et al. 1997; de Roode et al. 2004, 2005; Bell et al. 2006;
Wargo et al. 2007). Competitive suppression within hosts
also substantially reduces transmission of individual
clones to mosquitoes (de Roode et al. 2005). Therefore,
the removal of sensitive strains by chemotherapy leads to
competitive release of resistant strains (de Roode et al.
2004; Wargo et al. 2007).
We have found in our experiments with rodent
malarias that differences in clone performance are greatly
magnified by this crowding effect. An example is given in
Fig. 3. Pyrimethamine-resistant and sensitive clones are
shown. Alone, the resistance clone produces fewer trans-
mission stages. However, when the two clones coinfect
the same host, the difference is amplified by clonal com-
petition. We are currently doing experiments to see
whether this competitive disadvantage increases as more
sensitive coinfecting strains are added. In high transmis-
sion regions, infections can consist of five or more clones;
if crowding increasing with the number of clones, the fit-
ness disadvantage of resistance could substantially increase
with the force of infection.
Thus, the within-host ecology is likely to be a primary
determinant of the strength of selection of any resistant
mutant in the absence of chemotherapy: the ecologic cir-
cumstances can magnify fitness differences way beyond
those due simply to ecology-independent genetic trade-
offs (Hastings and D’Alessandro 2000; Mackinnon 2005;
Hastings 2006b). Except perhaps where single clone infec-
tions dominate (as can be the case in low transmission
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regions; Arnot 1998), infection context is almost every-
thing. Within-host genetic diversity is in turn determined
by the epidemiology (force of infection), since this is
what determines frequency of mixed infections in a popu-
lation. We suggest that standard population genetics
approaches to model drug resistance are likely to be of
very limited value in malaria. Explicit evolutionary epi-
demiologic models (Restif 2009) are needed instead. They
are in their infancy in this context (e.g. Hastings 2006b),
but there is no escaping this complexity: the epidemiology
determines the strength of selection and hence the evolu-
tion, and the evolution in turn determines the epidemio-
logic dynamics.
A highly contentious and unorthodox possibility is sug-
gested by the above considerations (Wargo et al. 2007).
Crowding by drug sensitive parasites will suppress trans-
mission stage densities of resistant parasites in untreated
hosts. This suggests it might be possible to harness these
within-host dynamics for human benefit: the use of
patient treatment regimes which do not remove all the
sensitive parasites may restrict the transmission of resis-
tance. Some evidence that this might be feasible comes
from one of our experiments with rodent malaria (Wargo
et al. 2007). We found that treating mice with half the
normal dose of antimalarials alleviated the symptoms as
effectively as a full dose, but a degree of in-host competi-
tion was retained, with the consequence that the trans-
mission potential of the resistant clone was significantly
less than in mice given standard doses. Considerably
more work needs to be done to evaluate the merits of
abandoning the parasitologic cure orthodoxy which cur-
rently form the basis of WHO (2006) patient treatment
guidelines, but we note that overwhelming chemotherapy
is also the way to most effectively up-select resistant
mutants in laboratory settings (e.g. Peters 1987), and that
host immunity can very effectively clear parasites, espe-
cially following drug treatment (Cravo et al. 2001). The
theoretical and experimental analysis of the possibility of
optimizing patient treatment regimes with respect to both
patient health and resistance management is long over-
due. For instance, would the best regime actually be what
is currently considered heretical: take drug treatment until
the patient feels better, then further treatment if there are
any symptom-associated relapses?
Fallacy 5: Fixation of resistance is inevitable if
drug pressure is maintained
A very interesting implication of in-host competition is
that the costs of resistance must be frequency-dependent.
When a resistant mutant first becomes established in a pop-
ulation, it will typically share its host with competitively
more able sensitive strains. As resistance becomes more fre-
quent, resistant strains will increasingly share their hosts
with other resistant strains. Because competition magnifies
differences in competitive ability as described above, this
means that the costs of resistance will be highest early in
the spread process, and will decline as resistant strains are
increasingly likely to be competing with strains with similar
competitive abilities.
Moreover, the benefits of resistance will be similarly fre-
quency dependent. For malaria, the benefits of resistance
accrue from two sources: (i) improved survival in a drug-
treated host, and (ii) removal of competitors (Hastings and
D’Alessandro 2000; de Roode et al. 2004). This competitive
release, whereby the resistant clone is able to expand into
‘niche space’ emptied by chemotherapy has the potential to
greatly magnify the survival benefits of resistance – and
indeed, it can shorten the therapeutically useful lifespan of
a drug many-fold below that expected if resistance evolu-
tion were powered only by the survival advantage (Hastings
and D’Alessandro 2000). Direct evidence of competitive
release cannot be ethically obtained for humans, but in
rodent malaria infections it is seen following both prophyl-
atic and therapeutic chemotherapy (Fig. 4; de Roode et al.
2004; Wargo et al. 2007). As this potent selective advantage
arises only when a resistant clone is in a coinfection with
sensitive clones, it will become progressively weaker as

































Figure 3 An example of how competition between parasites within
infections magnifies differences in performance between sensitive and
resistant parasite lines. Top panel – the performance of the two
clones when in separate infections. Bottom panel – the performance
of the two clones together in the same infection. The lower perfor-
mance of the resistant clone is further lowered by competition. Plot-
ted points are the mean (±SEM) density of transmission stages of
Plasmodium chabaudi in peripheral blood through time from three to
six laboratory mice per group (S. Huijben, A. R. Wargo, B. H. K. Chan,
D. Drew, A. F. Read, unpublished data). Parasite densities were quan-
tified by real time quantitative RT-PCR (Drew and Reece 2007).
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Thus, both the costs and benefits of resistance depend on
the frequency of resistance in a population. Hastings
(2006b) has pointed out that this means that resistance
evolution is likely to have dynamics which are considerably
more complex than the standard S-shaped curve of rising
allele frequencies through time seen in introductory
population genetics textbooks. He suggests that this might
explain why, for several different countries and drugs, resis-
tance has apparently stabilized at frequencies well short of
fixation (e.g. over 8 years in eastern Sudan, chloroquine
resistance fluctuated seasonally around an apparently stable
equilibrium frequency of 40%; Babiker et al. 2005).
More generally, given the enormous regional and sea-
sonal variation in the force of infection, which is the
major determinant of the genetic diversity of malaria
infections (Arnot 1998), it may be that there are pro-
found regional differences in the patient treatment
regimes and drug deployment strategies which are opti-
mal for resistance management. Existing global recom-
mendations (WHO 2006) may be too simplistic.
Open questions
In addition to the unresolved issues which arise in the
context of the preceding fallacies, there are a very large
number of other open issues which seem to us unlikely to
be resolved without the input of professional evolutionary
biologists. Consider, for example, the following:
1 Why did resistance to chloroquine and SP become
established so rarely when resistance spread so globally?
In particular, why is so much drug resistance arising
in Southeast Asia? There are at least five hypotheses
(Klein et al. 2008), most of which focus on the
observation that drug resistance seems to have arisen
in areas of low or unstable transmission (White and
Pongtavornpinyo 2003).
2 Will vector control enhance the spread of drug resis-
tance? Historically, resistance seems to have emerged
predominantly in low-transmission areas and spread
more effectively in low transmission areas (White
2004; Klein et al. 2008). The large-scale deployment
of bednets envisaged by GMAP is aimed at reducing
malaria transmission (Roll Back Malaria 2008). Will
this lead to more rapid resistance evolution, and
necessitate a faster drug pipeline? The influence of
transmission rate on resistance evolution has been
hotly debated. Several arguments have been put for-
ward that high transmission intensity promotes the
spread of drug-resistance. Clonal diversity in infec-
tions is higher, exacerbating benefits of resistance, as
discussed above. Higher transmission also means
that, for a given level of drug use, more parasites will
be exposed to drug selection (Mackinnon and Has-
tings 1998). On the other hand, genetically diverse
infections will generate more outcrossed progeny
infections, and will thereby lead to the destruction of
multi-locus resistance genotypes (Talisuna et al.
2004; Mackinnon 2005). Moreover, areas with low
transmission intensity typically harbor fewer immune
individuals, who have (i) a higher parasite biomass
and so more mutations (White and Pongtavornpinyo
2003), (ii) more symptomatic infections, and hence
stronger drug selection (Talisuna et al. 2004; Mack-
innon 2005), and (iii) a reduced capacity to clear
drug-resistant parasites (Cravo et al. 2001). How
these and other conflicting forces play out has yet to
be established.
3 Is the WHO-recommended radical parasite cure really
optimal for either patient treatment or resistance man-
agement? We have already questioned above whether
radical parasite cure really is the best way of both
treating patients and managing resistance evolution.
Analyses of the question could also consider the fol-
lowing. In high transmission regions, where people
receive more than one infective bite per day (Arnot
1998; Beier et al. 1999; Hay et al. 2000), does radical
cure of a symptomatic infection have a sufficiently
large clinical beneficial effect to offset the greatly
enhanced exposure of parasites to drugs? Does com-
plete parasite clearance make it easier for new para-
sites to invade?
(A) (B)
Figure 4 Competitive release of resistant parasites following the
removal of sensitive competitors by chemotherapy. The total number
of resistant parasites present in infections where sensitive parasites
have been removed by drug treatment or allowed to remain (no
drugs) are shown. Plotted points are the mean (±SEM) cumulative
total number of Plasmodium chabaudi parasites present in peripheral
blood of mice, based on three to five infections per group. Therapeu-
tic treatment is applied when the hosts first start to show symptoms
of malaria (weight loss, anemia); prophylactic treatment is applied at
the time host are infected. Data from Wargo et al. (2007), and de Ro-
ode et al. (2004) respectively.
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4 Will chemotherapy select for more virulent or less
virulent parasites? Chemotherapy could enhance the
circulation of more virulent strains by keeping alive
patients who would otherwise have died from virulent
infections (Gandon et al. 2001; Porco et al. 2005). It
could also be that drug tolerance varies with virulence,
for instance if more rapidly replicating parasites are
more vulnerable to drugs (higher metabolic sensitiv-
ity) or less vulnerable (faster population recovery once
drug pressure has stopped). For one clonal lineage of a
rodent malaria, less virulent parasites were more
strongly suppressed by subcurative chemotherapy than
more virulent parasites, suggesting that virulence evo-
lution could indeed proceed in parallel with classical
resistance evolution (Schneider et al. 2008).
5 Will the HIV epidemic increase the rate of antimalar-
ial resistance evolution? There are about 18% more
malaria parasites in sub-Saharan Africa as a result of
the HIV-associated immunosuppression (Van Geer-
truyden et al. 2008). Does this increase in parasite
number increase the chance of resistance mutations
becoming established? If HIV-infection increases the
severity of malaria or impairs immune clearance, will
drug use become more common, strengthening the
selection for resistance?
Coda
We hope that this review of some recent work and ideas
in malaria drug resistance has made our general point
that, from the perspective of evolutionary science, there is
nothing fundamentally uninteresting or easy about drug
resistance – and that solutions to the issues could have
profound impacts on human health and wellbeing. Evolu-
tionary biologists could conceivably contribute as much
as drug discovery specialists (and much more cheaply). It
is very hard to imagine that the world will indefinitely
fund a malaria drug discovery pipeline at $US1.5 billion
per decade, or indeed that there is an unlimited supply of
drug classes to be discovered. Using the compounds we
already have in the pipeline more effectively is a very high
priority. Evolutionary geneticists have and continue to
play a crucial role in reconstructing the history of drug
resistance (e.g. Fig. 2). The challenge is to add to this an
understanding of the processes that shaped this history,
and use that understanding to change the future.
For those evolutionary biologists interested in general
principles, the issues we have raised here in the context of
malaria are relevant across a diverse range of pathogens,
from RNA viruses to worms. Our bias is that, at least
when it comes to policy and patient treatment, there has
been too much focus on simple generalities and not
enough focus on the important consequences of disease-
specific natural history and indeed location-specific epide-
miology. It may also be that considering the drug resis-
tance problem alongside other problems of resistance
management, such as mosquito resistance to insecticides,
pest resistance to GM crops, and weed resistance to herbi-
cides, would provide novel insights for human health,
especially since for some of these, the evolutionary analysis
is more advanced (e.g. Labbé et al. 2007), and evolution-
ary biologists have had a profound impact on policy and
implementation on the ground (e.g. Bates et al. 2005).
A major focus of evolutionary biology has been the
adaptation of traits where group and individual interests
conflict. This way of thinking will undoubtedly prove to be
a fertile area in drug resistance too, not least as a guide to
the identification of drug targets (Andre and Godelle
2005). But there is also an urgent need to identify resis-
tance management strategies which are good for the group
(the currently uninfected, and the patients of the future)
without being detrimental to individual patients seeking
primary health care right now. In the limit, there is a
trade-off between patient treatment and resistance man-
agement (the latter being optimized when very few patients
are treated with a drug). But such trade-offs are extreme
cases. Even where it is necessary to treat effectively large
numbers of patients, there are many ways patients can be
treated, and among those that similarly restore patient
health will be some which are better at resistance manage-
ment than others. As we have pointed out above, clinical
cure is the object of patient treatment, and this need not
require parasitologic cure. From a public health perspec-
tive, what is the best way to treat patients, impact trans-
mission, and slow the spread of resistance?
More generally, there is a real need to engage with
those who deliver and receive health care, and the econo-
mists and social scientists who study the process. What
sort of resistance management strategies can patients,
physicians and public health planners cope with, particu-
larly if they involve an understanding of evolution?
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